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Abstract 
This thesis investigates the structural details of catalysis associated with the human en-
zyme, Glutathione Transferase Omega 1 (hGSTOl-1), a member of the most recently 
discovered class of Glutathione Transferase. The human genome contains two Omega class 
genes {hGSTOl and 2) and their transcribed products have been found at varied lev-
els within almost every tissue of the human body. The crystal structure of hGSTOl-1 
displays a distinguishing cysteine residue in the active site, a feature that undoubtedly 
plays a role in the novel biochemistry it displays. Of most interest is the hGSTOl-1 
mediated reduction of mono- and dimethylated arsenic species that result from human 
arsenic exposure. The enzyme is also essential for the enzymatic detoxification of alpha-
haloketones to acetophenones and exhibits a novel dehydroascorbate reductase activity. 
The following dissertation reports major progress in understanding the details of these 
chemical mechanisms. By observing these reactions within the crystallised enzyme using 
X-ray diffraction, several states within these catalytic cycles have been observed in great 
detail. Subsequently, hypotheses have been drawn about the product inhibition inferred 
during dehydroascorbate reduction, the existence of glutathione intermediates inherent to 
its interaction with methylated arsenicals, and the fundamental understanding of Omega 
mediated catalysis obtained by observing the enzymatic complex of oxidized glutathione 
and S-(4-Nitrophenacyl)glutathione simultaneously. In addition, adaptation of experimen-
tal conditions has led to the discovery of two new crystal forms with which to study the 
structural dynamics of this protein and its chemistry. The structiu'e of a naturally occur-
ring polymorphism involving the deletion of glutamate 155 has also been solved, revealing 
pronounced structural plasticity that correlates well with the apparent instability of the 
mutant enzyme in vivo. Discussions explore the broad implications for interpreting the role 
of hGSTOl-1 in the pathomechanisms of human disease states such as Alzheimer's disease 
and the biological mechanisms of arsenics' newly discovered potential as an anti-cancer 
agent. 
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Chapter 1 
Introduction 
The biochemical transformations of detoxification were first classified as either Phase I 
(functionalisation) or phase II (conjugation) (Figure 1.1) forms of enzymatic catalysis over 
60 years ago 2|. Since then, much has been learnt about the biological macromolecules 
responsible for both of these transformations. Of the first, the predominant members by 
far are those of the cytochrome P450 family, estimated to have a hand in the metabolism of 
at least 60% of drugs ingested by the human body |1]. Those belonging to the second phase 
of enzymatic detoxification are so named due to their substrates frequently arising from 
the chemical alterations achieved during the first. Their mode of action is characterised by 
the subsequent conjugation of bulky and water soluble moieties to these compounds. This 
is a process of which the glutathione transferase enzymes (GSTs) are an integral part, and 





Although numerous other metabohtes are also formed, shown above is one possible fate of 
benzo[a)pyrene upon entering a cell. Due to its hydrophobic character, the xenobiotic freely diffuses 
across the phospholipid membrane before becoming the subject of Cytochrome P450 and Epoxide 
Hydrolase Phase I catalysis. The activated hydrocarbon ring is subsequently subjected to phase II 
nucleophilic attack by a glutathione transferase (red). The glutathione conjugate can then be 
extruded by the cell using a phase III transmembrane active transporter. Such conjugates are 












Glutathione (L-7-glutamyl-L-cysteinylglycine) is maintained at millimolar concentrations within 
the cell. Being maintained principally in its reduced (upper), rather than the disulfide linked, 
oxidized form (lower), this tripeptide is a principal component of the reducing environment so 
essential for proper functioning of the cell. 
The glutathione transferases are a superfamily of enzymes that ubiquitously employ 
the tripeptide glutathione (GSH) during the chemical transformations they perform (Fig-
ure 1.2). These include nucleophilic aromatic substitutions, Michael additions, epoxide ring 
openings and even isomerization reactions. They are a diverse group of biological catalysts, 
generally found within the cytosol of almost all cellular life, affecting the detoxification and 
disposition of a broad range of chemical species, including carcinogens and drugs. Their 
substrates are typically electrophilic compounds with internal leaving groups, however, 
they are also essential for the removal of reactive oxygen species and the regeneration of 
S-thiolated proteins, two characteristic artifacts of oxidative stress |3|. 






F igure 1.3 
The topology of the hGSTOI structural unit is represented with a cartoon (PDB identifier: l EEM) 
|4| demonstrating the canonical fold of this enzymatic family. The N- and C-terminal domains are 
coloured magenta and cyan respectively. The unique extensions of these domains within the Omega 
class are labelled accordingly. These consist of a random coil motif at the N-terminus, that forms an 
unusual interaction with the C-terminal region, comprised in this instance by the novel «9 - 10 
helices. The binding of glutathione is shown in stick representation, coloured according to atom type. 
Introduction 
l l unique hGSTOI 
N-terminal extension 
Figure 1.4 
A structural comparison of representative human cytosolic GSTs with bound glutathione. Overlaid 
in cartoon representation are equivalent subunits of hGSTA3-3 (green, PDB identifier: ITDI) |5|, 
h G S T M l a - l a (orange, PDB identifier: 1XW6) [e], h C S T P l - l (yellow, P D B identifier: 5GSS) [T], 
hGSTT2-2 (magenta, PDB identifier: ILJR) |8|, hGSTSl-1 (red, PDB identifier: 1PD2) |9| and 
hGSTZ (salmon, PDB identifier: f F W l ) [10|. The equivalent monomer of hGSTOl -1 is shown in 
gray (PDB identifier: lEEM) |4l, in the same orientation as Figure 1.3 on the preceding page for 
reference. Correspondingly coloured molecules of GSH are shown in stick representation. 
within humans. Several other microsomal classes are known, as well some others found in 
plants and insects. Each is defined based on amino acid sequence similarity and designated 
with a Greek letter (a, fi, TT. 9. a, C and u> for Alpha, Mu. Pi, Theta, Sigma. Zeta and 
Omega respectively) [4, 11|. Despite pronounced differences at this level, comparing the 
crystal structures of each demonstrates the shape and structure that is characteristic of all 
cytosolic GSTs (Figure 1.4 on the preceding page). The tertiary structure of each subunit 
can be divided into a N- and C-terniinal domain. The former clearly adopts the alternating 
0 — a thioredoxin fold shared by several other GSH and cysteine binding proteins. The C-
terminal domain of these polypeptides consists of an all a-helical motif that is unique to the 
GST family, providing the binding site and specificity of secondary substrates (Figure 1.3 
on page 3). GST quaternary structure can be homo- or heterodimeric, involving the 
hybridization of different subunit types from within a given class [3|. Subunit composition 
is designated by Arabic numerals separated with a hyphen. The human Mu class for 
example, displays both possibilities. l iGSTMl - l and hGSTlMl-2 indicates a homodimer 
composed of identical type 1 subunits, and a heterodimer, composed of a type 1 and type 2 
subunit. respectively. The lower case prefix "h'. indicates that the enzyme originated from 
humans. As a general matter, they catalyse the conjugation of glutathione to electrophilic 
substrates; 
GSH + R-X ^ GSR + HX 
Such enzymatic activity is exemplified by the nucleophilic aromatic substitution of 
l-chloro-2,4-dinitrobenzene (CDNB), historically used to identify the presence of GSTs 
due to its easily detectable absorbance change at 340 nm upon GSH conjugation to yield 
l-(S-glutathionyl)-2,4-dinitrobenzene [12] (Figure 1.8 on page 12). The interaction with 
glutathione is typically mediated via an active site tyrosine or serine. Located in the 
crevice formed at the boundary of the N- and G-terminal domains, this residue facilitates 
catalysis by stabilising the GSH associated thiolate with a hydrogen bond. A much stronger 
case can be argued for this side chain hydroxyl acting as a hydrogen bond donor, as 
opposed to a hydrogen bond acceptor, due to the pK^ of tyrosine and serine inhibiting 
ionisation at neutral pH. Spectroscopic investigation of the GSH thiolate confirms a shift 
in pKa from 9 to 6.7 |11]. Within the Alpha class, this thiolate is also stabilised by the 
positively charged side chain of an arginine residue. A conserved hydrophilic binding pocket 
for GSH surrounds this active site residue and is termed the "G-site'. while the binding 
of typically hydrophobic, secondary substrates occurs in the adjacent 'H-site' |4. 11. 3|. 
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While either positive or negative cooperatively has yet to be observed in a wild type 
enzyme, disruption of a putative ion pair in the N-terminal domain of hGSTPl-1 decreases 
affinity for GSH, concurrently triggering a positive kinetic cooperation. The C47A or 
C47S mutation, located in the (32 - a2 loop of the N-terminal domain, is hypothesised to 
interrupt an interaction of its thiolate form with a protonated side chain of a nearby lysine. 
This interaction appears to be essential for conformational stability and G-site structure. 
While the resulting plasticity of this region decreases the affinity for the tripeptide, it also 
allows structural communication between subunits, with an observed increase in the Hill 
coefficient from 1.01 to 1.43 |13|. 
1.1 Glutathione Transferase Omega 
Omega is the most recently discovered class of mammalian GST. There are two Omega 
class GST enzymes actively expressed within the human body and they have been found 
at varying levels within almost every human tissue examined. The enzymes are charac-
terised by an atypical cysteine active site residue, a feature that undoubtedly contributes 
to the distinguishing biochemical attributes of these enzymes. Designated liGSTOl-l and 
hGST02-2, they possess dehydroascorbate and methyl arsonate reductase activity. The 
former also possesses the ability to reduce phenacylglutathiones to acetophenones and has 
been implicated in the post-translational activation of interleukin-1/3. While its isozyme 
has proved difficult to purify and solubilize, hGSTOl-1 has proved more amenable to study 
|4, 14, 15|. The research discussed in this dissertation principally focused on discovering 
the chemical mechanism of catalysis with which this enzyme is involved. 
1.1.1 Genetics and polymorphisms 
The two functional hGSTO genes were localised to adjacent regions of chromosome 10, 
and designated hGSTOl and hGST02 respectively 114]. Several polymorphisms of the 
former were observed within human populations. Many are within non-coding regions 
and their eff'ects on splicing, transcription and subsequent inRNA stability have yet to be 
evaluated |16|. Several that occur within coding regions have been studied in more detail 
|14, 17, 18, 19|. The two of most interest are a single nucleotide polymorphism (SNP) 
causing an alanine to aspartate substitution at position 140, and a 3 base pair deletion 
at the exon/intron 4 boundary, resulting in a splicing abnormality and the subsequent 
deletion of glutamate 155 in the mature transcript |17|. 
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While the A140D substitution displays no change in enzymatic activity in vitro |17|, it 
has been associated with an increased risk of hepatocellular carcinoma, cholangiocarcinoma 
and breast cancer |20|, and also implicated in the closely related pathogenesis of Alzheimer's 
and Parkinson's disease, vascular dementia and stroke |21, 22|. Imnmnostaining of the 
atherosclerosis plaques that lead to vascular dementia reveal a co-localization of hGSTOl-
1 and Interleukin 1 alpha (IL-la) |23|, supporting the notion that hGSTOl-1 may influence 
cerebrovascular disease via regulation of IL-1 expression in macrophages and monocytes 
[23, 24| (Chapter 6 on page 131). 
The A155 polymorphism is characterized by two haplotypes involving a glutamate or 
lysine at position 208 and its frequency is found to fluctuate between ethnic groups, with 
over 10% possessing the deletion mutation in one Chinese sample |25, 26, 14]. Recombinant 
expression of this polymorphism in E. Coli resulted in an enzyme possessing enhanced 
activity in vitro and a compromised heat stability [25. 14]. The T-47D breast cancer 
cell line has been shown to be hemizygous for the E l55 deletion and displays decreased 
l iGSTOl- l activity. Furthermore, the same study found that lymphoblastoid cell lines from 
individuals heterozygous for the allele had only 50% of normal activity towards the specific 
substrate S-(4-Nitrophenacyl)glutathione (4NPG) (Chapter 5 on page 97), indicating the 
enzyme is severely compromised in vivo [27[ (Appendix A on page 181). 
1.1.2 Structure 
While adopting the canonical GST fold, the crystal structure of h G S T O l reveals unique 
extensions of both its N- and C-terniini (Figure 1.3 on page 3). The proline rich N-terminal 
region of approximately 19 residues is observed to undergo several hydrogen bonding in-
teractions with the two extra a-helices of the C-terminus, forming a unique element of 
continuous secondary structure on its surface (Figure 1.6 on page 10). Additionally, the 
mode of glutathione binding has two distinctive differences from almost all other GSTs. 
Firstly, the tyrosine or serine residue residing at the active site of almost all other GSTs 
is replaced by a cysteine within the Omega class, and is observed to form a mixed disulfide 
bond with glutathione in the associated crystal structure [4[. The only other instance of 
this GST active site motif has been in the bacterial Beta class [3|. 
Physiologically active as a honiodimer, the cleft between the subunits of l iGSTOl- l 
is notably larger than that of most GSTs (Figure 1.5 on page 9), such that it's binding 
to other polypeptides is conceivable [4. 28[. The second distinguishing difference in GSH 
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binding and this feature of hGSTOl-1 quaternary structure are related. Due to the large 
cleft at the interface, the GSH binding to each monomer does not interact with the adjacent 
monomer. A salt bridge between the N-terminal amino-group of the tripeptide is typically 
mediated by an acidic residue on helix o(4 of the adjacent monomer within almost all 
other GSTs. Indeed, most of the interactions at the hCSTOl-l dimer interface are non-
polar in character. There are no hydrogen bonds and the only two salt bridges, the two 
occurrences of K114-E91 |4| (Figure 1.6 on page 10). Such hydrophobic dimer interfaces are 
a structural feature characteristic of GSTs, with only the sigma class displaying atypically 
polar interactions in this region [3]. 
Unlike the dimer interface however, the H-site of liGSTOl is an atypically polar en-
vironment. Characterised most definitively by the side chains of R183 and W222, this is 
suggestive that the many distinguishing features of Omega may have evolved to deal with 
more polar substrates than the rest of its family. Observed to be orientated with its in-
dole nitrogen pointing directly into the binding pocket, this hydrogen bond contributed by 
W222 belongs to the unique C-terminal extension of the liGSTOl polypeptide (Figure 1.7 
on page 11) [4]. 
1.1.3 Chemistry 
Quite distinct from most other GSTs, the Omega class enzymes have no appreciable activ-
ity towards CDNB^ (Figure 1.8 on page 12). hGSTOl and hGST02 were rather discovered 
via a database search of more than 10® expressed sequence tags (ESTs). A segment of nu-
cleotides corresponding to the Zeta class was used as a query sequence |4|. Together with 
the Theta class, these are the only other mammalian GSTs known to lack activity towards 
this substrate. Once cloned and expressed, the resulting enzymes were found to possess 
'thioltransferase' activity, a mode of catalysis quite distinct from the 'glutathione conju-
gation' behaviour exhibited by almost all of its family members (Figure 1.8 on page 12) 
|4, 17]. Such chemistry is reminiscent of the glutaredoxin enzyme family, a group of en-
zymes that also exhibits an active site cysteine and thioredoxin like fold |3, 30|. This change 
in the usual GST catalytic cycle has manifested itself as several unprecedented biochem-
ical activities within Omega, including the rejuvenation of oxidized ascorbate (Chapter 3 
on page 43), the metabolism of arsenic (Chapter 4 on page 61) and the detoxification of 
'Although an independent investigation has reported that h G S T 0 2 - 2 does show high enzymatic activity 
towards C D N B |29|, this claim has not been supported by the thorough characterization of this enzyme 
being currently performed by my colleagues (unpublished data). 
§1.1 Glutathione Transferase Omega 
Figure 1.5 
A cartoon representation of the liGSTOl-1 pliysiological dirner as reported by Board et. ai, |4l, 
viewed approximately perpendicular to the twofold axis of symmetry. The active site cysteine and 
bound glutathione are shown in stick representation, coloured according to atom type. Each subunit 
of the homodimer is coloured magenta and cyan respectively. 
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Figure 1.6 
A cartoon representation of the hGSTOl-1 physiological dimer as reported by Board et. ai, |4], 
viewed approximately parallel to the twofold axis of symmetry. The structural fold common to all 
GSTs is displayed in magenta, with the novel N- and C-terminal extensions of hGSTOl -1 in cyan. 
The continuous element of secondary structure formed by their interaction is highlighted with a 
correspondingly coloured molecular surface. The active site cysteinyl-GSH mixed disulfide is shown 
in stick representation, coloured according to atom type, with the associated molecular surface 
coloured white. Also shown in stick representation are the lone instances of polar interactions found 
at the dimer interface. Highlighted in yellow, these are the two instances of the glutamate 9 f-lysine 
114 salt bridge. The crystallographic distance of these interactions are given in Angstroms ( A ) . 
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( a ) The crystallographically determined 
'G-site' of h G S T O l . Polar interactions with 
the tripeptide glutathione are indicated with a 
dashed black line. The crystallographic 
distance of each is given in A. 
(b) The well defined cavity of h O S T O f , 
corresponding to the 'H-site' of substrate 
binding in other GST classes. The relatively 
hydrophilic group of amino acids defining this 
wide and deep pocket are highlighted in 
magenta. 
Figure 1.7 
The catalytic active site of h G S T O l . The polypeptide fold is shown as a cyan coloured cartoon 
covered in a translucent molecular surface. Glutathione and relevant amino acids are shown in stick 
representation, coloured according to atom type. White and magenta are used to highlight the 
'G-site\ and putative 'H-site' of the enzyme, respectively |4|. 
phenacylglutathiones to acetopheiioiies (Chapter 5 on page 97) |15, 17, 25|. The atypically 
wide orientation of monomers within the hGSTOl-1 physiological dimer suggests another 
application of its thioltransferase activity may be the glntathionylation or deghitathiony-
lation of other enzymes, a mechanism commonly observed to modulate protein fmiction 
|4|. Although the presence of a stabilising hydrogen bond donor has not yet been identi-
fied, this active site cysteine is crystallographically observed directly over the N-terminus 
of the helix-oil dipole |4|. Facilitated in this case by the cis-proline residue it precedes, 
such positioning of a cysteine residue substantially lowers its pK^, |31|. This active site 
cysteine has been shown to be essential to the enzymes thioltransferase activity |17| and 
also the target of several covalently modifying inhibitors |32, 24| (Chapter 6 on page 131). 
In contrast, mutating this cysteine to alanine greatly enhances the glutathione conjugating 
activity of hGSTOl with the 'universal' substrate, CDNB. Its removal presumably allows 
glutathione to assume its usual role as an attacking thiolate (Figure 1.8 on the following 
page) |17|. 
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(a) The typical catalytic mechanism of GSTs (b) The atypical thioltransferase activity of the 
towards the xenobiotic Omega class GSTs. 
l-chloro-2,4-dinitrobenzene. 
Figure 1.8 
The catalytic mechanism of a typical GST enzyme (red) compared to that of GST Omega. Most 
GST classes have been discovered via their activity to the 'universal' substrate, 
l-chloro-2,4-dinitrobenzene (CDNB) shown in (a) |33, 12|. Omega GSTs have little to no activity 
towards this xenobiotic however and preferentially display a thioltransferase activity instead (b) . 
This atypical mode of catalysis, a biochemical mechanism often involved in the modulation of 
enzymatic activity in vivo, is undoubtedly related to the cysteine residue characteristic of this 
enzymatic class. Unlike the hydroxyl moiety observed in other GST classes, the hydrogen bond 
donor responsible for stabilising the nucleophilic thiolate in the Omega catalytic mechanism has not 
as yet been identified [4]. 
1.1.4 Other features of GST Omega 
The crystal structure of hGSTOl-1 has revealed striking similarity to a nuclear chloride 
channel, CLIC-1 |34, 28], and prompted a subsequent investigation as to whether the 
protein could form or modulate ion channels. Conducive to hGSTOl-1 being able to 
modulate other proteins via its thioltransferase activity, this study has revealed its ability 
to significantly affect the activity of Ryanodine receptor Ca "^"" channels in vitro. The active 
site cysteine was shown to be essential to this mode of action [28]. 
hGSTOl-1 has also been shown to be upregulated to levels greater than tenfold in 
human estrogen receptor negative breast cancer cells, relative to estrogen receptor positive 
cells. Within breast carcinomas, their exists an inverse relationship between estrogen 
receptor expression and several rnestatic properties, such as mobility and invasiveness ]35]. 
Upregulation of hGSTOl-1 has also been shown to be statistically significant in cancer 
cells resistant to the cheniotherapeutic agent cis-platinum ]36]. 
1.2 Research Objectives 
This project specifically aimed to elucidate the details of hGSTOl -1 mediated chemistry, 
the mechanism of specific inhibitors, and to gain insight as to how these interactions infiu-
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eiiced the structural dyuaniics of the euzyme. To achieve this, a variety of X-ray diffraction 
experiments were performed upon several crystal forms of the enzyme that involved var-
ious substrates, substrate analogues, inhibitors and the site directed mutagenesis of it's 
active site residue. This information is crucial to developing a more detailed picture of 
the role played by liGSTOl-l within the body, its contribution to the disease states with 




An overview of the experimental 
methods 
Crystallographic investigation of mechanism is often hiiuiered by the expediency of 
catalysis, snch that the fleeting interactions of substrates are difficult to capture in the 
relatively long time scale recjuired to collect a dataset. It was thus envisioned to attempt 
the cloning and crystallisation of some l iGSTOl active site mutations, specifically, the con-
version of the active site cysteine to an alanine and a serine residue. It was also envisioned 
to employ the substrate analogue, glutathione sulfonic acid, in crystal growth. By thus 
removing the necessary reducing equivalents at various stages of the catalytic mechanism, 
it was hoped the enzyme could be 'stalled' in intermediary stages of catalysis that would 
prove more amenable to investigation by X-ray diffraction. As my research progressed, 
other experimental parameters were interactively altered to affect change within the crys-
tallographically observed active site. This included adjusting the molar ratio of substrates 
and co-substrates relative to the enzyme, combining potential allosteric inhibitors during 
co-crystallisations with substrate, incubation of substrates and inhibitors with the enzyme 
at room temperature before crystallisation at 4°C, and the alteration of redox conditions 
used in purification combined with additive screens during crystallisation, eventually lead-
ing to the discovery of two new crystal forms (Chapter 6 on page 131). 
This chapter is designed to give a brief introduction to the standard techniciues used 
throughout the course of this research. More detailed information i)ertaining to the exper-
imental conditions of particular experiments will be given in the relevant chapters. 
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2.1 Site directed mutagenesis 
The alanine active site mutant of hGSTOl had previously been made by a colleague [17| but 
first needed to be transferred from the pQE30 plasmid (Qiagen), to the expression vector 
pHUE |37| (Figure 2.2 on page 19 and Section 2.2 on page 18), to facilitate large scale 
protein expression with a removable his-tag for crystallization. This was performed via a 
complementary restriction digest of both vectors, followed by gel visualisation, isolation and 
purification of the insert and vector fragments, respectively . The two DNA fragments were 
then ligated, before transfecting into E. coli (Section 4.2 on page 66). After subsequently 
purifying the plasmid, the active site mutation was then confirmed unequivocally by DNA 
sequencing (Figure 4.3 on page 67). 
The cysteine to serine substitution was performed via site directed mutagenesis, using 
native hGSTOl in the pGEM-T plasmid (Promega) as a template. Primers containing the 
desired nucleotide change were employed in a PGR reaction to perform a whole plasmid 
replication. As shown in the Stratagene 'QuikGhange' protocol (Figure 2.1 on the facing 
page), this allowed the amplification of only the mutated plasmid, while template plasmid 
could subsequently be digested with a methylation specific restriction enzyme. After trans-
fecting E. coli, the mutated plasmid was purified and the cysteine 32 to serine substitution 
also confirmed via DNA sequencing (Figure 3.4 on page 47), before restriction digest and 
ligation into the pHUE vector as above. 
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S t e p 1 
P l a s m i d P r e p a r a t i o n 
S t e p 2 
T e m p e r a t u r e C y c l i n g 
^ ^ Mutagenic 
primers 
S t e p 3 
D i g e s t i o n 
S t e p 4 
T r a n s f o r m a t i o n 
/ Mulaled plosmid 
(contains nicked 
circulor strands) 
Gene in p lasmid with 
target site ( • ) for mutat ion 
Denature the p lasmid and anneal the 
o l igonuc leot ide primers ( ) conta in ing 
the desired mutat ion ( x ) 
Using the nonstrand-displacing 
act ion of PfuTurbo D N A polymerase, 
extend and incorporate the 
mutagenic primers resulting 
in nicked circular strands 
Digest the methylated, nonmutated 
parental D N A template with Dpn I 
Transform the circular, nicked dsDNA 
into XLl -Blue supercompetent cells 
After t ransformat ion, the XLl -Blue 
supercompetent cells repair the 
nicks in the mutated plasmid 
LEGEND 
— P a r e n t a l DNA piosmid 
^ ^ ^ Mutagenic primer 
Mutated DNA plasmid 
FIGURE 1 Overview of the QuikChonge site-directed mutagenesis method. 
F i g u r e 2 . 1 
T h e ' Q u i k C h a n g e ' s i t e d i r e c t e d i m i t a g e n e s i s p r o t o c o l a s s h o w n in t h e S t r a t a g e n e i n s t r u c t i o n 
m a n u a l ( w w w . s t r a t a g e n e . c o m c a t a l o g u e # 2 0 0 5 1 8 ) . 
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2.2 The pHUE expression system 
An E. coli based expression vector recently developed by Cantanzariti et. at, [37| was 
employed in the purification of native and active site mutants of liGSTOl. This simple 
and effective expression system utilizes the eukaryotic protein Ubiquitin as a histidine 
tagged fusion product of the desired polypeptide. Apart from offering a natural yield 
enhancement to the protein of interest, the use of a customised deubiquitylating enzyme 
affords great ease in purification (Section 2.3 on the facing page). As this deubiquitylating 
protease also contains a Histidine tag, its use prior to a single round of immobilised metal 
affinity chromatography leaves the desired, unmodified polypeptide as the only soluble 
product. 
Known as the Histidine-tagged Ubiquitin Expression vector, pHUE, this vector facili-
tates the quantitative purification of authentic proteins via precise removal of the histidine 
tag-ubiquitin fusion. Through the use of a SacII restriction site in the 5' cloning of insert 
genes, the deubiquitylating protease, Usp2-cc, is designed to cut precisely after the C ter-
minal glycine of ubiquitin, leaving unlabeled polypeptides with unmodified amino termini. 
The separated affinity tag can be removed simply by passing the mixture through a Nickel 
column. This cleavage reaction occurs at a high efficiency, irrespective of the N-terminal 
amino acid residue, with the exception of proline. The enzyme shows maximum catalytic 
activity at a pH of 8.5, however retained >80% efficiency between pH 7.5 and 9. Simi-
larly tolerant of ionic strength, the enzyme showed maximum activity at 0 mM NaCl, but 
maintained >90% of activity in salt concentrations as high as 300 mM |37|. 
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F i g u r e 2 . 2 
T h e plasmid map of Histidine-tagged Ubiquitin Expression vector, pHUE, ( A ) . T h e inducible T 7 
R N A polymerase promoter (black triangle) is immediately followed by the His-tagged Ubiquitin 
(Ub) cod ing region. T h e appropriate restriction sites are indicated. Other abbreviations are as 
follows: A m p r , (3-lactamase gene; ori, E. coli origin of replication; l a d , l a d repressor gene. (B) 
Shows the 5' and 3' ends of the ubiquitin construct . T h e engineered Sacl l site by which a precise 
fusion can be made is underlined. (Adapted from Catanzariti et ai, |37|). 
2.3 Purification of hGSTOl 
After growth of traiisfected E. coli to the appropriate optical density, protein expression 
was chemicaUy induced and the culture was allowed to reach maximal capacity before 
ceiitrifugation, resuspension of the bacterial pellets and lysis with a French pressure cell. 
Purification of h G S T O l was subsequently performed by subjecting the lysate to nickel 
affinity chromatography. This involves the use of Ni2+ ions partially coordinated to ni-
trilotriacetic acid (Ni-NTA) resin immobilised within a column (Figure 2.3 on the next 
page). The remaining coordination sites are tightly bound by the imidazole nitrogens 
of the protein associated poly-histidine tag as the lysate is passed through the cohunn, 
h G S T O l was then separated from non-specifically bound proteins by applying a Fast Pro-
tein Liquid Chromatography (FPLC) mediated concentration gradient of soluble imidazole 
(Figure 2.4 on page 21). Elution of protein was identified by absorbance of aromatic amino 
acids at 280 nrn, allowing specific fractions to be checked for the presence of hGSTOl via 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) (Figiu'e 2.5 on 
page 22). The most i)ure fractions were pooled and dialysed in buffer, before perfornung 
a cleavage reaction via addition of the Usp2-cc ubiciintinase (Section 2.2 on the facing 
page). Tiie ubiquitin-histidine tag, ubiciuitiuase and any remaining impurities could then 
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Figure 2.3 
Ni-NTA resin coordinated by a protein associated poly-histidine tag. (Adapted from Astatke, 2008 
|38|). 
removed by another pass through the Ni-NTA column (Figure 2.5 on page 22). The re-
sulting flow through containing only pure protein, was finally exchanged into new buffer, 
before concentrating and usage in crystallisation screens. 









F igu re 2.4 
An example of the FPLC mediated purification of liGSTOl-1. Tiie elution of protein from the 
'His-trap' (GE Healthcare) Ni-NTA column is shown by absorbance of the elutant at 280 nni, 
indicated by the blue graph. This is shown in comparison to the imidazole concentration of the Wcish 
buffer, indicated by the green graph. The composition of each elution fraction was then anaylsed by 
SDS-PAGE (Figure 2.5 on the next page). 
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SDS-PAGE analysis of hGSTOl purification. As imidazole is a histidine analogue, its increasing 
concentration corresponds to tagged protein elution. (A) Lanes Al -10 correspond to protein eluting 
at an imidazole concentration of R!70 mM to Ri370 mM respectively. The l i G S T O l / U b construct is 
clearly observed at kDa. Collected protein corresponding to lanes A5 and onwards were 
combined and digested with Usp2-cc protease. (B) Upon inspection of the column flow through 
(post Ni) and subsequent washes with buffer, pure h G S T O l is observed (fisSO kDa) as the only 
soluble product, effectively demonstrating the efficiency of this two step process. The impurities 
previously present are observed to elute upon washing with excess imidazole. 2 (jil of low molecular 
weight (LMW) protein mixture (GE Healthcare) is shown in the left most lanes of each gel. The size 
of its constituents are given for reference. 
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2.4 Purification of the Deubiquitinase, Usp2-cc 
A small quantity of cloned Usp2-cc in pET15b (Novagen) was obtained from colleagues at 
the John Curtin School of Medical Research (JCSMR). 1 fiL of this plasmid construct was 
used to transform a 50 IJ.L aliquot of heat shock competent E. coli cells of strain DH5a 
via incubation on ice for 10 minutes, followed by heat shock in a 42°C water bath for 45 
seconds^. The transformed cells were inmiediately spread onto an agar plate containing 
0.2 nig/ml Ampicillin. After incubation at 37°C overnight, the resulting colonies were used 
to grow a starter culture of luria broth (LB) also containing 0.2 mg/ml Ampicillin. The 
resulting cells were spun down and used to generate a larger volume of the plasmid using a 
Mini Prep kit (Qiagen). 1 fiL of the purified plasmid was subsequently used to transform 
a 50 /,iL aliquot of electroporation competent E. coli cells of strain BL21. This was then 
streaked out on an agar plate (0.2 mg/ml Ampicillin) and subsequently used to grow a 
5L volume of transformed culture. As the pET15b-f/.spf-cc construct also encodes an N-
terminal poly histidine tag fused to the ubiquitinase, it was purified via French pressure 
cell lysis of cells and subsequent Ni-affinity chromatography as in Section 2.3 on page 19. 
Cell resuspension and post-purification dialysis liowever, was in a slightly altered buffer 
(300 niM NaCl. 50 niM Sodium Phosphate, 10 niM imidazole and 30% Glycerol, pH 8) 
|37|. 
2.5 X-ray crystallography 
X-ray crystallography was the principal method used to study the structural basis of 
hGSTOl-1 catalysis during this investigation. It is essentially a way to visualise what 
happens to protein molecules and their substrates during catalysis. As the resolution of 
any microscopic investigation is physically limited by the wavelength of radiation used. 
X-rays with wavelengths of approximately 1 A are ideal to resolve the complex bonding 
arrangements of atoms within crystals. Conventional forms of microscopy typically use 
a lens to refocus scattered light into a magnified image. The lack of a physical lens ca-
pable of refocusing X-rays however, means they must alternatively be diffracted through 
an ordered 3-dimensional array. This effectively amplifies the diffraction pattern, which 
can then be sampled in a 3-diniensional pattern of discrete spots. Application of accm-atc 
'Competent cells were kindly prepared by resident lab tedinicians, Mr llnliu Qui and Miss Tracy 
Murray. 
24 An overview of the experimental methods 
phase information then facihtates creation of an image. The only 3-dimensional arrays for 
this purpose are crystals. The resulting diffraction pattern has a physical relationship to 
the arrangement of atoms at each lattice point of the crystal. It is a relationship that is 
described precisely by a mathematical operation known as the Fourier transform. Electro-
magnetic radiation can be described in terms of its amplitude (half the height of each wave, 
from peak to trough), wavelength (distance between successive peaks) and phase (lateral 
displacement of the wave relative to an arbitrarily chosen origin). Once this information 
about each X-ray beam diffracted from the crystal is known, the Fourier transform can 
be used like the lens of conventional light microscope, creating a picture of the protein's 
electron density that is repeated throughout. 
The detailed theoretical proofs of X-ray crystallography and their derivations have been 
well established for several decades and will not be reproduced here. Wha t follows is a brief 
introduction to some crystallographic methods, in the context of how they were employed 
in this research. For an introductory textbook to the subject, the reader is directed to 
'Crystallography Made Crystal Clear' by Gale Rhodes [39|. This intuitively written text 
regularly makes use of figures that visually convey the theoretical concepts involved in a 
simple and concise fashion. Some have been adapted below to illustrate the methods used. 
2.5.1 Crysta l symmetry and crystal l izat ion. 
Crystals can be described as a 3-dimensional lattice of symmetrically equivalent points. 
Each is in an identical environment, such that an observer would have the same perspective 
of the crystal lattice from each. The lattice points dictate the boundaries of what can be 
thought of as many tiny, identical boxes, stacked tightly against each other. These boxes 
are known as unit cells, and their packing in 3-dimensions is compatible with several shapes, 
known as crystal systems. In order of descending symmetry, these are cubic [a = b = c 
and a=/3=7=90^) , tetragonal {a = b ^ c and q=/3=7=90° ) , orthorhornbic {a ^ b ^ c and 
hexagonal {a ^ h ^ c and a = /? = 90°, 7=120«^), rhombohedral {a = b = c 
and a = = 7 ^ 90®), monoclinic {a ^ b ^ c and a = 7 = 9 0 ° , > 90°) and triclinic 
(a ^ b ^ c and a ^ 7 ) . Several lattice centerings are also possible, known as lattice 
types. A unit cell that contains lattice points at its vertices only is known as a primitive 
centered lattice type. Wi th in crystal systems other than triclinic, 3 others are also possible: 
body centered (an additional point in the centre), face centered (additional lattice points 
in the centre of each unit cell face) and a, b or c centered (two additional lattice points in 
§2.5 X-ray crystallography 25 
the centre of two opposing faces). The non-redundant combination of the 4 lattice types 
with the 7 crystal systems leads to the 14 unique types of unit cells known as the Bravais 
lattices. 
The miit cell is the smallest element that can reproduce the entire crystal by purely 
translational synmietry, but they generally contain internal symmetry as well. This in-
cludes rotational and reflective symmetry elements, i.e., rotation axes and mirror planes. 
These can also be combined with translational elements, creating screw axes and glide 
planes. This internal synnnetry of a unit cell is described by its space group, a symbol 
that describes the combination of symmetry operations applied to the asymmetric unit. 
This is the smallest element that can reproduce the unit cell with translational and ro-
tational/reflective symmetry operations. Applying a particular space group symmetry to 
an asynunetric unit, and then translating the resulting unit cell in 3-dimensions, generates 
the entire crystal lattice. In total, there are 230 different space groups compatible with 
3-dimensional translational symmetry. Due to the presence of only L-configured amino 
acids in proteins however, this number is nuich lower within the crystals they form: only 
the 65 enantiomorphic space groups that do not contain mirror planes, glide planes or 
other reflective elements are relevant. 
As an example, hGSTOl readily crystallizes in the space group P3i21, with unit cell 
dimensions of 56.2 x 56.2 x 139.5 A |4|. The capital letter T ' , designates the primitive 
lattice type, numbers indicate rotational symmetry, and subscript numbers indicate a screw 
axis. Within P3i21 crystals of hGSTOl, the asymmetric unit is a single protein monomer 
and there is 3-fold screw axis (3i) down the unique unit cell axis. This means that an iden-
tical position within the crystal lattice is achieved by combining a 120° (36073) rotation, 
with a translation of the asymmetric unit by i/s its length. There is also a 2-fold rotational 
axis of symmetry (2) perpendicular to this, happening to correspond to the 2-fold axis of 
the physiological dimer. 
By concentrating and purifying proteins to homogeneity, before combining them with 
various salts, buffers and precipitants in controlled environments, they can sometimes 
be coaxed into forming such crystals. Since the theory of crystal formation is poorly 
understood, this is typically a trial and error process. Many different combinations of 
different chemicals are screened to find initial hits that can then be optimised. Over 
time, some compounds have been identified as being particularly effective. The techniciue 
of vapovn- diffusion is employed in this process, whereby protein is mixed with various 













F igu re 2.6 
On the left is a schematic of the popular 'hanging drop/vapour diffusion' method of growing protein 
crystals, showing the changes in precipitant concentration as a result of vapour diffusion. The 
middle and right hand side show a typical phase diagram, and describe the concurrent changes in 
protein and precipitant concentration during crystal formation respectively (adapted from 
'Crystallography Made Crystal Clear' |39l, with permission). 
additives in a small drop, and then allowed to equilibrate with a reservoir of a larger 
volume within a closed system. This results in the lower concentration of additives in the 
drop slowly equilibrating with the solution of higher concentration in the reservoir via the 
vapour diffusion of water. This slow increase in protein concentration leads to a decrease 
in solubility, at which point there are typically two possibilities: the protein can come out 
of the solution as an amorphous precipitate, or as an ordered protein crystal. For the latter 
possibility to eventuate, additive concentration needs to equilibrate within a range suitable 
for crystal nucleation. As the protein crystals form, the concentration of soluble protein 
should ideally fall into a range optimal for crystal growth, resulting in crystals suitable 
for X-ray diffraction. This process is often represented with 'phase diagrams', as shown in 
Figure 2.6. 
2.5.2 Data collection and Fourier methods 
When X-rays interact with electrons in a molecule, the fluctuating electromagnetic field 
of the incident radiation forces them to oscillate at the same frequency. The radiation 
that is generated from this interaction is of the same wavelength, but precisely 180° out 
of phase with the incident wave. This is known as coherent scattering and occurs in all 
directions. When monochromatic X-rays interact with molecules within a crystal, coherent 
scattering also occurs in all directions, but the symmetrically ordered lattice means that 
the many secondary waves are superimposed on each other. When waves superimpose such 
that their peaks and troughs align, i.e., in phase, the amplitude of the wave increases in a 
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Shown on the left, coherent scat ter ing of X-rays by adjacent a toms and its relationship to Bragg's 
law (Equat ion 2.1) on the right. This s ta tes t ha t two waves scat tered by a set of planes must have a 
difference in pa th length equal to an integral number of their wavelength in order to satisfy the 
requirements for construct ive interference, where X = wavelength, d = interplanar spacing of a toms 
and 0 - the angle of reflection. (Adapted from h t tp : / / en .wik iped ia .o rg /wik i /Bragg ' s_ law) . 
cumulative fashiou (constructive interference). When these waves superimpose such that 
their peaks and troughs are out of phase relative to each other, they effectively cancel each 
other out (destructive interference). This phenomenon is known as diffraction and results 
in a pat tern of discrete spots when used to expose photographic film or a modern day CCD 
(charged coupled device) detector. These spots correspond to waves whose intensity have 
been enormously amplified by the process of constructive interference, and must exit from 
the crystal at an angle that satisfies Bragg's law: 
nX = 2dhkisin9 (2.1) 
Diffracted waves can be thought of as 'reflections' off of planes of electron density 
within the crystal. Each can be assigned a set of Miller indices describing what plane 
each was diffracted from. If a unit cell has dimensions a, h and c, and a diffracted wave 
has Miller indices of h,k,l, it originated from the set of planes that intercept the unit 
cell h times at intervals of a/h, k times at V^ and 1 times at ^/i. Bragg's law states that 
for constructive interference to occur, the diffraction angle ((9), and interplanar spacing (d) 
nnist be such that the differential path length of two superinii)osing waves (2dsin0), is equal 
to an integral number of wavelengths (nX). The basis of this mathematical relationship is 
shown in Figure 2.7. 
Another way of appreciating Bragg's law is from the persi)ective of reciprocal space. 
The diffraction of a lattice is also a lattice, but has dimensions that are inversely proi)or-
tional to that from which it originated. This is the physical relationshii) between the unit 
cell of a crystal and it's diffraction pattern. Distances within the imit cell measured in 
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Figure 2.8 
Ewald's sphere shown intersecting the reciprocal-lattice planes hOl and hll. Reciprocal lattice point 
012 is shown contacting the sphere, concurrently producing a ray R, at an angle of 26 relative to the 
impingement beam of X-rays X, that will be recorded as reflection 012 on the detector. Its direction 
is defined by drawing a line between the origin (000) and reciprocal lattice point 012, that has a 
length of V<'oi2 and a direction normal to the 012 plane of electron density. (Adapted from 
^Crystallography Made Crystal Clear' [39], with permission). 
A correlate to distances of reciprocal angstroms Thus, this lattice is referred to 
as the reciprocal lattice, and it is composed of measurable reflections in reciprocal space. 
The position of these reflections in reciprocal space are defined by lines drawn from the 
origin of the crystal lattice, normal to their corresponding planes of electron density, and 
of a length i/d^fci. It can be shown that the geometric conditions required for a reflec-
tion to be measured in reciprocal space are exactly the same as those required to satisfy 
Bragg's law in real space. A sphere of radius '/A, representing the wavelength of X-rays 
in reciprocal space, generates a geographical construction by which it is satisfied. As the 
crystal lattice is rotated about its origin, so too is the reciprocal lattice. As points of the 
reciprocal lattice contact the sphere, Bragg's law is satisfied, and a reflection occurs. This 
construction is known as the sphere of reflection or Ewald's sphere, and is demonstrated 
graphically in Figure 2.8. This implies that the position of reciprocal lattice points are 
entirely dependent on the size and orientation of the unit cell, and not on its contents. As 
will be shown below however, it is the intensities and phases of these reflections that give 
us the structural information we seek. 
The Fourier transform is a mathematical function that describes the relationship 
between a crystal and its reciprocal lattice precisely. It converts the complicated 3-
dimensional electron density fimction into its many component wave functions. Of most 
importance, it is a reversible operation, such that a reciprocal lattice can be used to cal-
culate the crystal lattice parameters, and vice versa. Fourier demonstrated that for any 
function f{x), there exists another function F{h), who share the relationship: 





where F{h) is the Fourier transform of f{x), i is the imaginary mmiber and the units 
of the variable h are the reciprocal of the units used for x. For convenience, the phases 
are implicitly specified in Equation 2.6 by the following relationship of complex number 
theory, known as Euler's fornmla: 
cos0 + is in0 = e'® (2.3) 
Conversely, the same mathematical transformation that created F{h) from f{x), can also 





In the context of X-ray diffraction from crystals however, Fourier's relationship be-
comes slightly more complicated. Firstly, the diffracted rays responsible for spots in a 
diffraction pattern are not simple X-ray waves, but structure factors, each a Fourier sum-
mation of the coherent scattering from every atom in the crystal. While the orientation 
and dimensions of the unit cell dictate the positions of the reflections, the detailed infor-
mation about its contents are encoded in the phase and amplitude of each. Secondly, the 
above eciuations pertain to f-dimensional functions, while the electron density within a 
crystal is 3-dimensional. Similarly, the terms involved in it's Fourier transform are also 
3-diniensional: 
Fhki= [ (2.5) 
Jv 
Here, each structure factor. Fhki, is a sunnnation of contributions from each volume ele-
ment, V, within the unit cell. The electron density, p{x,y,z), is in turn the transform of 
the structure factors: 
= (2.6) 
hkl 
Assuming that the variables within Ecination 2.6 are ac:curately known, calculating 
electron density maps is therefore a simple process of vector siunniation. Unfortunately, 
this is not possible because both the amplitude and phase of the X-rays are reciuired, and 
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only the former is currently able to be measured experimentally. A detector capable of 
measuring phase would require a sensitivity high enough to differentiate the undulating 
wave intensity of a coherent X-ray source on a time scale considerably less than the wave's 
time period (time taken for the wave to travel one wavelength). For X-rays possessing a 
wavelength of 1 A, this can be calculated: 
Q^—10 ^ 
since T = i / / and c = / A , T ^ A/, = ^ — ^ 3.3 x seconds (2.7) ' 3.0 X 10^ m • sec~^ 
where T is the time period of the wave, / is the frequency of the wave and c is the speed of 
light. Since the corresponding time scale of data collection is minutes to hours when using 
conventional X-ray sources, or seconds when using synchrotron radiation, this is clearly not 
possible. All phase information is lost when X-rays are accumulated for such long periods 
of time. This unknown variable in the measurement of experimental diffraction data is 
commonly known as the phase problem. 
2.5.3 The phase problem and molecular replacement 
When solving crystal structures that are isomorphous with a known structure, the cal-
culated phases from the known structure can be used directly as initial estimates. For 
instance, when performing experiments with crystals of the previously published trigonal 
space group of hGSTOl |4|, phases could be obtained from the known contents and orien-
tation of the asymmetric unit immediately. The observed amplitudes (proportional to the 
square root of measured intensities) of the experiment were simply combined with calcu-
lated phases from a Fourier transform of the known structure. Even though these phases 
were not accurate, they were close enough to calculate interpretable electron density and 
hence, solve the structure. The information encoded within the measured amplitudes were 
then sufhcient to reveal any minor differences between the two, such as ligand binding. 
This concept is eloquently demonstrated by Kevin Cowtan's 'fourier cats' (Figure 2.9 on 
the facing page) |39|. 
In Figure 2.9 on the next page, the cat and the manx cat are in identical positions and 
orientations. If they were not, the cat would first need to be superimposed onto that of 
manx cat before its calculated phases could be used as estimates. This superposition is 
known as molecular replacement and was used to solve the structures of the h G S T O l A l 5 5 
isoform (Appendix A on page 181), as well as the two novel crystal forms of wild type 
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Figure 2.9 
The 'Fourier cats' of Kevin Cowtan (l ittp: / /www.ysbl.york.ac.uk/" A 
tailed cat is sliown with it's Fourier transform, but is devoid of phase information (grayscale image) 
(a). Similarly, a 'manx' (tailless) cat is shown with it's Fourier transform, containing intact values of 
phase (different values within the colour spectrum correspond to different values of phase) (b). This 
is an analogy of the situation often faced in crystallography during isomorphous replacement and 
molecular replacement. The question is, are the amplitudes powerful enough to reveal differences in 
the new structure when combined with phases from the old? By performing a reverse transform 
combining the inanx phases with the cat amplitudes (c), we can see that they are. The tail, albeit at 
partial occupancy, is clearly visible (d). (Adapted from 'Crystallography Made Crystal Clear' |.'59|, 
with permission). 
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hGSTOl identified during this research (Chapter 6 on page 131). This involved searching 
for the orientation and position of the asymmetric unit within the new crystals by using the 
previously solved structure (PDB identifier; lEEM), expected to be similar. Although the 
problem could theoretically be approached by calculating the dimensions and orientation 
of the new unit cell from the raw diffraction data, then calculating phase estimates at 
every conceivable position, the required computational time is decreased dramatically by 
separating this complicated search into two separate searches of orientation and position. 
This can be achieved by using the Patterson function. Mathematically, it has the general 
form: 
Piu,v,w) = (2.8) 
hkl 
Since the Patterson function contains no phases, it can be computed from any set of raw 
crystallographic data, and because the previously solved structure was expected to be very 
similar to that in the new crystals, it follows that they would have very similar Patterson 
maps. In contrast to a contour map of electron density that displays high peaks of density 
that correspond to atoms {x,y,z), the Patterson function creates a contour map that 
displays peaks corresponding to vectors between atoms, {u,v,w). There are many more 
vectors between atoms than there are atoms, so Patterson maps are more complicated. 
Conceptually, an arrow (vector) is drawn between every atom and every other atom in a 
protein molecule. The tail of each is then moved to the origin to create the Patterson map. 
Since the distances between atoms in a protein are independent of the proteins position, it 
is only the orientation that determines the appearance of the Patterson function. As the 
structure rotates, so does the Patterson map. This can be used to find the best orientation 
of a protein within a new unit cell. Using the results of this rotation function, a separate 
search can then be performed to find the best position. This is achieved using a translation 
function, in which the optimally orientated model is translated about the unit cell in 
real space. Intensities are iteratively calculated and compared with those observed in the 
diffracting pattern. At a certain position, these differences will be at a minimum. This can 
be quantified using the crystallographic R-factor (Equation 2.13 on page 41), correlation 
coefficient or maximum likeliliood fimction. The resulting reduction in computational time 
and effort required to find a solution is enormous. 
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2.5.4 An introduction to anomalous scattering 
The electrons orbiting the nuclei of atoms do so within specific orbitals. Each of these 
orbitals possess a specific energy. In order for electrons to pass from one to another, 
energy must be emitted or absorbed. As energy of the incident radiation increases, so 
does the absorption of the element, until it sharply drops away. This is known as the 
elements absorption edge. Just above this value, there is sufficient energy to eject inner 
shell electrons from their orbitals. This results in X-rays of a specific wavelength being 
emitted as outer shell electrons fall down to take their place. This wavelength directly 
corresponds to the gap in energy between the two orbitals. 
At synchrotrons, the wavelength of X-rays can be finely tuned such that it corresponds 
to the absorption edge of heavy elements such as arsenic (Figure 2.10 on the next page), but 
not lighter elements such as C, N and O, due to their absorption edges not occurring within 
the range of X-ray radiation useful for crystallography. This results in radiation being 
absorbed and re-emitted with an altered phase. This is known as anomalous scattering or 
anomalous dispersion. As crystal lattices are inherently synnnetrical, so are their diffraction 
patterns. The principle effect of anomalous scattering is the break down of this synmietry 
relationship, known as Friedel's law. This law states that a particular reflection, with Miller 
indices hkl. will have an intensity equal to the reflection with the same indices, but with 
opposite sign, hkl. One can think of each of these reflections coming from the same planes 
of electron density at the same angle, but from opposite sides. Friedel's law is broken 
because the phase contribution of absorption and re-emittance is synnnetrical in its real 
component, but not in its imaginary component (Figure 2.10 on the following page). This 
is demonstrated with vector diagrams in Figure 2.11 on page 35. 
Subtraction of native and anomalous intensities dramatic-ally simplifies the Patterson 
function (Ecjuation 2.8 on the facing page) to just a few atoms. This very simple 'struc-
ture' is easy to solve, subsequently allowing the position, and thus the phase, of the heavy 
atoms to be calculated (Equation 2.6 on page 29) [4()|. Therefore, an electron density map 
can be calculated (Section 2.5.5.2 on page 37) of just these atoms, but in the absence of a 
molecular replac;ement model, can also be used to generate initial phase estimates for the 
whole protein as well. Since all atoms in the molecule contribute to the generation of all 
structure factors, the (juantifiable contribution of anomalous disi)ersion allows an initial 
estimate of phase to be ('alculated for each. In practice, this recjuires several datasets col-
lected at wavelengths with varying anomalous dispersion contributions. Often 3 datasets 
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The anomalous scattering coefficients of Arsenic 
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Due to its application in this research, the theoretically determined real ( f ) and imaginary ( f ) 
anomalous scattering coefficients of Arsenic are shown to demonstrate the physical basis of 
anomalous dispersion. Experimentally, the imaginary component of this phenomenon is directly 
proportional to the observed X-ray absorption and fluorescence. Once the f ' spectrum has been 
determined, it can be used to calculate that of f . This wavelength dependent contribution to 
structure factor phase and amplitude can be exploited by the variable wavelength of synchrotron 
radiation to locate the position of the atoms responsible. Subsequently, this information can be used 
to calculate phase estimates for the entire structure. The methodo logy is demonstrated most 
eloquently by representing structure factors as vectors on the complex number plane (Figure 2.11 on 
the next page). This figure was generated using the 'edge plots ' too l at the University of 
Washington web server (h t tp : / / sku ld .bmsc .wash ington .edu / s ca t ter / ) . 
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( a ) The structure factors of a Friedel pair 
represented on a complex number plane. The 
colour spectrum represents the corresponding 
phase value. 
(b) At wavelength A2, Fhki is no longer the 
mirror image of F ^ due to anomalous 
scattering. While the phase shift of anomalous 
scattering is mirrored in its real component 
(AFr ) , this is not the case for its imaginary 
component ( A F J . The resulting asymmetry in 
phase leads to an asymmetry in amplitude. 
Measuring the same reflection using Ai, in the 
absence of anomalous dispersion, allows its 
contribution to be clearly visualised by simple 
subtraction. This quantifiable contribution of 
the anomalous diffraction to each structure 
factor, coupled with the knowledge of the 
positions of the atoms responsible, allows a 
phase estimate to be calculated for each. 
Figure 2.11 
A depiction of Friedel's law on the complex number plane in the absence and presence of anomalous 
dispersion. The x and y axis represent the real and imaginary number planes. Each structure factor 
is represented as a vector, with its amplitude and phase indicated by the vector length and angle 
formed with the real axis, respectively. The real and imaginary contributions of anomalous 
dispersion can be quantified via head to tail summation. (Adapted from 'Crystallography Made 
Crystal Clear' |39|, witli permission). 
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are collected in order to adequately overdeterinine the phase problem: one at the peak of 
f" absorption, another at the peak of f absorption, and a native dataset at a wavelength 
far from the absorption edge. This technique is known as multiple-wavelength anoma-
lous dispersion (MAD) [41|, and is the most commonly used technique in the structural 
determination of novel protein folds. 
2.5.5 An introduction to in silico methods of macromolecular structure 
determination 
2.5.5.1 Data processing 
Throughout the course of this research, the HKL2000 package [42] was invariably used 
for processing of the raw diffraction data, each a 2-dimensional projection of a curved 3-
dimensional slice of reciprocal space. The process of reducing single crystal diffraction-data 
into a list of indexed reflections can be broken down into several steps. These can be sum-
marised: (1) the visualisation of the original, unmodified detector data, (2) assigning the 
many reflections with a corresponding hkl index, (3) refinement of the crystal and detector 
parameters to reflect the experimental conditions, (4) integration of the diffraction inten-
sities, (5) applying a scale factor to equivalent reflections to account for variables such as 
crystal thickness, (6) a global precise refinement of crystal parameters using all recorded 
reflections, and (7) the statistical analysis and merging of reflections related by crystal 
symmetry. The HKL2000 package includes the Denzo and XDisplayF programs to index 
and integrate the reflections (steps f-4), while the scaling of equivalent reflections into a 
single list of indexed intensities (steps 5-7) is performed by the program Scalepack. The 
first step in indexing is to perform a 'peak search' within XDisplayF. This identifies reflec-
tion peaks in a single diffraction image. Denzo then uses a novel algorithm that combines 
a priori knowledge about the experimental geometry to map them into reciprocal space. 
The program performs a search of all possible indices of all reflections, and exploits the 
ability of each hkl index to be determined independently of the other two. This ultimately 
allows the possible unit cell size and orientation to be determined. The crystallographer 
is then given a list of the Bravais lattice symmetries (Section 2.5.1 on page 24) coupled to 
a distortion index. As a general matter, the lattice of highest symmetry which displays a 
modest distortion index will be a clear outlier given good data. A trial and error process 
of comparing the merging statistics of synmietry related reflections when scaled can then 
ascertain the correct choice of space group. Calculation of initial phase estimates of the in-
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tegrated and scaled refiectioiis can then occur, for e.g., via MAD (Section 2.5.4 on page 33) 
or molecular replacement (Section 2.5.3 on page 30) experiments discussed previously. 
2.5.5.2 Calculation of electron density maps 
Due to the calculated phases being only rough estimates, the initial electron density maps 
can be somewhat uninformative. Crystallographers improve these phases by iterative meth-
ods, sometimes referred to as 'bootstrapping', whereby identifiable features in the electron 
density are successively included in the next round of map calculation. Within real space, 
the major method of phase improvement involves altering the model to fit the experimen-
tally determined electron density. The Fobs electron density map, calculated by combining 
the observed amplitudes with the calculated phase estimates from the search model, may 
initially only show a rough outline of the molecular envelope. 
The function is first modified to reflect known properties of protein and water within 
crystals. Knowing protein crystals generally contain about 50% water, the ratio of high 
to low density can then be adjusted to agree with that of protein to solvent. Commonly 
used techniques include 'solvent flattening', 'skeletonisation' and 'histogram matching'. 
Solvent flattening involves an algorithm that first defines the molecular envelope occupied 
by protein, and then averages out aberrations in the remaining unit cell contents to reflect 
the homogenous diffractive qualities of solvent. Skeletonisation then attempts to trace a 
continuos 'tube' of electron density within the envelope corresponding to the polypeptides 
main chain. These atoms are generally the most ordered and therefore expected to yield 
the most interpretable electron density. Regions of positive density not within a reason-
able bonding distance of this main chain model are then also down weighted to reflect 
the expected density of solvent. Histogram matching then matches the electron density 
function of successive atoms to resemble those of high resolution crystal structures in the 
PDB. This manipulated function describing the electron density is then input into Eciua-
tion 2.5 on page 29 to compute structure factors. These updated phases are then combined 
with the observed amplitudes for the next round of map calculation using Equation 2.6 on 
page 29. The old phases are not thrown out straight away, but are weighted in terms of 
their reliability, so as not to overly bias the data. If the new phase estimates are indeed 
better, the molecular envelope will be clearer and the cycle is repeated. If there is non-
crystallographic synuuetry present (NCS) , the map may also be improved by averaging 
the density over the different molecules within the asynnnetric unit, eflectively increasing 
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the signal to noise ratio and facilitating a clearer image of the molecule. Finding NCS 
within an asymmetric unit is another application of the Patterson map, referred to in this 
context as a self-rotation function. 
At some point in the phase improvement process, the map becomes clear enough to 
locate specific features of the model such as the shapes of amino acid side chains, which 
can then be used to calculate atomic structure factors instead: 
n 
Fhkl = ( 2 . 9 ) 
i=i 
Conversion from a density based model to one based on the coordinates of an atomic model 
greatly increases the number of refinable parameters however. If introduced too early, 
there is a risk of biasing the refinement process. This is especially likely when obtaining 
phases from molecular replacement, in which calculated phases from the phasing model 
may disproportionately influence the electron density. This effect is known as phase bias. 
Although the observed amplitudes of structure factors are capable of restoring missing 
information, it can be easily obscured by the inaccuracies within their calculated phase. A 
randomly assigned phase has a more profound effect on the electron density function than 
a randomly assigned amplitude does. If not detected, the crystallographer may mistake 
vestigial features from the phasing model as real, further reinforcing this error in subsequent 
calculations. It is therefore advantageous to use Fourier syntheses that minimize this bias 
as much as possible. Amplitudes in the Fourier sum of Fobs — Fcalc and 2Fohs — Fcaic are 
the most common. Using the Fobs — Fcalc coefficients as an example, electron density could 
be calculated: 
= i ^ ( | F o | - (2.10) 
hki 
where FQ are the observed structure factor amplitudes, and FC and aj.^ ;^  are the amplitudes 
and phases calculated from the model. Maps created using these types of Fourier syntheses 
are termed FQ — FC and 2Fo — F c maps respectively, and give the observed amplitudes the 
greatest chance possible of guiding the crystallographer to the correct structure. While the 
latter creates a 3-diniensional contour map into which the molecular model can be built, the 
former allows minor differences between the amplitudes of the calculated structure factors 
and those observed in the diffraction pattern to be visualised. The presence of a structural 
feature in the model that was not corroborated by the observed structure factors would 
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be reflected as a negative peak in the FQ - FQ map, whereas missing structural features 
in the map not accounted for by the model would create a positive peak. Often structural 
aberrations such as an incorrect amino acid side chain rotamer assignment, or the need for a 
main chain carbonyl flip, can be identified by the placement of a negative peak associated 
with the model, immediately adjacent to a positive peak over a neighbouring region of 
unfilled space. In this way, the working model can then be adjusted slightly vmtil local 
aberrations in the FQ - FC map subside, at which point the observed intensities match 
those calculated from the model almost exactly. The 2Fo - Fc map on the other hand is 
usually all positive, and gives the crystallographer a much more intuitive and interpretable 
guide to correcting the structure. Note that in Figure 2.9 on page 31, the missing feature 
of the tail is only restored at half occupancy. This only occurs when the phase estimates 
are almost correct. The factor of a half arises from the observed amplitudes only correcting 
the structure factor in the direction parallel to the calculated phase. Due to the error in 
it's phase angle however, it also requires correction in the perpendicular direction, and 
this correction is statistically likely to be equal in magnitude. This suggests that one can 
double the observed amplitudes and subtract from this those that are calculated. The 
resulting map should show features in the current model at full weight, but should also 
show the multiplied information from missing structural features at full weight as well. 
Some crystallographers prefer a 3Fo - 2Fc map for this purpose, a compromise between 
the two. Using the standard deviation and maximum likeliliood methods, weighting these 
map coefficients is also commonplace, to further guard against the introduction of bias. 
The equivalent to FQ — Fc maps in this case is rriFo — DFc maps, where rn is a figure 
of merit for each phase calculated from the model, and D is an overall estimate of atomic 
coordinate error. When the model has been fitted to the map to the best of their ability, 
specialized software can be used to further improve the model within reciprocal space. In 
some applications of this Fourier synthesis, D is replaced by a A- bi this instance, D has 
been corrected for completeness of the current model. 
2.5.5.3 Model building and refinement 
Once the phases have become accm-ate enough to allow the building of a near atomic 
model, interactive computer graphics can be used to manually place aberrant parts of the 
model into its respective electron density. These programs also contain numerous other 
features to assist in model building, such as 'real-space' refinement of amino acids into 
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electron density by the method of least squares, and a 'regularize' function, that imposes 
ideal bond lengths and angles to freshly rebuilt regions of the polypeptide. Throughout 
the course of this research, the program Coot |43] was employed for this purpose. 
When the crystallographer has fitted the model to the electron density to the best 
of their ability, the structure can be subsequently refined in reciprocal space. Due to 
the number of parameters to be fitted usually outnumbering the number of observations 
(reflections) recorded in macromolecular crystal diffraction, the refinement software also 
enforces realistic bond length and geometry constraints based on those of ultra-high resolu-
tion crystal structures. This effectively increases the 'observations', allowing the refinement 
process to be sufficiently overdetermined. Mathematically, the process of reciprocal space 
refinement minimises a function <&, whose form is: 
$ = J 2 ^ h k i ( \ F o \ - l F c l f h k l (2.11) 
hki 
bonds 
+ Y , Mdf""^ -
i 
angles 
where di is the length of bond i, and (pj is the bond angle at position j. Whkl is a weight-
ing term that reflects the accuracy to which these variables are known. Statistically, this 
would typically be defined as V^Ln where cjhki is the standard deviation from multiple 
measurements of \Fo\- Since a crystallographic dataset often does not contain sufficient 
measurements to calculate a standard deviation, other weighting schemes have been de-
vised. This function simultaneously minimizes the differences between (1) the observed 
and calculated reflection amplitudes, (2) model bond lengths and ideal bond lengths, and 
(3) model bond angles and ideal bond angles. Perturbations of parameters that make the 
model less realistic are therefore penalized. The parameters refined initially are tightly 
constrained by ideal geometries. As phase estimates become more accurate however, the 
Wi and Wj terms become smaller while the Whki term tends towards unity, gradually re-
laxing constraints on the structure as more experimental parameters are included in 
These include variables such as the temperature factor Dj, or _B-factor of each atom j (also 
known as the atomic displacement parameter), that quantifies the extent to which an atom 
oscillates about its specified position in the model due to thermal motion. Another is the 
occupancy nj of each atom j, that reflects the percentage of the crystal lattice occui)ied 
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by a group of atoms. Flexible side chains such as that of glutamate can often adopt al-
ternate conforniers within the crystal lattice. This phenomenon is most prevalent at the 
solvent interface of the polypeptide or in the vicinity of ligand binding. The term F c in 
Equation 2.11 on the preceding page can thus be expanded: 
F c = G - Y , • e-'^^I""®/^!', (2.12) 
i 
where G is an overall scale factor to convert all Fcs to a convenient value, rij is the 
occupancy of atom j and Bj is its temperature factor, whose effect is proportional to the 
angle of reflection [sill's/A]. 
As refinement proceeds, the agreement between the model and the raw diffraction data 
is commonly quantified with the residual index, or R-factor: 
D 11-^ ofcs I ~ I-fca/c 11 I'OIQ'i 
The R-factor essentially compares calculated amplitudes with those observed. The lower 
the R-factor, the better the agreement. To avoid 'overfitting' the data (refining more 
experimental parameters than there is experimental observations), the free R-factor is also 
employed, generally calculated from 5-10% of the measured reflections that are not refined 
against. This independently tests the ability of the model to predict reflection amplitudes 
that were not used to guide its refinement during previous Fourier transforms, and is 
generally regarded as a less biased quantifier of model accuracy. 
The structures presented in this dissertation where refined using the Refmac |44| and 
Phenix [45| programs, that both employ the maximum likelihood target fmiction during 
refinement. The latter even has a 'simulated annealing' option, which sinmlates heating 
the structure up and then cooling it down, allowing it to escape from local energy nnnima 
introduced by factors such as phase bias. 
This process of reciprocal and real space reflnenient of the structure was repeated until 
the reduction in R, and R-free values converged and in most places, the model flt the 
calculated electron density precisely. At this stage, the structure was validated using the 
program MolProbity |46|, or the comprehensive validation tools inbuilt into Phenix |45|. 
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Chapter 3 
The complex of hGSTOl with 
ascorbate: 
An active site binding mode suggestive of product inhibition 
Due to the considerable instability of the substrate clehydroascorbate, the product ascor-
bate was alternatively employed in crystallisation. It was aimed to discover the binding 
mode of the product at the conclusion of the catalytic cycle. One such experiment has al-
lowed the binding of this antioxidant to be characterised in the active site of hGSTOl , but 
in a mode indicative of a product inhibition mechanism. The implications for its proposed 
mechanism of enzymatic reduction are discussed. 
3.1 Introduction 
Although the reduction of oxidized vitamin C by hGSTOl-1 was initially reported over a 
decade ago [4], the expression and subsequent characterisation of hGST02-2 was initially 
problematic. Recent developments have since allowed its biochemical activity to be defined, 
and it's activity to this substrate was found to be approximately 100-fold greater than that 
of its previously characterised counterpart. In addition, a survey of published mannnalian 
dehydroascorbate reductase (DHAR) activity shows its activity to be far in excess of en-
zymes found in other mammals, suggesting this may be the main role of hGST02-2 within 
the body |25|. h G S T 0 2 shares a high level of sequence similarity with hGSTOl , including 
the active site cysteine residue at position 32 |14|. While the activity of l iGSTOl- l towards 
this substrate is lower than that of it's isozyme, the chemical mechanism and mode of bind-
ing is likely to be highly conserved between the two. Based on a previous characterisation 
of this reac:tion in the context of a mannnalian glutaredoxin |47|, the mechanism shown in 






A proposed mechanism of deliydroascorbate reduction by hGSTOl-1, based on the characterisation 
of this rection when catalysed by pig liver thioltransferase (glutaredoxin) [47|. 
HOH2C +H2O HOH2C 
Figure 3.2 
The hydration equilibria of DHA, in which the bicyclic hemiacetal hydrate 2, has been shown to 
predominate [48]. 
Figure 3.1 could be proposed. 
While the 1,2,3-tricarbonyl structure of dehydroascorbate (DHA) (left hand side of 
Figure 3.1) is the chemical form reported in many textbooks, the true nature of this species 
in solution is somewhat more complicated. Quantum mechanical calculations suggest that 
the tricarbonyl would only be stable for fractions of a second, and combined with evidence 
from crystal structures of various derivatives, and the H^ and C^^ NMR spectroscopy of 
this compound in solution, the most representative structure of this species is presently 
thought to be the hemiacetal hydrate 2 [48], shown in Figure 3.2. 
The conversion of ascorbate to this bicyclic intermediate is an inherently multistep pro-
cess that requires the loss of two electrons and two protons. The principal intermediate of 
this reaction is the radical species semi-dehydroascorbate (SDAH), CeOeHe'" . Although 
the precise structure of this anion-radical is unknown, it primarily participates in a dis-
proportionation reaction to give ascorbate and DHA. Kinetic analysis suggests that this 
mechanism features a dimer of unknown structure that participates in a reaction with 
hydrogen donors to yield the products (481. 
For clarity, DHA and its derivatives will continue to be represented in the tricarbonyl 
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form in subsequent discussions of mechanism. However, the reader is asked to keep in 
mind the complex interaction of cycHsation, radicahsation and dimerisation that would 
concurrently occur. 
Convergent genetic mapping has implicated the Omega class GSTs in early onset of two 
neurodegenerative conditions, Alzheimer's and Parkinson's disease |49, 22|, and hGSTOl-1 
has been shown to be the target of anti-inflammatory drugs affecting cytokines also impli-
cated in their pathogenesis |24| (Chapter 6 on page 131). This is provocative given that 
ascorbate is suspected to play a key role in protection from the oxidative stress implicated 
in the pathogenesis of these conditions. This may be of particular importance in the brain 
where its concentrations is most tightly regulated |50|. 
Soaking and co-crystallisation experiments with native hGSTOl has resulted in non-
diffraction and a failure to crystallise respectively. Experiments involving crystals of the 
C32A and C32S active site mutants were therefore employed, hoping that the resulting 
enzymatic inactivity would stabilise the binding mode of the product within the hGSTOl 
active site, allowing it to be visualised. Here, the cysteine 32 to serine active site mutant 
is presented in a high resolution crystal structure. Although an analogous binding mode 
is expected within the C32A mutant, no crystals of this isoform having been soaked or 
co-crystallised with the compound diffracted to a sufficient resolution to enable this to be 
confirmed. 
3.2 Experimental Protocols 
The C32S active site nmtant first needed to be made and cloned into the pHUE vector. 
After transformation, expression and purification. hGSTOl was co-crystallised with L-
ascorbate. Further details of each experimental step are outlined below. 
3.2.1 Site directed mutagenesis 
Mutagenic primers of 23 base pairs in length were designed with a svutable melting tem-
perature and obtained from GeneWorks Pty Ltd. KOD Hotstart polymerase (Novagen) 
and Pfu Turbo polymerase (Promega) were then used to perform multiple C32S mutagenic 
polymerase chain reactions (PGR) (Figure 2.1 on page 17) upon pGEM-T-hGSTOl tem-
plate. The methylation specific endonuclea.se, Dpnl (NEB), was subseciuently employed 
to digest template DNA before transforming electroporation comi)etent E. coli cells of 
strain DHScx with the mutagenic plasmids. These were immediately used to inoculate LB 
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F i gu re 3.3 
An ethidium bromide agarose gel visualisation of site directed mutagenesis products, post Dpnl 
digestion. All even numbered lanes were loaded with PGR reactions containing 4 ng of 
pGEM-T-/iG5T0i template, all odd numbered lanes were loaded witii reactions containing 2 ng. 
The PGR products loaded in lanes 1,2, 7 and 8 were performed using Pfu Turbo polymerase 
(Proraega), those in the remaining lanes used K O D Hotstart polymerase (Novagen) instead. 5 ^L of 
each 50 reaction was loaded in each lane. 1 fil. of NEB 2-log DNA ladder was loaded in the lane 
on the far left. A reference figure indicating the size of each band in the ladder is shown adjacent. 
agar plates (0.2 mg/ml Ampicillin) that were incubated face down overnight at 37°C. The 
next morning, single colonies were used to inoculate 10 ml cultures of LB (0.2 mg/ml 
Ampicillin). Subsequent to a 'MiniPrep' (Qiagen) purification of plasmid, the success of 
the reactions was confirmed via separation on a 1% agarose gel in electrophoresis buffer, 
containing 0.5 //g/ml of ethidium bromide. The gel was subseciuently visualised with a UV 
transilluminator at 366 nm. (Figure 3.3). Plasmid from 6 of the 8 rrmtagenesis reactions 
performed was observed at the expected positions relative to the simultaneously loaded 
'2-log' DNA ladder (NEB). A complementary Xmal/SacI (NEB) digestion of this DNA 
was then used for gel purification of the insert fragment, and subsequent ligation into the 
pHUE vector as described in Section 4.2.1 on page 66. The desired TGC to TCC (serine) 
mutation was then confirmed unequivocally by DNA sequencing (Figure 3.4 on the next 
page). 
3.2.2 Purification of h G S T O l C32S 
The purification procedure used to obtain protein for crystallization was as follows. The 
\)\{\]E-hGST01 C32S plasmid was transfected into E. coli cells of strain BL21 via elec-
troporation. Streaking onto an LB agar plate containing 0.2 mg/ml of Ampicillin and 
incubating face down overnight at 37°C resulted in multiple single colonies. One of these 




The DNA sequencing chromatograrn of the cysteine 32 to serine active site mutation unequivocally 
confirming the TGC (cysteine) to TCC (serine) nucleotide permutation. The forward and reverse 
primers used to introduce the serine residue are also shown above its sequence. The corresponding 
trinucleotide is shown with a bar, with the mutagenic nitrogenous bases highlighted in red. 
colonies was then used to inoculate a 50 mL starter culture of LB (also containing 0.2 
mg /m l of Ainpicillin), before subsequent shaking at 37°C overnight. 10 niL aliquots of this 
starter culture were then used to inoculate five 1 L volumes of LB (0.2 mg/ni l Ampicillin) 
in culture flasks. These were then grown at 37°C with gentle shaking until their optical 
density reached «0 .6 at 600 nni. At this point, hGSTOl expression was induced via the 
addition of Isopropyl [3-D-l-thiogalactopyranoside ( IPTG) to a final concentration of 50 
^ M , and the cultures grown for an additional 3 hours. Cells were subsequently pelleted via 
centrifugation in a 8K-10 centrifuge (Sigma) at 5000 rpm for 30 minutes using a Nr.12510 
rotor. The cellular pellets were then transferred to a large beaker and frozen at -20°C. 
Except were noted, all subsequent steps were performed at 4°C. The following day, the 
pellets were thawed in ice, followed by resuspension in Buffer A (300 n iM NaCl, 50 m M 
Sodium Phosphate, 20 m M imidazole 10% Glycerol, pH 7.5) containing 0.3 n iM of the pro-
tease inhibitor 4-(2-Aniinoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) using a 
magnetic stirrer and bar. Lysis was then mediated via a French pressure cell. Cell debris 
was pelleted by centrifugation in a RC5C centrifuge (Sorval) at 15 000 rpm for 20 minutes 
using a SS-34 rotor. Floating nuclear material was removed with a pipette before the su-
pernatant was vacmun filtered through 0.45 fan filter paper. The filtrate was then passed 
through a pre-packed 5mL His-trap HP (GE Healthcare) Ni-NTA colunm. An FPLC medi-
ated imidazole gradient from 20-500 niM in Buffer A was then used to elute boiuid protein. 
Fractions containing eluted protein were indicated by an absorbance change at 280 nm and 
were subsequently checked for purity with SDS-PAGE (room temi)erature). The combined 
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fractions found to contain hGSTOl-1 in sufficient purity were then dialysed overnight in 5L 
of Buffer A, using pre-equihbrated 12 kilo Dalton (kDa) molecular weight cut off (MWCO) 
dialysis tubing. The next day, the purified Ub-hGSTOl-1 fusion product was removed 
from dialysis. The deubiquitylating enzyme and dithiothreitol (DTT) was then added to 
final concentrations of 25 /ig/ml and 1 mM respectively. The cleavage reaction was al-
lowed to proceed for 2.5 hours with gentle shaking before dialysis in Buffer A to remove 
the imidazole and DTT (the latter would reduce the Ni2+ within the Ni-NTA resin and 
cause precipitation). A subsequent pass through the Ni-NTA column facilitated selective 
removal of cleaved Ub, uncleaved Ub-hGSTOl-1 construct and co-purified contaminants. 
hGSTOl-1, now devoid of an affinity tag, was collected in a high purity and yield in the 
flow through as judged by SDS-PAGE (room temperature). Protein solutions were then 
dialysed overnight in a final dialysis buffer of 60 mM NaCl, 20 mM Tris, 5 mM DTT, 
pH 8 before concentrating to 25 mg/ml using a 10 kDa cutoff Amicon Ultra centrifugal 
device (Millipore, Cork. Ireland). Protein concentration was finally determined using a 
NanoDrop 'ND-1000' spectrophotometer (NanoDrop Technologies) via absorbance at 280 
nm (room temperature). Molar extinction coefficients were calculated using the Swiss-Prot 
Proteomics server |51|. 
3.2.3 Crystallisation, data collection and processing 
The C32S active site mutant was crystallised using the hanging drop, vapour diffusion 
method as previously described (Section 2.5.1 on page 24), with the following exceptions. 
A precipitant versus pH screen found that optimal crystal growth was slightly different to 
that previously published |4|: 2.2 M (NH4)2S04 and 100 mM Sodium Acetate, pH 4.75. 
This may have been due in part, to these crystals being grown in the presence of 100 mM L-
ascorbate and a-tocopherol succinate (vitamin E) (Table 3.1 on the next page). The latter 
was included in this experimental design due to reports of it acting as an uncompetitive 
inhibitor of hGSTOl-1 rnonomethylarsonate reduction (Chapter 4 on page 61) [52, 53|. As 
the binding site of methylarsenate species and dehydroascorbate were expected to be the 
same, it was hypothesised that the tocopherol ester may also be an uncompetitive allosteric 
inhibitor of hGSTOl-1 mediated dehydroascorbate reduction, and therefore stabilise the 
enzyme-product complex. The affect of this inhibitor if any, was not observable in the 
resulting crystal structure. 
Cryoprotection was via transfer of the crystal from the crystallization drop, to an equal 
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Crystallisation Experimental Parameters of hGSTOl C32S-ascorbate 
complex. 
Reservoir solution 2.2 M (NH4)2S04 
100 niM Sodium Acetate pH 4.75 
Crystallisation drop 1 jjlI hCSTOl - l C32S 
1 100 niM L-ascorbate 
1 [il Saturated aqueous a-tocopherol succinate. 
1 reservoir 
Cryoprotectant solution 2 M Li2S04 
100 niM L-ascorbate pH 4.75 
5 niM cx-tocopherol succinate in acetone (5% v / v ) 
2.5% (v /v ) Glycerol 
Data collection 
Resolution limits, A 30.0-1.70 (1.76-1.70^) 
Space group P3i21 
Unit Cell. A a - b - 5 6 . 9 2 c-140.51 
Total reflections 215 202 
Unique reflections 29 768 
Completeness, % 99.2 (98.7^) 
I ' a 40.9 (4.14t) 
Redundancy 7.2 (7.3^) 
Refinement 
R-work/Rfreei % 16.9/21.2 
rrnsd bonds, A 0.019 
rmsd angles, ° 1.641 
Number of waters 205 
Ligands L-ascorbate, glycerol, acetate 
T the highest resohitioii shell (1.76-1.70 A ) . 
Table 3.1 
Crystallisation and structure determination statistics of the hGSTOl C32S-ascorbate complex. 
sized drop of the cryo-solutioii. Litliiuni. rather than aniiiionium sulfate was used, due to 
its ability to suppress crystal formation at low temperatures. In addition, cx-tocopherol 
succinate was added from a 100 niM acetone solution to avoid precipitation. The resultant 
5% concentration of acetone also served to contribute to the cryoprotection of the solution 
already afforded by the 2.5% concentration of glycerol. Further details of the crystalli-
sation and cryoprotection conditions are outlined in Table 3.1. Data was subsequently 
collected with X-rays of an energy of 13001.10 electron-volts (eV), using the PX2 protein 
crystallography beamline at the Australian Synchrotron, Melbourne, Australia. 
The diffraction data was indexed, measured and scaled with the HKL2000 package |42|. 
Phase estimates were calculated from the previously published native structure (PDB iden-
tifier: lEEM) |4|. Subsociuent model building and refinement was performed alternatively 
with Coot |43| and either the Refmac |44| or Phenix |45| programs, respectively. 
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3.3 Results and Discussion 
Seen to be undergoing a jz-stacking interaction with phenylalanine 34, the 1.70 A structure 
shows ascorbate residing 5 A from the mutated C32S residue, occupying a portion of the 
'G-site' typically inhabited by the y-glutamate moiety of glutathione [4|. The other side of 
the carbon heterocycle is accommodated by a hydrophobic interaction with the side chain 
of L71. The only significant structural perturbation is the alternate conforniers of E85. In 
addition to the rotamer previously interacting with the 7-glutamyl amine of glutathione [4|, 
the binding of ascorbate has evoked its movement by several angstroms with an occupancy 
of 0.45 (Figure 3.5 on the facing page). The new conformer concurrently engages in polar 
interactions with the c-6 (for numbering please see Figure 3.1 on page 44) hydroxyl of 
ascorbate and the side chain of S86. The main chain amide of the latter also forms a 
hydrogen bond with its c-5 hydroxyl. Other interactions within the active site include 
a hydrogen bond between its c-3 hydroxyl group and the backbone carbonyl of V72. A 
secondary interaction between the introduced S32 residue and the c-2 hydroxyl of ascorbate 
is also mediated by an acetate molecule, observed 2.65 A from the serine hydroxyl group 
(Figure 3.6 on page 52). 
The observed proximity of the enzymatic product to the active site residue, in this 
case artificially mutated to a serine, is suggestive that this binding mode is physiologically 
relevant. It's occlusion of the G-site however, implies this may not be a mode of binding 
relevant to catalysis, but may instead be suggestive of product inhibition. In the mechanism 
proposed (Figure 3.1 on page 44), generation of ascorbate is coupled to the formation of 
a mixed disulfide between the active site cysteine and glutathione. This would be difficult 
to reconcile with the mode of ascorbate binding observed, since it is the same position 
observed to accommodate the glutathionyl functionality of this disulfide in the hGSTOl 
native crystal structure |4|. Likewise, the observed binding mode of the product is imlikely 
to be transposable to a preliminary docking position of the substrate, since the removal of 
conjugation between the 1-carboriyl and the 2,3-alkene within the heniiacetal heterocycle 
(Figure 3.2 on page 44) destroys its planarity, both of which would make the equivalent 
TT-stacking interaction with the side chain of F34 unfavourable (Figure 3.6 on page 52). The 
crystal structure might therefore feature within a negative feedback loop, inhibiting the 
generation of ascorbate when its intracellular concentration becomes too high by blocking 
entrance to the G-site. Such a mode of binding would have been encouraged in this 
experiment by the artificially high concentration of ascorbate present (100 mM). 





The observed binding mode of L-ascorbate in tlie active site of hGSTOl. The 2mFo - DFc 
electron density map corresponding to ascorbate and the adjacent acetate molecule is depicted as 
contoured isomesh at a level of la . A translucent molecular surface, highlighted in magenta, 
demonstrates the shape of the binding pocket. The hGSTOl fold is shown as a cartoon 
representation with relevant side chains as sticks, coloured according to element. The alternate 
conformers of E85 were refined with equal occupancy. 
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Figure 3.6 
A view of L-ascorbate binding equivalent to Figure 3.5 on the preceding page, with the molecular 
surface removed and polar interactions shown as dashed lines. The crystallographically observed 
distances of each is given in A . Solvent molecules have been omitted for clarity. 
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Indeed, such a hypothesis has precedence in the hterature. Kinetic studies of the DHAR 
of spinach chloroplasts has indicated uncompetitive inhibition by 20 mM ascorbate with 
respect to dehydroascorbate. GSSG was also found to participate in product inhibition, 
as a competitive inhibitor with respect to dehydroascorbate, and a mixed type inhibitor 
with respect to GSH |54|. This plant DHAR shares 28% and 62% sequence identity and 
similarity with hCSTOl respectively, and the two are likely to have evolved from a common 
ancestor. Both contain a conserved C-P-F-X-X-R active site motif (Figure 3.8 on page 56) 
and a search of the Conserved Domain Database (CCD) |55] revealed a shared G S T _ C 
domain (Figure 3.9 on page 57). 
In light of this primary, and hypothesised secondary structural similarity, the catalytic 
mechanism of dehydroascorbate reduction in the two enzymes may also be conserved. The 
kinetic analysis of dehydroascorbate reduction by spinach chloroplast DHAR suggested a 
bi-uni-uni-uni-ping-pong mechanism analogous to that shown in Figure 3.1 on page 44: 
the initial binding of dehydroascorbate forming a cysteinyl-thioketal complex, followed by 
nucleophilic attack of GSH to yield a mixed disulfide and the reduced product. The active 
enzyme is then rejuvenated by another molecule of GSH, concurrently producing GSSG 
in the process. The kinetic analysis of product inhibition by GSSG mentioned above is 
consistent with this sequence of substrate binding and product release [54|. 
This mechanism is disputed however, by other authors studying the functional diver-
gence of GSTs in plants, who discovered 3 novel DHAR enzymes in Arabidopsis thaliana 
|56l, based on sequence similarity to liGSTOl. Using hGSTOl as the query sequence of 
a BLAST (Basic Local Alignment Search Tool) search identified a sequence in rice with 
DHAR reductase activity (GenBank'^^' accession immber AB037970). Using this sequence 
to search the genome of A.thaliana resulted in four related sequences, one of which was 
later discovered to be a pseudogene, showing 60-70% sequence similarity with the rice gene. 
Subsequent cloning, expression in E.coli and Ni-affinity chromatography piu'ification re-
sulted in enzymes showing high DHAR activity (2000-15 600 nanokatals . mg^^protein) 
and moderate thioltransferase activity when assayed with HED (2-hydroxyethyl disulfide) 
(15-131 nanokatals . mg^'^protein). Like hGSTOl, the conserved active site cysteine was 
shown to be essential to both activities, and lacked the glutathione conjugation activity 
towards CDNB characteristic of most other GSTs |56|. In contrast, this study could not 
find evidence of product inhibition by ascorbate, although the assayed concentration (5 
niM) was lower than that used in the study of spinach DHAR |54| (20 niM) or the struc-
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tural findings presented here (100 rnM). While the enzyme-GSH mixed disulfide of the 
reaction mechanism could be observed using ESI-TOF MS (electrospray ionisation time of 
flight mass spectrometry), the intermediacy of the hypothesised thioketal-enzyme covalent 
intermediate could not, and no evidence of this species could be found in other studies. 
This led the authors to propose a new mechanism based on single electron transfer (SET) 
(Figure 3.7 on the next page). Such a process would include the generation of SDAH. 
A known intermediate, its resonance stabilisation gives rise to the powerful anti-oxidant 
properties of ascorbic acid. Subsequent abstraction of hydrogen from the cysteinyl-thiol 
of GSH would be consistent with the well established ability of thiol compounds to act as 
hydride donors during radical reactions. The resulting thiyl radicals, GS" and ES", would 
then spontaneously react to yield the ESSG mixed disulfide, observed in the AtDHARs 
{Arabidopsis thaliana dehydroascorbate reductases) by ESI-TOF MS, and in the hGSTO l 
crystal structure |4|. In support of this mechanism, the authors cited chemical studies 
on dione systems analogous to dehydroascorbate, suggesting initial attack of the cysteine 
(Figure 3.1 on page 44, step 1) would lead to a dead-end thioketal-enzyme complex [57|. In 
addition, the known SET reductants Cu(I) and Fe(n). were recently shown to be capable 
of reducing L-dehydroascorbic acid to L-ascorbic acid, and its c4 epinier, L-erythroascorbic 
acid [58|. Both of these species are also formed in the non-enzymatic reaction of dehy-
droascorbate with GSH, indicating that a stereospecific delivery of hydride to the enolic 
tautomer of the radical intermediate would feature as part of the catalytic mechanism 
(Figure 3.7 on the next page) |56|. If accurate, the high level of sequence conservation ob-
served between plant DHARs and enzymes of disparate species such as hGSTO l suggest 
it may be a conserved mechanism, evolved from an ancestral fold responsible for binding 
GSH. The high degree of sequence similarity between the divergent plant D H A R and GST 
enzymes with hGSTOl is exemplified graphically in Figure 3.8 on page 56. 
It should be noted that the BLAST search with the hGSTOl sequence by Dixon et.al, 
[56| also discovered the proteins In2-1 in maize and Cla30 in wheat. These also bear 
sequence similarity to GSTs, contain a cysteine active site residue within a conserved GSH 
binding site and lack conjugating activity to CDNB. Subsequent BLAST searches with their 
respective gene sequences revealed that they are more similar to the mammalian Omega 
class than any plant GST, but were sufficiently different to justify classification within their 
own class, designated A (Lambda). Searching within the A. thaUana genome with the In2-
1 gene sequence revealed two sequences of a high homology, designated gstll and gstl2. In 
















The SET mechanism of dehydroascorbate reduction as proposed by Dixon eta/.,[56). A similar 
mechanism is observed non-enzymatically in which both c4 epimers of ascorbic acid are generated 
|58|, implying that the enzymatic mechanism would feature the si face specific delivery of hydride to 
the enolic tautomer of the second intermediate [56]. 
contrast to the AtDHARs, cloning and purification of the resulting gene products resulted 
in polypeptides that displayed no dehydroascorbate activity, but retained thioltransferase 
activity as assayed with HED [56]. 
While the specific activity of liGSTOl-l towards this substrate is approximately 3-
fold lower than that observed for MMA^, the dehydroascorbate activity of hGST02-2 has 
been found to be 70-100 fold higher. There is 64% sequence identity shared by the two 
enzymes [17], and by comparing the ascorbate bound structure of hGSTOl with the apo-
coordinates of liGST02 (Dr. Huina Zhou, unpublished data), it appears that all but one of 
the side chains associated with ascorbate binding are conserved. The lone exception is the 
replacement of leucine 71 with a histidine in liGST02, indicating an important contribution 
of this residue to the varying activity towards dehydroascorbate observed. Another feature 
of interest is the shift in helices a9-10 by several angstroms to provide a more 'open' active 
site within the hGST02 structure. The labile nature of this C-terniinal extension was also 
observed when comparing the 3 monomers within the asymmetric unit of the hGST01A155 
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I^PESLPIyKS»«p»IF|RDSFVK|IMlfDVIAaWAKHTS 266 M1VPESFP|V«NMTLF1IJ)SPEK1|HEKYVISGWAPKVNP 213 
VDBXPKLKLWMAAl«EDP|VSALLT|EK|vateFLELlLQNSPE*<|BaL - 241 
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|ElIIGRPNLAAIHEQIINKllVAaQiB|s|YVVNiFKRFM 235 250 260 270 280 290 
Figure 3 . 8 
T h e sequence comparison of liuman G S T omega enzymes with related D H A R |54, 59, 56| and G S T L 
[56] enzymes from plants discussed in the text. A m i n o acid residues are coloured according to 
chemical commonal i ty and corresponding sequence similarity is indicated by the gray co lumn graph. 
The highly conserved active site moti f is highlighted by a red box. This highly conserved sequence 
similarity between plant and mammalian enzymes involved in dehydroascorbate reduction may be 
reflective of a structure and mechanism that has survived divergent evolution from an ancestral fold 
associated with G S H binding. This figure was generated using the program ClustalX |60|. 
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Chain A, Glutathione Transferase From Homo Sapiens 
gi l l0120947lpdb l lEEMIA 
.lii.... 100 il20 ,140 1160 1150 1200 
1 : 241 (241 residues shown) 
JIL. 120 [140 |160 |200 |220 241 
Sequence 1EEM_A: Chain A, Glutathione Transferase From Homo Sapiens 
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B dehydroascorbate reductase [Spinacia oleracea] 
gill0952512lgbl AAG24945.1 lAFl 95783_1 
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1 : 266 (266 residues shown) 
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Sequence AAG24945.1; dehydroascorbate reductase [Spinacia oleracea] 
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F igu re 3.9 
The observed sequence similarity between omega class GSTs and plant enzymes involved in 
dehydroascorbate reduction (Figure 3.8 on the facing page) is exemplified by commonalities within 
the C D D |55|. A comparison of conserved domains within hGSTO l witli the DHAH. of spinach 
chloroplasts |54| (A and B respectively) demonstrates a conserved G S T _ C domain and GSH 
binding motif. The graphical representations of conserved structural domains above was generated 
by the graphics interface of the National Centre for Biotechnology Information (NCBI) proteins 
database (http://www.ncbi.nhn.nih.gov/guide/proteins/). 
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crystal structure (Appendix A on page 181), and may play an essential role in catalysis. 
Interestingly, this region contains a conserved tyrosine residue, at position 229 and 230 in 
l iGSTOl and h G S T 0 2 respectively, that could function as the yet unidentified hydrogen 
bond donor (Section 1.1.3 on page 8) responsible for stabilising the C32 or GSH associated 
thiolate during omega mediated catalysis (Figure 3.10 on the next page). While it's position 
and rotamer conformation within Omega structures to date have shown it to be outside the 
range of hydrogen bonding, the apparent mobility of the C-terminal domain may facilitate 
this interaction to occur. A survey of published mammalian dehydroascorbate reductase 
activities indicates that h G S T 0 2 is far in excess of other enzymes previously characterised 
[25|, implying it may be the principal enzyme facilitating the regeneration of this essential 
antioxidant within the body. 
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Figure 3.10 
The h G S T O l active site coinplexed with ascorbate (Figure 3.6 on page 52) compared to that of 
h G S T 0 2 . The Structural fold of h G S T O l is shown in a cyan cartoon with amino acid side chains 
expected to be relevant in dehydroa-scorbate reduction shown in stick representation, coloured 
according to atom type. The equivalent residues and fold of h G S T 0 2 is overlayed in magenta. An 
abstracted view of the active site allows visualisation of the conformational shift of the labile 
C-terminal extension comprised of Q-helcies 9 and 10. Structural plasticity of this region Wcis also 
implicated in the structural and folding studies of the hGST01A155 enzyme we have recently 
published (Appendix A on page 181). It is possible this movement may facilitate the stabilisation of 
an active site thiolate in the native enzyme via translocation of a conserved tyrosine resichie (at 
'positions 229 and 230 within h G S T O l and h G S T 0 2 respectively) to within hydrogen bonding 
distance of the active site cysteine, or a molecule of GSH during catalysis. 1 am indebted to Dr. 
Huina Zhou for allowing me to use the coordinates of h G S T 0 2 prior to publication. 
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Chapter 4 
hGSTOl-1 complexed with 
methylarsonate reduction 
intermediates: 
Evidence for the glutathione intermediate pathway of human 
arsenic biotransformation 
Two high quahty crystal structures contain organic arsenic species in the active site of 
h G S T O l , and the identity of these species was unequivocally confirmed by anomalous dif-
ference electron density. As these crystal structm-es involve the C32A active site mutation 
of the enzyme, it was expected that the bomid substrate, monomethylarsonate, would 
be observed relatively unmodified. Strikingly, the observed compounds appear to be the 
non-enzymatic products of methylarsonate reduction. The dithiol D T T , present in the 
experimental conditions, appears to have been sufficient to reduce the arsenic center to the 
• 3 oxidation state, while the unaffected glutathione conjugating activity of the enzyme 
has allowed substitution of its hydroxyl ligands with molecules of GSH. These structiu'cs 
confirm that the hGSTOl active site has a hight affinity for trivalent mono-, and pos-
sibly diglutathionyl methylarsenite, suggesting they would feature during it's catalysis. 
Implications to the understanding of human arsenic metabolism are discussed. 
Coincidentally, one of the crystal structures has also revealed a derivative of the model 
substrate, CDNB, concurrently revealing several aspects of the active site dynamics within 
the 'H-site', implicated in its catalysis. 
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4.1 Introduction 
Through the work of Frederick Challenger and his colleagues in the first half of the twen-
tieth century |61|, a conceptual model of the mammalian metabolism of inorganic arsenic 
(iAs) was developed that involved successive cycles of reduction, followed by oxidative 
rnethylation. Consistent with this hypothesis, Crecelius [62] was the first to conclusively 
observe methylated arsenicals in the urine of volunteers who ingested water or wine con-
taining iAs'" or iAs^. Contemporary research that observed these species in the urine of 
humans exposed to an environmentally high arsenic burden |63, 64, 65] was also consis-
tent with this hypothesis. While the main metabolites were found to be the pentavalent 
species, monomethylarsonate (MMA^) and dimethylarsinate (DMA^), some authors also 
reported the presence of the trivalent monomethylarsenite (MMA'") and dimethylarsinite 
(DMA'") as well. While Purine Nucleoside Phosphorylase (FN?) purified from human 
liver was found to reduce iAs^to iAs'" in the presence of the natural dithiol lipoic acid, 
it was unable to do so given organic varieties of pentavalent arsenic as a substrate ]66]. 
The subsequent discovery that Omega GSTs were capable of catalysing this step in the 
proposed biotransformation lead to the proposal of the scheme shown below (Figure 4.1a 
on the facing page) ]25]. 
This scheme has had to be reconsidered however, in light of recent findings that a 
common synthetic method used to create the organic trivalent arsenical standards of the 
HPLC (high pressure liquid chromatography) chromatographic coelution TCP-MS (induc-
tively charged plasma mass spectrometry) method of identification ]67], results in a thiol-
containing arsenical as the major product ]68]. Indeed, it has become apparent that the 
MMA'" and DMA"' identified in urine, were likely the hydrolysis products of the corre-
sponding complexes with GSH and that furthermore, the presence of methylated pentava-
lent arsenicals may have resulted from their spontaneous oxidation subsequent to sample 
collection ]69]. Chromatographic experiments under conditions aimed to replicate those 
of a protein-free mammalian hepatocyte cytosol, indicates that trivalent arsenicals spon-
taneously form complexes with GSH and that the methylated varieties of these complexes 
are more stable than their inorganic counterparts [70]. It is now clear that trivalent, diglu-
tathionylated arsenicals, are obligatory substrates of the enzyme responsible for arsenic 
methylation in humans, Arsenic 3-t- methyltransferase (hAS3MT, also known as cytl9) 
]7f, 72]. This has led to a new scheme of arsenic metabolism being proposed by Hayakawa 
and colleagues (Figure 4.1b on the next page) ]71|. The results of this research suggest that 
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Hayakawa et ai, |71|. 
F i g u r e 4 . 1 
Two contemporary schemes describing the biotransformation of iAs within the human body. (PNP; 
Purine Nucleoside Phospliorylase, As3MT; Arsenic(III) Methyltransferase, SAM; S-adenosyl 
methionine, SAHC; S-adenosylhomocysteine, GSAHC; glutathionyl S-adenosylliomocysteine, 
ATG; arsenic(III) triglutathione, MADG; methyl arsenic(III) diglutathione, DMAG; 
dimethyl arsenic(III) glutathione). 
of these two postulates put forth in the hterature to describe iAs metaboUsin in humans, 
the latter is the most physiologically accurate. 
The particular affinity of arsenic for thiol ligands was first identified in studies involving 
its toxic effects on nucleated red blood cells in the early 1900s, and evidence indicating that 
its target may be the thiol dependent urease [73]. This eventually lead to an antidote to 
Lewisite (chlorovinyldichloroarsine), a war gas that was developed in the period between 
the World Wars, but was never extensively deployed. Starting in 1939, British scientists 
used their fundamental understanding of As-thiol biochemistry to design dithiols capable of 
complexing this toxin and removing it from the body. The result was British Anti-Lewisite 
(2,3-dirnercaptopropanol), an early attempt at directed drug design |73|. 
Chronic arsenic poisoning via contaminated drinking water is currently a global health 
pandemic [18|. At present, approximately 100 million people in India, Bangladesh and 
other developing nations are drinking water that contains iAs at levels up to 100 times the 
safe limit of 10 ng per liter advised by the World Health Organisation (WHO) |74|. The 
ingestion of arsenic occurring in these parts of the world have been referred to as the largest 
mass poisoning in history |75|. The resulting toxicology of this vast population includes 
the increased development of skin lesions, heart disease and several cancers, although little 
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The pathomechanism of acute promyelocytic leukemia as described by SC Kogan |80|. 
is known about how these pathologies are affected [71, 76|. 
Paradoxically, the metabolism of arsenic has also become of considerable interest due to 
its recent use as a therapeutic. Although used in traditional Chinese medicine for thousands 
of years [77], arsenic trioxide (ATO) has recently been employed in the treatment of acute 
promyelocytic leukemia (APL) to dramatic effect (Figure 4.2). As the most malignant 
form of acute leukemia, its symptoms include a severe bleeding tendency and fatality often 
in a matter of weeks. In combination with all-trans retinoic acid (ATRA) however, this 
quite simple compound has allowed the percentage of complete remission to be raised 
beyond 90% [78]. The cause of APL is a translocation mutation between chromosomes 
15 and 17, resulting in a fusion of the promyelocytic leukemia (PML) and retinoic acid 
receptor alpha (RARa) genes (Figure 4.2) [79[. While the native P M L protein is considered 
a tumour suppressor, regulating the expression of genes involved in differentiation while 
compromised DNA is repaired, the resulting fusion product has quite the opposite effect. 
Joined to RARct, it's ability to block cellular differentiation at numerous places within the 
genome becomes constitutively turned on and tfie differentiation from promyelocytes to 
mature neutrophils is blocked. This results in the unchecked replication of these immature 
white blood cells and subsequent leukemia [8()[. Although previous research has shown 
that the cytotoxic effect of ATO may be associated with the generation of reactive oxygen 
species (ROS) [81[[82[, conclusive studies have recently demonstrated that the efficacy of 
ATO is principally via direct binding to cysteine residues within the 'zinc-finger' DNA-
binding region of PML. Combined with ATRA binding to RARot, this is thought to cause a 
conformational change that favours interaction with small ubiquitin-like protein modifiers 
(SUMOs), marking the polypeptide for degradation |83||84[. 
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PMLs role in regulating gene expression has also been implicated in other forms of can-
cer. Chronic myeloid leukemia (CML) for instance, exemplifies the hypothesis that some 
leukemias are sustained by a core population of cells that posses stem cell like character 
and are resistant to conventional therapy. Evidence of these 'Leukemia Initiating Cells' 
(LICs) continues to grow, and it has been suggested that they are at the source of many 
relapses. After conventional therapy has appeared to eradicate the cancer cell population, 
it is thought that this quiescent population again propagates the disease after a period of 
latency. Targeting PML has been shown to eradicate such cells [85]. PML has also been 
shown to be a key regulator of the p53 tumour suppressor, mutations in which are the 
most common genetic factor in human cancers. PML actively increase the transcription 
of mutant p53 and is important in the development of the oncogenic 'gain of function' 
properties it often displays [86|. This raises the possibility that this highly effective treat-
ment of APL, in combination with the current treatment of these forms of cancer, may 
reduce their malignancy and minimise the probability of relapse. A principle objective 
of this research was to resolve the chemical species of arsenic resulting from l iGSTOl- l 
catalysis, since it may be these and/or other metabolic derivatives of ATO that affect 
its anti-cancer properties via interaction with PML. A synthetic glutathione derivative of 
trivalent arsenic, para-4-[N-(S-glutathionylacetyl)amino|phenylarsenoxide, displays potent 
cytotoxic anti-cancer activity and is currently undergoing clinical trials |87|. 
Soaking of native l iGSTOl crystals with high concentrations of MMA^ and DMA^ 
consistently resulted in an inability to observe the arsenicals bound in the h C S T O l active 
site. This result was independent of the omission or inclusion of glutathione at varying 
concentrations, and similarly unresponsive to combinations of the methylated arsenicals 
with the substrate analogue, glutathione sulfonic acid. Similarly, co-crystallisation ex-
periments with these arsenicals in the presence or absence of glutathione, or its inactive 
analogue, were also unsuccessful. Analogous experiments with the C32S mutant were also 
unproductive. The reasons for this are unclear, but will be discussed in more detail below 
(Section 4.3 on page 71). Soaking and co-crystallisation experiments with the C32A mu-
tant however, did achieve a crystallographic observation of arsenic in the h C S T O l active 
site, and was unequivocally confirmed \ising anomalous difference density (Section 2.5.4 
on page 33). Despite the enzymatic inactivation resulting from the mutation, the arsenic 
centre was surprisingly discovered with an altered oxidation state and ligand substitution. 
Here, two high cjuality crystal structures are presented. The first confirms the specific 
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binding of glutathionyl methylarsenite in the hGSTOl active site, while the second sug-
gests a high affinity for diglutathionyl methylarsenite as well. Through a serendipitous 
combination of experiments on a single crystal, the former has also revealed the binding of 
an entirely different compound: several angstroms away from glutathionyl methylarsenite, 
residing in the hitherto putative H-site, a derivative of the model compound CDNB was 
observed, l-hydroxy-2,4-dinitrobenzene (HDNB). 
4.2 Experimental Methods 
The alanine active site mutant had previously been made by my colleague Majorie Coggan 
|17], but first needed to be transferred to the expression vector pHUE [37] (Figure 2.2 on 
page 19 and Section 2.2 on page 18). Subsequent to expression in E. coli and purification 
by Ni-affinity chromatography, the binding of MMA^ to the hGSTOl active site imitant 
was investigated via co-crystallisation and soaking experiments involving various concen-
trations of MMA^, GSH and (tris(2-carboxyethyl)phosphine) (TCEP). In a particular 
co-crystallisation experiment, a crystal grown in the presence of MMA^ was subsequently 
'back soaked' in a solution containing CDNB and GSH, yielding unexpected results. 
4.2.1 Cloning of hGSTOl C32A into the pHUE vector. 
The alanine active site mutant was obtained in the pQE30 plasmid (Qiageri) and had to be 
cloned into the pHUE expression vector before protein could be purified for crystallisation. 
This was achieved via a complementary Xmal/Sad (NEB) mediated restriction digest of 
both. The digestion products were then separated on 1% agarose gels in electrophoresis 
buffer, both containing 0.5 ^ g^/m\ of ethidium bromide. The gels were subsequently visu-
alized with a UV transilluminator at 366 nm. While the digested pHUE vector was easily 
discernible from a digest of DNA equivalent to 1 niL of overnight culture, digested DNA 
equivalent to 10 rnL of overnight culture was needed to observe the hGSTOl cysteine 32 
to alanine insert fragment. Both were found at the expected positions relative to the si-
multaneously loaded 'GeneRuler' DNA marker (Fermentas), visualized at 5.9 Kb and 0.7 
Kb, respectively. After careful removal with a scalpel, the DNA fragments were purified 
using a 'QIAquick gel extraction kit' (Qiagen). Ligation with T4 DNA ligase (Roche) 
was then performed, followed by transformation into heat shock competent E. coli cells 
of strain XLIBL. These were inmiediately used to inoculate a LB agar plate (0.2 ing/ml 
Ampicillin) that was subsequently incubated overnight at 37°C. The resulting colonies were 
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Figure 4.3 
The DNA sequencing chromatograms of the C32A active site mutation, unequivocally confirming 
the TGC (cysteine) to GCC (alanine) nucleotide permutations. 
used to make LB cultures for a 'Miuiprep' kit (Qiagen) DNA extractiou. A SacII/NotI 
restriction digest was subsequently performed and the products separated and visualized 
using an ethidiiun bromide agarose gel as above. As these two restriction sites occur ex-
clusively within the hGSTOl gene and not within the pHUE vector, the identification of 
two fragments of DNA could confirm a correctly ligated gene construct, and not just an 
empty pHUE vector conferring resistance to the antibiotic. Indeed, the vector was ob-
served between the 2 Kb and 3 Kb markers, and the insert observed parallel to the 0.8 
Kb marker, as expected. A DNA sequencing reaction was then performed and submitted 
to the Biomolecular Resource Facility (BRF), JCSMR, for interpretation. The resulting 
chromatogram unequivocally confirmed the presence of desired TGC (cysteine) to GCC 
(alanine) nucleotide change (Figure 4.3). 
4.2.2 Purification, crystallisation, data collection and refinement 
Protein was purified to homogeneity as described in Chapter 3 (Section 3.2.2 on page 46). 
Crystallisation of the protein was then performed using the hanging drop/vapour diffusion 
method. Crystallisation conditions were optimised by screening against pH and precipitant 
concentration, based upon previously published conditions |4|. There are two crystal struc-
tures of hGST01-C32A involving species of methylated arsenic discussed in this ("hapter. 
The first was co-crystallised with 100 inM M M A ^ pl l 7.5, before being 'back soaked' in 
a solution prepared by combining 1 /xL of 10 niM CDNB. 10 niM GSl l . pH 7.5 and 1 /iL 
well solution, and allowing it to equilibrate within the seakxl reservoir of the hanging drop 
experiment for 48 hours. This step was due to previously solved structures under analogous 
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conditions failing to show binding of the arsenical, and the need at the time for crystals 
of hGST01-C32A to investigate the increased activity of this active site mutant to CDNB 
(Section 1.1.3 on page 8) [17|. This resulted in species derived from both experiments 
being observed in the active site. 
The second was grown under 'apo' conditions and then transferred to an equilibrated 
soaking solution of reservoir solution and 5 mM MMA^, 10 mM GSH and 5 mM TCEP, 
pH 7.5. The latter was included to simulate the reducing power of the wild type enzyme. 
Both datasets were collected at the Stanford Synchrotron Radiation Lightsource (SSRL), 
California, USA, using radiation corresponding to the anomalous absorption edge of arsenic 
(12680 eV). Initial phase estimates were calculated from the previously solved structure 
(PDB identifier: lEEM) [4]. The details of the crystallisation, data collection and re-
finement of each are tabulated in Table 4.1 on the next page, and Table 4.2 on page 70, 
respectively. 
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Crystallisation Experimental Parameters of hGST01-C32A, glutathionyl 
methylarsenite, HDNB complex. 
Reservoir sohition 2.2 M (NH4)2S04 
100 niM Sodium Acetate pH 4.25 
Crystallisation drop 1 tiL hGSTOl-C32A (30 mg/ml) 
1 [iL fOOmW MMA^pH 7.5 
1 ^L reservoir 
Soaking sohition^ 1 [iL lOniM CDNB pH 7.5 
f \iL fOniM GSH pH 7.5 
1 [iL reservoir 
Cryoprotectant solution 2.2 M Li2S04 
100 niM Sodium Acetate pH 4.25 
Sequential transfer from 5 % — > 1 0 % Glycerol solution 
Data collection 
Resolution limits, A 28.08-1.47 (1.52-1.47^) 
Space group P3i21 
Unit Cell. A a b-=56.17 c-::139.54 
Total reflections 562 469 
Unique reflections 44 388 
Completeness, % 99.8 (98.2^) 
l/a 47.5 (3.0t) 
Redmidancy 12.7 (s.ei') 
Refinement 
Rcryst Rfree: % 12.9/15.9 
rmsd bonds, A 0.012 
rmsd angles, 1.389 
Number of waters 269 
Ligands glycerol, acetate, glutathionyl methylarsenite. 
HDNB, CI" 
the highest resolution shell. allowcxi to equilibrate for 48 hours. 
Table 4.1 
Crystallisation details and structure determination statistics of the hGST01-C32A, glutathionyl 
niethylar.senite, HDNB complex 
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Crystallisation Experimental Parameters of hGST01-C32A, 
diglutatliionyl methylarsenite complex. 
Reservoir solution 2.2 M (NH4)2S04 
100 mM Sodium Acetate pH 4.25 
Crystallisation drop 2 jjlI hGST01-C32A 
2 [il reservoir 
Soaking solution^ 1 [il 5mM MMA^, 5mM TCEP, lOmM GSH, pH 7.5 
1 [jil reservoir 
Cryoprotectant solution 2.2 M Li2S04 
100 mM Sodium Acetate pH 4.25 
Sequential transfer from 5%—->10% Glycerol solution 
Data collection 
Resolution limits, A 50.00-1.46 (1.51-1.46+) 
Space group P3i21 
Unit Cell, A a=b=57.08 c -140.1 
Total reflections 499 079 
Unique reflections 81 805 
Completeness, % 92.5 (52.gt) 
l/a 14.5 (1.86t) 
Redundancy 6.1 (2.9t) 
Refinement 
Rcryst/R-free> % 17.4/22.2 
rmsd bonds, A 0.007 
rrrisd angles, ° 1.074 
Number of waters 115 
Ligands 
4- . _ 
804^", glycerol, acetate, diglutathionyl methylarsenite 
resolution shell. ^^  allowed to equilibrate for 48 hoiu's. 
Table 4.2 
Crystallisation details and structure determination statistics of the hGST01-C32A, diglutatliionyl 
methylarsenite complex 
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4.3 Results and discussion 
Sereiidipitously, the clearest, and most unequivocal crystal structure obtained to date of 
the interaction of hGSTO l with a methylated arsenic species also revealed a derivative of 
the model substrate CDNB. Crystals of the hGST01-C32A active site mutant, previously 
co-crystallised with M M A ^ , were subsequently soaked within a drop containing CDNB, 
well solution and glutathione overnight (Section 4.2 on page 66). The resulting crystal 
structure showed species originating from both experiments bound within the active site 
of l iGSTOl (Figure 4.4 on page 73). Despite the active site mutation, the arsenic species 
was observed reduced to the +3 oxidation state, with one of its hydroxyl ligands displaced 
by a molecule of glutathione. Hypothesised to have been displaced from a molecule of 1-
giutathionyl-2,4-dinitrobenzene (Figure 4.14 on page 86), the resulting compound, HDNB, 
was observed binding within the previously hypothesised 'H-site' of the enzyme (Figure 1.7 
on page 11). Its Cl~ leaving group was observed bonded to the side chain of an arginine 
residue 10 A away (Figure 4.8 on page 77) |4|. 
While the structure referred to above shows a single glutathione complexed to a 
trivalent arsenic atom, other results support the suggestion of Hayakawa [71], that the 
metabolism of monomethylated arsenic occurs via a diglutathionylated trivalent species 
(Figure 4.1b on page 63). Although the high resolution of the crystal structure allowed the 
coordination by two As-S bonds to be identified with certainty, the presence of the dithiol 
DTT in the experimental conditions, combined with ambiguous electron density, allowed 
only one of these to be assigned to glutathione unequivocally. 
4.3.1 Structural features of glutathionyl methylarsenite and HDNB/C l " 
binding in the active site of hGSTO l 
Glutathionyl methylarsenite was observed with an occupancy of 0.58 with native glu-
tathione occupying the remaining 48% of the crystal lattice (Figure 4.5 on page 74). Using 
X-rays at the anomalous edge of arsenic absorption, coupled with the high resolution of 
diffraction data obtained, allowed the former species to be identified absolutely (Figure 4.2 
on page 66 and Figure 4.6 on page 75). Although binding of the glutathione moiety in 
both instances was as previously observed |4|, the crystal structure reveals a novel polar 
interaction between Y229 and the lone electron pair of arsenic, mediated by a bridging 
water molecule (Figure 4.6 on page 75). 
Only a few angstroms away, a derivative of the model substrate CDNB was observed 
72 hGSTOl-1 coniplexed with methylarsormte reduction intermediates 
within the predicted 'H-site' |4|. A lack of strong 2mFo - DFc electron density corre-
sponding to the chlorine atom was indicative of substituion to a hydroxy group, to form 
HDNB. and refined to an occupancy value of 0.75. Indeed, the displaced chloride ion (oc-
cupancy ^0 .71 ) was observed binding to the guanidinium group of R37, approximately 10 
A away. Modeling a water molecule in this position consistently produces a large positive 
peak in the mFo - DFc electron density and an abnormally low B-factor. The interdepen-
dence of these species is attested to by the close correlation of their independently refined 
occupancy values. 
In addition, the binding of HDNB is associated with a conformational change in two 
neighbouring side chains. R132 has moved several angstroms to form a polar interaction 
with the compounds hydroxyl group, at the same time forming a salt bridge interaction with 
a novel sulfate ion. Similarly, W222 has adopted an alternate rotamer conformation such 
that its indole nitrogen is now orientated away from the binding pocket to form a hydrogen 
bond with the sulfur of an alternate conformation of M187, effectively demonstrating a 
mechanism that may facilitate Omega class binding promiscuity (Figure 4.8 on page 77). 
Interestingly, this latter interaction with M187 has been facilitated by an intriguing 
conformational change within the a-helix 6 to 7 junction, located immediately behind the 
H-site. The a-helical character of this region has been abolished, causing residues 183-196 
to adopt significantly different conformations to those previously observed in the complex 
with GSH (Figure 4.9 on page 78) [4|. Although less pronounced, this conformational 
change is also induced by binding of GSSG (Figure 5.5 on page 108). 
4.3.2 Hypothesised binding of diglutathione methylarsenite 
Although the electron density is not definitive, another high resolution structure suggests 
the glutathionyl methylarsenite observed above may subsequently progress to a diglu-
tathionyl species within the hCSTOl active site. This is the chemical form suggested by 
Hayakawa and Thomas et. al., |72, 71|, to be necessary for hAS3MT catalysis. The 1.5 A 
structure has been modeled with 2 molecules of native glutathione in alternate conforma-
tions, and one molecule of diglutathionyl methylarsenite overlaid in equivalent positions 
within the active site. The three molecules have been refined to occupy approximately 
one third of the crystal lattice each. For clarity, this is represented with colour coding in 
Figure 4.10 on page 80. While one glutathionyl ligand of diglutathionyl methylarsenite is 
seen to occupy it's previously observed position in the G-site, the second has been modeled 
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Figure 4.4 
The 1.47 A resolution crystal structure of l iGSTOl in complex with glutathionyl niethylarsenite, 
glutathione and a derivative of CDNB, HDNB. All three ligands are shown in stick representation 
and were observed at partial occupancies, refining to occupancy values of 0.58, 0.42 and 0.75 
respectively. The disassociated chloride ion (green, occupancy - 0.71) was observed 10 A away, 
forming a salt bridge interaction with an arginine guanidinium group. Due to the crystal used for 
the CDNB/glutathione soaking experiment previously being co-crystallised with M M A ^ , species 
from both experiments were observed in the resulting crystal structure. The crystallographic fold of 
l iGSTOl is shown as a cyan cartoon overlaid with a translucent molecidar surface. The binding of 
glutathionyl niethylarsenite and HDNB are highlighted with magenta and yellow respectively. Both 
binding sites are within A of each other and occ\ir within the crevice formed at the C-terminal 
(upper hemisphere) and N-terminal (lower hemisphere) domain interface. 
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Figure 4.5 
Glutathionyl methylarsenite and associated side chains are shown in stick representation. The 
binding of native glutathione is shown as a translucent superposition. The arsenic derivative was 
refined to an occupancy value of 0.58, with native glutathione occupying the remaining 42% of the 
crystal lattice. The weighted 2mFo - DFc electron density corresponding to the former is depicted 
as gray isomesh, contoured at a level of l a . hGSTOl is shown as a cyan cartoon. A translucent 
molecular surface highlights the binding pocket of glutathionyl methylarsenite in magenta 
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Figure 4 .6 
A view of the polar interactions a-ssociated witli glntathionyl methylarsenite binding in relation to 
HDNB. The crystallographic distance of each is given in A . A solvent molecule mediating a 
hydrogen bonding interaction between the Y229 hydroxyl group and the arsenic lone pair is shown 
as a red sphere. Other solvent molecules have been omitted for clarity. The glutathione adduct of 
the trivalent methyl arsenical and associated side chain residues are shown in stick representation, 
coloured according to a tom type. Shown in green isomesh contoured at 2Qa, the anomalous 
difference density generated by the arsenic atom of glntathionyl methylarsenite confirms its identity 
unequivocally. 
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Figure 4.7 
The binding of HDNB is shown in stick representation. The corresponding 2mFo - DFc electron 
density is depicted as gray isomesh, contoured at a level of lo. The crystallographic fold of hGSTOl 
is shown as a cyan cartoon. A translucent molecular surface highlights the binding pocket of HDNB 
in yellow. 
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F i gu re 4.8 
Details of the interactions between HDNB and the dissociated C P ion with associated residues of 
hGSTO l are shown in stick representation. Binding of HDNB has caused a dramatic conformational 
change in the side chains of R132 and W222. Their previously observed positions are overlaid in 
translucent magenta [4|. The former has been reoriented by several A to form a polar interaction 
with the 1-hydroxyl group, and is being concurrently stabilised by the novel binding of a sulfate ion. 
The latter accommodates the hydrophobicity of the compoimds aromatic core via adoption of an 
alternate rotamer conformation. This has reoriented its polar indole group away from the binding 
pocket, to form a hydrogen bonding interaction with the sulfur of a neighbouring methionine 
(Figure 4.9 on the next page). The ortho- and para-substituted nitro groups display limited polar 
interactions, the only identifiable hydrogen bond being with an ordered molecule of solvent (red 
sphere). The disassociated CI " is observed approximately 10 A away, participating in a salt bridge 
with the guanidinium group of R37. Other solvent molecules have been omitted for clarity. 
Crystallographically observed distances are given in A . 
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Figure 4 .9 
The Q-helical character of the Q6-a7 junction, posterior to the H-site, has been abohshed by a 
hgand associated conformational change. The crystallographic fold of the h G S T O l C32A methyl 
glutathionylarsenite/HDNB ternary complex (cyan) is compared with the aligned coordinates of the 
glutathione complex (magenta) [4]. HDNB and the associated H-site residues, W222 and R132, are 
shown in stick representation coloured according to atom type, as are residues 183-196. The weak 
polar interaction that is now formed between the reoriented indole group of W222 and the sulfur 
lone pair of an M187 alternate conformation is shown with a dashed line, the crystallographically 
observed distance is quoted in A. Above, an abstracted view of the h G S T O l s t ructural fold shows 
the location of this region relative to ligand binding from orthogonal perspectives. This s t ructural 
riposte to ligand binding was also observed in the 4NPG/GSSG ternary complex, but in a different 
conformation to the one observed here (Figure 5.5 on page 108). 
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to extend tipwards towards the C-tenniiial domain. Here, its 7-ghitamyl carboxylate may 
accept a hydrogen bond from the indole amine of VV180 (Figure 4.11 on page 81), while 
the polar interactions of the glycinyl portion are hypothesised to be entirely mediated by 
surrounding solvent. In contrast to the ternary complex with IIDNB mentioned above, 
the side chain of VV222 has not adopted an alternate conformation, while the side chain of 
R132 is seen to be disordered. Associated conformational change within the region of the 
aG to a7 helix junction is relatively minor (data not shown). 
The lack of defined protein-ligand interactions with this portion of the arsenical, com-
bined with its many rotatable bonds, may contribute to an inherently disordered binding 
mode and hence, the lack of conclusive electron density. While this second coordinating 
glutathione does not produce associated negative peaks in the mFo - D F c map or unre-
alistically high B-factors in the atoms lacking 2mFo - DFc density, it should be noted 
that DTT was present within the experimental conditions and could also be responsible 
for the As-S density observed. Altering the experimental conditions of protein purification 
to exclude this non-physiological reducing agent subsequently resulted in a space group 
change upon crystallisation (Chapter 6 on page 131). 
4.3.3 Discussion of the mechanistic imphcations for methylarsonate re-
duction and glutathione conjugation reactions 
Proposed reaction mechanisms of MMA"^ reduction in vivo are shown in Figures 4.12 on 
page 83 and 4.13 on page 84. While these reaction mechanisms are given for the native 
enzyme, the species highlighted in blue and red wore modeled in crystal structures of 
the C32A active site mutant. Given that these chemical species were not present in the 
crystallisation conditions (Table 4.1 on page 69 and Table 4.2 on page 70) and that this 
active site mutation has been shown to abolish the characteristic thioltransferase activity of 
hGSTOl-1 |15, 17|, the question that nmst be asked is how these compounds were formed 
at all? The foremost explanation is perhaps that their formation was non-enzymatic, and 
high affinity to the liGSTOl active site subsequently allowed them to be observed crystal-
lographically. Indeed, Percy |70| has confirmed the spontaneous formation and stability of 
trivalent glutathionyl methyl arsenicals under physiological conditions. There is the possi-
bility however, that even without a functional active site residue, liGSTOl-l may still have 
catalysed the conjugation of glutathione to the arsenic center sei)arately to its reduction. 
As noted previously (Section 1.1.3 on page 8), the same mutation actually increases its 




Shown in stick representation, the carbon atoms of the various ghitathione molecules have been 
colour coded to allow their occupancy values to be distinguished. Within the 'G-site', unmodified 
glutathione is overlaid in orange (0.32 occupancy). Another molecule of glutathione with an 
alternate conformation of its sulfhydryl occupies the .same position within the remainder of the 
crystal lattice (cyan), however, it has been modeled as part of a diglutathionyl methylarsenite 
molecule 33% of the time (green). Atoms are otherwise coloured according to atom type, with 
arsenic shown in magenta. The experimentally observed 2mFo - DFc electron density'is shown as 
gray isomesh contoured at la . While the density corresponding to most of the green glutathione 
molecule is not complete, the trivalent arsenic atom coordinated by two sulfur atoms is 
unmistakable. The high resolution of this crystal structure allows these characteristically long As-S 
bonds to be modeled with certainty, although there is the possibility that the latter could be due to 
coordination by a disordered molecule of DTT , also present in the experimental conditions. 
hGSTOl IS shown as a cyan cartoon overlaid with a translucent molecular surface. The binding site 
of diglutathionyl methylarsenite is highlighted in magenta. 
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Figure 4.11 
Diglu ta th iony l methy la rsen i te , refined t o occupy approx imate ly one tii ird of tlie c rys ta l lat t ice, is 
shown in stick represen ta t ion along with its associated side chain residues. A t o m s are coloured 
accord ing to a t o m type . A l t e rna t e conf i rmat ions of na t ive g lu ta th ione and su r round ing solvent 
molecules have been o m i t t e d for clarity. Dis tances of t he observed polar in terac t ions wi th t h e 
po lypep t ide are given in A . T h e only novel ins tance of such is t he accep tance of a hydrogen bond 
f rom t h e t he indole amine of W 1 8 0 by a7-glutamyl ca rboxy la te of t he modeled ligand. 
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ability to conjugate glutathione to CDNB [17|, and the isoform could be expected to retain 
this functionality in the context of methylated arsenicals. As Figures 4.12 on the facing 
page and 4.13 on page 84 propose, the active site cysteine is not necessary for ligation of 
glutathione to arsenic, only for its reduction from the +5 to +3 oxidation state via donation 
of its lone electron pair. Given that one or both of the powerful reducing agents; DTT and 
TCEP, were present in the crystallisation conditions (Table 4.2 on page 70 and Table 4.1 
on page 69), it follows that they may have been able to provide the necessary reducing 
equivalents chemically, followed by enzymatic conjugation of GSH. or vica versa. Indeed, 
this has been observed crystallographically in a structure crystallised in the presence of 
DTT and cacodylate (DMA^) buffer [88|. This would however, be expected to require a 
hydrogen bond donor to stabilise the associated thiolate. In Figures 4.6 on page 75 and 4.12 
on the next page, the formation of a solvent mediated polar interaction between Y229 and 
the lone pair of the trivalent arsenic atom is shown. As mentioned previously (Section 3.3 
on page 50 and Figure 3.10 on page 59), this tyrosine may be the best candidate for the 
unidentified hydrogen bond donor of the omega class |4|. It has often been disordered in 
the routine determination of the hGSTOl crystal structure and belongs to the C-terminal 
domain identified to be highly labile in structural and biophysical investigation of the E155 
deletion mutant (Appendix A on page 181). It is conceivable that conformational change 
unobserved in the crystal structure could bring this residue close enough to stabilise either 
the glutathione or cysteine associated thiolate, especially if mediated by a molecule of sol-
vent. Although site directed mutagenesis studies were initiated to further investigate its 
role in the catalysis of liGSTOl-l, the time constraints of this research project precluded 
them from reaching completion. 
As mentioned above, the mutation of the active site thiolate to an alanine methyl 
group actually enhances the ability of hGSTOl-1 to conjugate glutathione to CDNB, why 
then, is a reaction intermediate observed in Figure 4.8 on page 77, and not the product 
shown in Figure 1.8 on page 12, l-glutathionyl-2,4-dinitrobenzene? Given that within the 
structure presented in Section 4.3.1 on page 71, glutathione was not present in the initial 
co-crystallisation conditions (Table 4.1 on page 69), perhaps the most likely sequence of 
chemical events is those presented in Figure 4.14 on page 86. Here, the GSH and CDNB 
constituents of the soaking solution are hypothesised to have reacted in an enzymatic, or 
iiori-enzyniatic, fashion to yield l-glutathionyl-2,4-dinitrobenzcne. Monomethylarsenite, 
previously reduced from MMA^ via chemical reduction by DTT, may have then displaced 
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Figure 4 .12 
The proposed mechanism for the enzymatic formation of glutathionyl methylarsenite (blue) and 
diglutathionyl methylarsenite (red) by h G S T O l native. These are the species modeled 
crystallographically, shown in Figure 4.5 on page 74 and Figure 4.10 on page 80 respectively. Two 
alternate pathways are given for the formation of the latter, but given the steric bulk associated with 
the penta-coordinated intermediate in scheme I, the latter is expected to be more physiologically 
accurate. Although within scheme II, the sequence of reactions is shown as glutathione conjugation, 
reduction and another conjugation, a sequence of two successive glutathionyl conjugations followed 
by a final reductive step with the active site cysteine could also occur. This mechanism is consistent 
with previous characterisation of microbial arsenate reductase enzymes (Section 4.3.4 on page 85), 
that show a direct interaction between the enzymatic thiol and the arsenic center. However, this 
reaction could likewise proceed by a deglutathionylation mechanism (Figure 4.13 on the next page) 
that would be more consistent with its mechanism of 4NPG reduction (Chapter 5 on page 97). 
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Despite previous characterisat ions of microbial arsenate reductases (Section 4.3.4 on the next page) 
observing a direct cysteine-arsenic covalent bond, the dist inguishing thiol t ransferase act ivi ty of 
h G S T O l - 1 (Section 1.1.3 on page 8) may be more accommodat ing to the mechanism shown here. 
This would still feature the cysteine-GSH mixed disulfide observed previously [4|, and is analogous 
to t he hypothesised mechanism of 4 N P G reduction (Chap te r 5 on page 97). Due to the 
deglutathionylat ion of the subs t ra te however, the diglutathionyl in termedia te hypothesised by 
Hayakawa et. ai, (Figure 4.1b on page 63) |71| would be precluded. 
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the glutathionyl functionality with one of its hydroxy Hgands, yielding the chemical species 
observed in the crystal structure (Figure 4.14 on the following page). 
4.3.4 Comparisons with other arsenic reductases 
Several studies of enzymes integral to the assorted mechanisms of microbial arsenic detox-
ification have recently been published |89, 90, 91. 92, 93, 94, 95|. Using structural and 
biochemical data, these investigations have successfully elucidated the variety of mecha-
nisms developed by these organisms to survive high loads of environmental arsenic, often 
in great detail. Perhaps the best characterised enzyme is the arsenate reductase (ArsC) 
of the gram-positive bacterium Staphylococcus aureus, that reduces iAs^ to iAs^^' via a 
coupled reaction with thioredoxin |92|. Encoded on plasmid pI258 with two other genes 
encoding a iAs transcriptional regulator and iAs^ ^^  efflux pump, the sequence and crystal 
structure of the enzyme suggests it has evolved from the low molecular weight protein ty-
rosine phosphatases (PTPases) |96. 93. 92|. These ubiquitous enzymes are responsible for 
the dephosphorylation of post-translationally modified tyrosine residues via a cysteinyl-
phosphate intermediate, a process essential in cellular signaling pathways, metabolism, 
differentiation and growth [97|. Indeed, S. aureus ArsC still displays PTPase activity, 
albeit at levels diminished by several orders of magnitude relative to its contemporary 
coimterparts. The chemical similarity of phosphorous and arsenic, residing adjacently 
within group 15 of the periodic table, means that arsenate and phosphate are highly iso-
niorphous tetrahedral oxyanions. This limits the ability of cellular transport systems to 
distinguish between the two and is the primary mechanism by which iAs enters the cell 
[89]. An evolutionary adaption to its detoxification appears to have assimilated the de-
phosphorylation scaffold of PTPases as a redox enzyme. Once reduced to the + 3 oxidation 
state, the toxicity of the species increases markedly, but allows its active extrusion from 
the cell |92, 96]. Both PTPases and ArsC share the characteristic C - X „ - R active site motif 
of h G S T O l (Figure 3.8 on page 56), but this appears to have arisen via a mechanism of 
convergent evolution to this class of reaction, since in all other respects, their structure 
and mechanism are distinctly different. Using several active site nmtants and specific redox 
conditions during purification and crystallisation, the structure of S. aureus ArsC has been 
solved in all states of its reaction cycle, and unequivocally confirmed to function via an 
intramolecular disulfide cascade |93|. After initial attack by CIO upon the arsenic centre, 
expulsion of a hydroxy ligand as solvent is followed by subsequent formation of a disulfide 





The sequence of chemistry hypothesised to have produced the chemical species presented in 
Figure 4,4 on page 73. The crystallographically observed intermediates are highlighted in blue. 
HDNB was likely observed in this experiment due to the enzymatic, or non-enzymatic, formation of 
l-glutathionyl-2,4-dinitrobenzene, followed by displacement of its glutathionyl functionality by 
methyl arsenite, chemically reduced to the + 3 oxidation state by the D T T present in the 
experimental conditions. 
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with nearby C82. This shuttles the electrons from the As-S bond to arsenic, concurrently 
releasing arsenite in the process. A major conformational change is then associated with 
C89 moving over 10 A to form a C89-C82 disulfide, resulting in the regeneration of the 
reduced CIO thiolate, and exposure of the new disulfide at the solvent interface. This effec-
tively shuttles the disulfide to a position accessible to reduction by thioredoxin, which can 
in turn be reduced by thioredoxin reductase and its co-substrate, N A D P H (Nicotinamide 
adenine dinucleotide phosphate) (Figure 4.15 on the following page) |96, 93|. O f particu-
lar interest, a covalent ClO-arsenic adduct within a C82S nmtant could not be observed 
crystallographically due to a futile reaction cycle with solvent (Step 1 in Figure 4.15 on 
the next page). The reversibility of this initial step in the reaction cycle was confirmed 
unequivocally by observation of solvent derived incorporation via mass spectrometry 
|93|. Such a mechanism may have similarly hindered attempts to observe the equivalent 
methyl arsenic intermediate in complex with native h G S T O l via co-crystallisation and 
soaking experiments involving M M A ^ and D M A ^ during this research. The pI258 ArsC 
CIO-Arsenic intermediate was finally able to be observed by using a C15A (non-catalytic 
residue) mutant that was crystallised with 10 n iM arsenite (+3 oxidation state) in the ab-
sence of DTT. The resulting crystal structure showed trivalent arsenic bound in a planar 
configuration perpendicular to the S-As bond |93|. A molecule of water was observed on 
the other side of the HAsOa " plane representing a hydroxy leaving group, and forming 
the other apex of a trigonal bipyrarnidal prism. The other two catalytic cysteines were 
observed engaging in a disulfide bond |93|. This co-crystallisation with high concentrations 
of trivalent product most likely resulted in the observation of the cysteinyl-arsenic adduct 
crystallographically, due to an artificial shifting of the reaction equilibrium within the crys-
tal to favour transition state complexation. At the time the equivalent experiments with 
h G S T O l were being performed, trivalent methyl arsenicals were unavailable commercially, 
making the application of the same strategy difficult. 
The two other families of arsenate reductases are represented by the ArsC enzyme of 
gram-negative E. coli encoded on plasmid R773 [91. 95|, and Acr2p from the eukaryote 
Saccharornyces cerevisiae (yeast) |90|. Although seciuence similarity suggests they are not 
related by evolution, Ijoth feature a nnxed disulfide mechanism involving an active site 
cysteine residue and glutathione, similar to h G S T O l . The mncellular arsenate reductases 
differ from the omega class in that they require a ternary complex with glutaredoxin (Grx) 
to regenerate the active enzyme. O f the two, the E. coli enzyme has been most thoroughly 





























The mechanism of S. aureus arsenate reduction as elucidated by Messens et. al, [93|. 
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characterised, and the cysteine at position 12 fonnd to be essential for catalysis |91|. Al-
thongh any of the 3 glntaredoxin enzymes of E. coli are cap)able of participating in the 
reaction, Grx2 has the highest affinity for the ArsC-Arsenate-GSH complex |95|. All three 
of these snbstrates are required for interaction with Grx to occur, however substitution 
with substrate analogs such as sidfate or S-hexyl glutathione also allow the ternary com-
plex to form, albeit with decreased affinity. Similarly, a C12S nuitant is also capable of 
complex formation, indicating that free thiols associated with ArsC and GSH are desir-
able, but not essential, for formation of the ternary complex to occur |91|. Only GSH was 
capable of catalytic turnover however, and was unable to be substituted by the free thiol 
functionalities of /?-mercaptoethanol or D T T [911. The structures of E. coli ArsC and Grx2 
have been solved by X-ray crystallography |95| and NMR spectroscopy |98| respectively, 
and their alignment with the scaffold of the l iGSTOl glutathionyl methylarsenite complex 
(Figure 4.4 on page 73) via the secondary structure matching (SSM) algorithm of Coot 
j43| reveals some striking similarities (Figure 4.17 on page 92). While the glutaredoxin 
fold is canonical of the GST family, the structural commonality of ArsC to the GST family 
was first noted during the preliminary NMR analysis of its structure [99|. It possess no 
detectable sequence similarity with hGSTOl . even within the segments of common sec-
ondary structure. The (3i - a i - (^ 2 - - 04 - " 3 "lotif aligns strongly (rmsd 2.32 A ) 
with the 140 residue fold of ArsC, however the latter contains a helix-turn-helix-loop-helix-
loop-helix domain (residues 35 to 93) that replaces helix a2 between /3-strands 2 and 3. 
The R773 ArsC also features a short anti-parallel loop-strand-loop-strand-loop motif at its 
N-terniinus that is absent in the omega class. Of most significance, this alignment results 
in an almost exact correlation between the active sites of the two enzymes (Figure 4.17 on 
page 92), with a distance between the superposed arsenic centers of just 4 A . 
In contrast, the 215 residue Grx2 displays 21% and and 45% sequence identity and 
similarity with hGSTOl respectively (Figure 4.16 on page 91) |1()()|. This is reflected in 
the highly similar topological arrangement of Grx2 secondary structure, the only exceptions 
being the uniciue N- and C-terminal extensions of h G S T O l , and the Grx2 insertion of a 
helix-turn-helix motif (residues 100 to 139) between a-helices 4 and 5. The two structures 
superpose with a core rmsd value of 2.82 A over 166 residues using the SSM algorithm of 
Coot 143]. 
The congruency of structural motifs between these enzymes could suggest a mecha-
nism of hGSTOl evolution that involved an ancestral gene fusion, effectively combining 
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the functionality of the E. coli ArsC-arsenate-Grx ternary complex into a single enzyme. 
The lack of a detectable sequence similarity between the R773 ArsC and hGSTOl how-
ever, is suggestive that a stronger case may be argued for divergence from an ancestral 
glutaredoxin gene that arrived upon the structural features ideal for arsenate reduction by 
a process of convergent evolution instead. Indeed, there is no topological characteristic of 
hGSTOl mirrored by ArsC that is not also present in Grx2, suggesting the glutaredoxin 
scaffold possesses all the features necessary to evolve into an arsenate reductase directly. 
For reasons that are unclear, gram-negative bacteria may have developed an evolutionary 
advantage in dividing their arsenate reductase mechanism between enzymes in the past. 
If so, this adaptation appears to have been lost in the subsequent evolution of mammals, 
who concurrently acquired a system of methylation. The enzyme identified to perform the 
equivalent reduction of iAs in humans, purine nucleoside phosphorylase (PNP), is a trimer 
that also shows no sequence similarity and limited structural congruency to the R773 ArsC. 
In any case, the complementary alignment of ArsC with hGSTOl suggests that features 
of their inorganic and methylated arsenical reduction mechanisms may be conserved. 
The proposed mechanism of R773 ArsC is shown in Figure 4.18 on page 94 |95, 101|. 
While roughly analogous to that shown for liGSTOl-l in scheme II of Figure 4.12 on 
page 83, there are several distinctive differences. Primarily, the glutathione is shown to 
only participate in coordination to arsenate, and does not form a mixed disulfide residue 
as observed in hGSTOl |4|. Secondly, although the arsenate-GSH-Grx binding sequence 
to ArsC has been well established by fiuorescence experiments involving the artificial inser-
tion of tryptophans within the ArSC active site |91|, the precise order of initial nucleophilic 
attack by these thiols within the active site of hGSTOl is still unknown. Given the close 
proximity of 2 tryptophan residues within the active site (VV180 and W222), it is possible 
that future research focused on this area of hGSTOl-1 catalysis could elucidate this infor-
mation by applying a similar strategy. Indeed, we have recently used the same methods 
to study the refolding kinetics of the hGST01Al55 mutant (Appendix A on page 181). 
While initial attack of the MMA"^ arsenic centre could either be by glutathione or cys-
teine, Figure 4.12 on page 83 hypothesises that the penultimate step of hGSTOl catalysis 
involves attack of a glutathione on the active site cysteine to release a glutathionylated 
arsenical. This is contrasted to the mechanism presented here by DeMel et. ai, (Fig-
ure 4.18 on page 94), where Grx attacks the sulfur of a glutathione molecule, to release 
non-glutathionylated arsenite. The liGSTOl-l equivalent of this mechanism is shown in 
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F i g u r e 4 .16 
The multiple sequence alignment of h G S T O l with the ArsC/Grx2 arsenate reductase couple of E. 
coli. The sequences corresponding to the h G S T O l C-X„-R active site motif is highlighted with a red 
box. Whi le the blastp program |100| showed Grx2 to posses 21% and 45% sequence identity and 
similarity with h G S T O l respectively, no similarity with the sequence of ArsG or Acr2p was 
detectable. In contrast, ArsC and Acr2p did show 23% and 42% sequence identity and similarity 
with each other. This would suggest that the striking correlation of ArsC's secondary structural 
motifs (Figure 4.17 on the next page) with parts of the h G S T O l crystal structure has arisen from 
convergent evolution with efficiency to the arsenate reductase reaction acting as a selection pressure. 
This figure was generated using the program GlustalX |60|. 
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inserted helix-tum-helix 
motif of Grx2 
Figure 4.17 
The SSM superpositions of hGSTOl (cyan) with the ArsC/Grx2 (magenta and yellow respectively) 
enzyme couple responsible for the reduction of arsenate to arsenite within E. coli is shown in the 
cartoon representation. The structure of the hGSTOl/methyl glutathionylarsenite complex 
(Section 4.3 on page 71) was first aligned with that of R773 ArsC (PDB identifier: 1.J9B) |95l, while 
the solution structure of Grx2 (PDB identifier; 1G70, ensemble conformer 21) |98l, was intern 
aligned to hGSTOl. The thiarsahydroxy derivative of the ArsC active site cysteine and the two 
molecules of arsenite observed in the crystal structure are shown in stick representation, coloured 
according to atom type. Overlaid in translucent stick representation is the position of methyl 
glutathionylarsenite shown in Figure 4.5 on page 74, demonstrating a conserved active site location. 
Elements of hGSTOl secondary structure are labelled for reference. The structural correlation 
between the GST and glutaredoxin enzymatic families is well known, and superposed with a rmsd 
value 2.96 A. Still, the 215 residue Grx2 enzyme features a helix-turn-helix motif (residues 100-139) 
inserted at the position corresponding to the hGSTOl a-helix 4-5 junction. Of most interest 
however, is the high coincidence of secondary structure between ArsC and the N-terminal domain of 
hGSTOl, despite the two enzymes sharing no detectable sequence similarity (Figure 4.16 on the 
previous page). The /3i - ai - ft - A - /34 - as motif of hGSTOl aligns strongly (rmsd 2.32 A) 
with the 140 residue fold of ArsC, however the latter contains an all a-helical domain (residues 35 to 
93) that links /3-strands 2 and 3. This could be evidence of a distant ArsC-Grx2 gene fusion, 
combining their functionality into a single enzyme from which hGSTOl may have descended. It is 
more likely however, that convergent evolution acted upon an ancestral glutaredoxin gene to arrive 
at the fold most suited to the reduction of pentavalent arsenicals. 
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Figure 4.13 on page 84. The former is hypothesised to be a more hkely feature of methyl 
arsenic reduction in mammals, since glutathionylated, trivalent methyl arsenicals have 
been shown to be the required substrate for hAS3MT |72, 711. Another striking difference 
between the two mechanisms is the presence of the ArsC-thiarsahydroxy species, hkely to 
be stabilised: Scysi2 — ^s"*" — OH ^ 5'^si2 = As — OH. This is corroborated by the 
correlation of the observed bond planarity and lengths with those of small molecules in the 
Cambridge structural database, both of which were known with certainty due to the high 
resolution of the ArsC crystal structure. Such an intermediate is favoured in ArsC by the 
close proximity of 3 arginines and a histidine residue that encourage the dissociation of 
its hydroxy ligand. The resulting positive charge is then stabilised by an adjacent sulfate 
|95|. The lack of many basic, proximal residues within the active site of h G S T O l however, 
suggests that a similar intermediate would not feature as part of its catalytic mechanism. 
The species is hypothesised to expedite catalysis due to its inherent instability causing 
rapid dissociation from the active site, concertedly reducing covalent product inhibition. 
It's authenticity was recently confirmed unequivocally by mutat ing one of the proximal 
arginines to a lysine or alanine. The resulting decrease in charge and steric repulsions 
allowed the charge neutral dihydroxy cysteinyl arsenite to be observed with a predicted 
decrease in catalytic efhciency |95|. Much like the structural investigation of S. aureus 
ArsC catalysis, this was achieved both times by soaking crystals in cryoprotectant con-
taining up to 0.4 M of arsenite prior to data collection |95, 1011. The crystallographic 
observation of the cysteinyl-glutathione adduct resulting from step 2 in Figure 4.18 on the 
following page has thus far eluded the authors, however in silico molecular modeling |101| 
suggests that glutathione would coordinate arsenic in a position roughly analogous to its 
mode of binding observed in superposed h G S T O l (Figure 4.4 on page 73), but translated 
by several angstroms and rotated by 180°. 
The Acr2p arsenate reductase of Saccharomyces cerevisiae has been less well charac-
terised, although its ability to restore a positive phenotype to an ArsC knockout strain 
of E. coll is indicative that it has a high level of functional and strvictural homology [OO]. 
Indeed, R773 ArsC and Acr2p share 23% and 42% sequence identity and similarity respec-
tively |100|. Notably, cloned Acr2p did not recjuire co-expression with any host proteins, 
the eukaryotic enzyme was able to participate directly with E. coli Grx enzymes during 
the reaction |90|. 
O f particular interest is that despite the lack of sequence similarity, like the ArsC 
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Figure 4 .18 
f 11011- While an analogous mechanism 
for h G S T O l IS shown in Figure 4.13 on page 84, the proposed mechanism of methyalted arsenic 
reduction shown in Figure 4.12 on page 83 is hypothesised to be more likely, since it is compatible 
with the release of glutathionylated products that are required by hAS3MT. This suggestes the 
would differ in the order of As-S bond formation and dissociation. In h G S T O l , it would be expected 
to be the Cys-As bond, rather than the GS-As bond shown here, tha t would provide the necessary 
reducing equivalents to the arsenic center. 
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enzyme of S. aureus, tlie S. cerevisiae Acr2p also appears to have descended from the 
PTPase family, but from the subgroup associated with the control of cell cycles |90, 93|. 
Identification of what appears to be an alternative branch of this evolutionarily pathway 
was recently made within the cyanobacterium Synechocystis sp. strain P C C 6803, that 
displays characteristics from both families of microbial ArsC enzymes |89|. This enzyme 
is a clear sequence homologue of PI258 ArsC and the alignment of 3 cysteines suggests it 
would also feature an intramolecular disulfide cascade. Unlike the resulting reduction by 
thioredoxin/NADPH in S. aureus however, the cyanobacterial enzyme was rather shown 
to be regenerated by an interaction with Grx and GSH, as in the mechanism of the R773 
ArsC from E. coli and Acr2p |89, 95, 91|. 
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Chapter 5 
The complex of hGSTOl with 
S- (4-Nitrophenacyl)glutathione and 
oxidised glutathione: 
Insights into the catalytic cycle afforded by the enzymatic 
complex of a specific substrate with bound product 
The detoxification of a-haloketoiies to non-toxic acetophenones is an enzymatic reaction 
specific to l iGSTOl - l within the body |15|. After the a-hahde is displaced by a dieniical 
reaction witli the high iiitracelhilar concentrations of GSH, recognition by hGSTOl and 
niicleophihc attack of its active site cysteine residne subsequently liberates the correspond-
ing acetophenone. Recently the novel compound S-(4-Nitrophenacyl)glutathioiie (4NPG) 
was synthesised and discovered to display a catalytic efficiency up to 15 times greater than 
conventional S-phenacyl glutathione |102|. It was a desirable outcome of this investigation 
to observe states within this catalytic cycle crystallographically to obtain a more funda-
mental understanding of l iGSTOl - l mediated chemistry. It was hoped that this would 
also provide insight into mechanistic commonalities with the other reactions it performs. 
Using crystals of the hGSTOl C32A active site nnitation, this research has succeeded in 
obtaining a high resolution structure of the ternary complex with this substrate and a 
reaction product, oxidised glutathione (GSSG). While the latter was observed within the 
active site, the binding mode of the substrate was unique, found to be residing at the dinier 
interface. 
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5.1 Introduction 
a-Haloketones are biologically active compounds that can often enter the human body 
via various pathways. They have been identified as metabolites of certain insecticides, 
are used in laboratory research and as a temporary incapacitating agent in the form of 
2-chloroacetophenone (tear gas). It is believed that a non-enzymatic attack by glutathione 
yields S-(phenacyl)glutathione derivatives that then act as substrates for enzymatic de-
composition [15]. Now known to be mediated by hGSTOl-1, this mechanism is thought 
to proceed via nucleophilic attack of the active site cysteine upon the cysteinyl sulphur of 
the S-(phenacyl) glutathione, forming a mixed disulfide with the molecule of glutathione 
removed from the substrate. The resulting departure of a carboanion would be stabilised 
via enolization, yielding a corresponding acetophenone after protonation (Figure 5.1 on 
the facing page) |102, 15]. Physiologically, the native enzyme would be regenerated by 
nucleophilic attack of another glutathione molecule upon the resulting mixed disulfide, 
generating a reduced active site cysteine and oxidized glutathione, in a manner analogous 
to the reactions discussed previously (Section 3.3 on page 50 and Section 4.3 on page 71). 
This reaction does not have a specific requirement for glutathione, and its substitution for 
/3-mercaptoethanol has been observed to increase the catalytic rate constant, kcat, by a 
factor of five ]15]. In contrast to all other activities of tlie Omega class, this reaction is 
unique to hGSTOl-1. hGST02-2 fails to show appreciable activity to this class of sub-
strate ]15]. A new compound, 4NPG, has recently been synthesised that has a turnover 
rate that is approximately 15 times higher, and displays a catalytic efficiency more than 
200 times higher, than previously observed with S-(phenacyl)glutathione ]102]. In addi-
tion, it allows hGSTOl-1 activity to be measured directly by a characteristic absorbance 
change at 305 nm. Previously, the enzymatic activity of l iGSTOl-l has been measured via 
an indirect spectrophotometric assay coupled to GSSG reduction by glutathione reductase. 
The concurrent oxidation of its co-substrate, NADPH, is associated with an absorbance 
change at 340 nm ]102]. 
The specificity of this reaction for l iGSTOl-l is exemplified by experiments with hu-
man breast cancer cell lines. The T-47D cell line is natively deficient in hGSTOl-1 and 
was correspondingly unable to catalyse the reduction of 4NPG to 4-nitroacetophenone. In 
contrast, cells of the same lineage that had been transfected with a plasinid expressing 
recombinant hGSTOl produced a robust absorbance change upon addition of substrate. 
Other breast cancer cell lines could similarly catalyse the reaction, effectively deinonstrat-
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Figure 5.1 
The proposed mechanism of 4NPG reduction by hGSTOl-1. 
ing the dependence of the cell upon hGSTOl for the mediation of this chemistry [102]. 
This presents for the first time, an assay that can identify the activity of hGSTOl-1 in 
human tissue as distinct from that of hGST02-2. The rate increase afforded by using 
/3-mercaptoethanol as the thiol co-substrate is essential for successful characterisation of 
hGSTOl-1 activity within crude tissue extracts by this method |102|. 
The aim was to observe the binding mode of this substrate with hGSTOl crystal-
lographically, in the hope this would allow a structural insight into its specificity. The 
resulting structural information could also confirm the details of its reaction catenation 
and mechanism likely to be conserved within other aspects of its chemistry, such as the 
hypothesised thioltransferase modulation of the Ryanodine calcium release channel |28]. 
Soaking and co-crystallisation experiments with 4NPG involving crystals of hGSTOl 
native consistently resulted in observation of the GSH-cysteine mixed disulfide as seen 
previously |4]. This was likely due to the formation of this reaction intermediate (step 2 in 
Figure 5.1) residing within a mininmm of the reactions energy landscape. The subsequent 
dissociation of acetophenone is expectedly too rapid for observation crystallographically. 
Crystals of the hGSTOl C32A mutant (Section 4.2 on page 66) were therefore employed 
in soaking experiments designed to discover the binding mode of 4NPG in its unreacted 
state within the active site. Yet the resulting crystal structures revealed an unexpected 
ternary complex, witli 4NPG complexed along a crystallographic two-fold corresponding 
to the hGSTOl-1 dimer interface. In lieu of the substrate, the active site was complexed 
with oxidised glutathione (GSSG) with an occupancy=0.7, despite the absence of this 
compoimd in the experimental conditions (Table 5.1 on page 101). GSH was also observed 
at this site within the remainder of the crystal lattice. Although the same binding mode 
would likely also occur within crystals of the hGSTOl C32S mutant, this was not confirmed 
experimentally in the current study. The insights into the enzymes catalytic cycle afforded 
by this high resolution crystal structures are discussed in more detail below. 
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5.2 Experimental methods 
Protein was purified as described previously (Section 4.2 on page 66), iiowever 5 mM DTT 
was substituted with 1 mM TCEP for the reducing agent in the final dialysis buffer. This 
was to prevent auto cleavage of the substrate in subsequent crystal soaking experiments via 
formation of a GSH-DTT mixed disulfide, in a manner analogous to the reaction with /3-
mercaptoethanol discussed above (Section 5.1 on page 98). Data was collected at the SSRL 
using a wavelength corresponding to 12 000 eV. In several equivalent experiments however, 
thermal motion in the glutathionyl portion of 4NPG prevented it from being modeled 
into electron density unambiguously. It was clear from inspecting the high resolution 
electron density of two such datasets that the mode of ligand binding in both datasets 
were identical, and that using information from both may facilitate a clearer image of the 
associated electron density. The two datasets were generated from crystals grown under 
similar conditions (Table 5.1 on the facing page) and collected within the same period of 
beamtime. They thus possessed coincident unit cell parameters, and could be combined 
using the 'Reflection file editor' utility within Phenix |45]. This effectively increased the 
observation to parameter ratio of the dataset, allowing the otherwise uninterpretable region 
of the electron density map to be modeled with substrate. While this did not alter any 
other structural details of the enzymatic fold, it did result in an artificially low number 
of modeled solvent molecules given the resolution (Table 5.1 on the next page). This is 
due to the position of many not being conserved, and their corresponding electron density 
peaks subsequently being averaged to zero. 
The crystallisation and soaking conditions of each, along with data collection and re-
finement statistics are detailed in Table 5.1 on the facing page. Note that crystal G5 was 
previously co-crystallised with an inhibitor (Chapter 6 on page 131). Other crystals grown 
under identical conditions with this compound had consistently revealed an empty, unmod-
ified active site, most likely due to the thiol reactive compound being unreactive with the 
hGSTOl C32A active site mutant comprising these crystals. It was therefore deemed suit-
able for direct use in a 4NPG soaking experiment. Similarly, crystal G2 was first soaked in 
a GSH/reservoir solution before transfer to a drop containing 4NPG. This was envisioned 
to remove any residual TCEP from the storage buffer, to ensure that subsequently observed 
modifications of the substrate would be physiologically relevant. Despite these differences 
in methodology, the observed binding modes of 4NPG and GSSG in the resulting crystal 
structures were extremely similar, justifying the combination of these datasets. 
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Experimental parameters of the hGSTOl-C32A complex with 4NPG and GSSG 
Crystallisation Crystal G2 Crystal G5 
Reservoir solution 2.2 M (NH4)2S04 2.2 M (NH4)2S04 
100 niM Sodium Acetate pH 100 mM Sodium Acetate pH 
4.25 4.75 
Crystallisation drop 1 [iL hCSTOl C32A (32 1 [iL hGSTOl C32A (32 
nig/ml) rng/rnl) (containing 150 nm 
of the 'compound 8' 
inliibitor^) 
1 ^L reservoir 1 [xL reservoir 
Soaking solution a^ 2 [jiL reservoir 2 [iL 10 inM 4NPG pH 7.0 
0.5 piL 100 niM GSH pH 7.5 2 [iL reservoir 
Soaking solution b'F 2 [iL 10 niM 4NPG pH 7.0 
2 ^L reservoir 
Cryoprotectant 2.75 M Li2S04 2.75 M Li2S04 
solution 
100 niM Sodium Acetate pH 100 mM Sodiimi Acetate pH 
4.75 4.75 
Sequential transfer from Sequential transfer from 
5% >10% >15% 5 % — > 1 0 % — > 1 5 % 
Glycerol solution Glycerol solution 
Data collection 
Resolution limits, A 50.0-1.81 (1.87-1.811') 28.5-1.68 (1.74-1.68^) 
Space group F3i21 P3i21 
Unit Cell, A a - b - 5 7 . 6 3 c -140.1 a - b - 5 6 . 9 5 c -139.8 
Total reflections 237 715 210 572 
Unique reflections 24 276 31 004 
Completeness, % 96.0 (68.4t) 98.0 (84.2t) 
I /a 37.1 (3.2t) 34.9 (1.8+) 
Redundancy 9.8 (5.9t) 6.8 (4.2t) 
Refinement 
Rcryst/Rfree, % 19.4/23.5 
rinsd bonds, A 0.007 
rmsd angles, 1.292 
Number of waters 91 
Ligands S04^~, glycerol, glutathione, 
GSSG, 4NPG 
the highest resohition shell. allowed to equilibrate for 48 hours. K Please see Chapter 6 ou 
page 131. 
Table 5.1 
Crystallisation details and structure determination statistics of the l iGST01-C32A, GSSG, 4NPG 
complex. 
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5.2.1 The calculation of average 'kicked' maps 
In order to reduce bias and noise, the phenix.maps utility |45| was used to generate av-
erage 'kicked' maps for visualisation of ligand binding. 'Kicked' maps involve introducing 
many small, random perturbations of the model coordinates, from each of which a map is 
calculated. The final map is an average of this series of perturbed maps, and effectively 
decouples any correlations in structure factors or chemistry terms (such as bond lengths 
and angles) that may be conveying phase bias (Section 2.5.5.2 on page 37). This technique 
was specifically employed in this instance both to ensure that either of the two combined 
datasets did not overly bias the result obtained, and because it has been shown to allow 
otherwise uninterpretable regions of electron density to be accurately assigned to the model 
|103|. This latter feature was particularly attractive given that regions of electron density 
corresponding to 4NPG and GSSG were difficult to decipher. 
In more detail, the electron density maps are calculated: 
AK = FT[Y^{2Fobs - k x Fwe/ ) ] (5.1) 
in which each individual 'kicked' \Fmodei\ amplitude is scaled to its respective jFofc l^, 
before individual 2Fobs - Fcaic maps are computed and added to the sum. The mean value 
of these functions then forms the final Average Kicked map (AK) |103|. Since the Fourier 
Transform (FT) is a linear operation, the process can be expedited computationally by 
replacing the real space averaging of maps with corresponding Fourier coefiicients, followed 
by a final map calculation at the end. 
5.3 Results and Discussion 
The aim of the experiment detailed above was to visualise unreacted 4NPG in the G-site of 
hGSTOl . Instead, this position was found to be occupied by GSSG with an occupancy of 
0.7, despite this compound being absent in the experimental conditions. Presumably, GSH 
oxidised to its homodimer spontaneously during the period of crystallisation. One half of 
the dirneric compound, extending upwards towards the C-terminal domain, interacts with 
residues of the H-site with its glycinyl group. The remaining 30% of sites within the crystal 
are occupied by reduced glutathione, in the same position observed in the native complex 
|4|. While the former is a product of all hGSTO l mediated catalysis, this is the first time 
its binding mode to the enzyme has been confirmed crystallographically. An associated 
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conformational change has again occurred in the a6-a7 loop, but is of a different nature 
than observed previously (Figures 5.3 on page 106 and 5.5 on page 108). 
The glydnyl moiety of 4NPG was observed just a few A from the 7 - g i u t a m y l tail of 
oxidized glutathione, binding along the crystallographic two fold axis of synnnetry cor-
responding to the dinier interface (Figure 5.2 on the following page). The nitrophenacyl 
functionality is observed pointing downwards into the dimeric cleft. This results in the cys-
teinyl sulfur of 4NPG residing 17 A away from the c-/3 atom of A32, suggesting this is not 
a catalytically relevant binding mode, a notion that has significant historical precedent in 
the literature. In fact, the GST family of enzymes were originally known as 'ligandins', due 
to their apparent capacity to bind a wide variety of large (>400 Da) lipophilic compounds 
such as bile acids, fatty acids and certain drugs, in addition to their function as enzymes. It 
is thought this may play a role in storage and transport of these compounds in the aqueous 
phase of the cell [104|. The position of several of these 'ligandin' or 'L-site' binding pock-
ets have been confirmed crystallographically in a broad spectrum of GSTs. While their 
positions within the (j) class of Arabidopsis thaliana |105| and the human tt class |106| were 
observed iimnediately adjacent to the active site, the binding of the anti-Schistosomiasis 
drug Praziquantel, to an a class GST of the parasitic worm Schistosoma japonica, was 
similarly found to occur at a position distal to the G-site, also within the dimer interface 
[107|. While this [)olyaromatic is dissimilar to 4NPG in structiu'e, an analogous glutathione 
conjugate, S-(3-iodobenzyl)glutathione, was found to bind in a similar position within a 
(T class GST of squid |108| (Figure 5.9 on page 113). Despite these structures suggesting 
the associated binding modes were not catalytically relevant, the close proximity of 4NPG 
and GSSG in this instance, may suggest a concerted mechanism in whic;h 4NPG may enter 
the active site as the latter departs. Indeed, the inability to observe both of these com-
pounds in isolation suggests that their binding modes are correlated within the enzymatic 
cycle. This is supported by the binding of 4NPG being associated with rearrangement of 
the symmetrically related E91-K114 salt bridges, the only instances of such interactions 
between the subunits. The fom- residues now form a four way interaction at the apex of 
which is a solvent mediated contact to the phenacyl carbonyl of the substrate (Figure 5.8 
on page 112). It is a possibility that such perturbation of inter-dimeric bonding may be 
able to infer binding cooperativity within the enzymes (luaternary structure. 
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Figure 5.2 
A view from above the hGSTOl-1 physiological dimer. Opposing monomers are shown in magenta 
and cyan cartoon representations covered by a translucent molecular surface. The ternary 
complexation with GSSG and 4NPG is shown in stick representation, with ligand binding 
highlighted in yellow. Whereas GSSG is observed to bind within the enzymatic active site, the 
interaction with 4NPG occurs along 2-fold axis of symmetry, that may correspond to a 'ligandin' 
binding mode observed in other GSTs |107, 104, 108, 105, 106|. The mutually inclusive binding of 
these ligands and their close proximity within the crystal structure however, suggests this may be a 
preliminary docking position of the derivatized xenobiotic, allowing it to move into the active site 
concertedly with GSSG departure. 
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5.3.1 Crystallographically observed mode of GSSG binding within the 
hGSTOl active site. 
The polar interactions with the half of GSSG occupying the G-site are analogous to those 
observed for reduced glutathione binding in the same position (Figure 5.4 on page 107). In 
contrast, interactions with the other half of the diineric molecule, extending upwards into 
the H-site, are almost exclusively hydrophobic in character. Exceptions are a hydrogen 
bonding interaction between its 7-glutaniyl carboxyl and the main chain carbonyl of L56, 
and an internal hydrogen bond between its 7-glutamyl carbonyl and the glycinyl amine 
occupying the G-site. This lack of defined interactions with the protein undoubtedly 
contributes to the relatively high 5-factors and ill defined electron density associated with 
this H-site bound half of the molecule, suggesting significant thermal motion (Figure 5.3 
on the following page). In addition, its complex formation is seen to be associated with 
the structural rearrangement of several amino acid side chains relative to the previously 
published complex with glutathione |4|. Of particular interest is the movement of Y229 to 
accommodate the 7-glutamyl residue, further highlighting the dynamic plasticity of this 
side chain within the h G S T O l active site. The side chain of W222 has also adopted its 
alternate conformer, as seen upon binding of HDNB (Figure 4.8 on page 77), however the 
reoriented indole group is now too distant to engage in a hydrogen bonding interaction 
with the sulfur lone pair of M187. Although residues 183-196 have again responded to 
H-site complexation with conformational change, it is of a different nature than observed 
in the ternary complex of giutathionyl methylarsenite/HDNB (Figure 5.5 on page 108). In 
addition, the nearby side chains of K57, 1131 and R132 have been disordered. 
5.3.2 Crystallographically observed 4NPG binding at the hGSTOl-1 
dimer interface 
Rather than the expected binding within the G-site, 4NPG was observed to bind along the 
crystallographic 2-fold corresponding to the l iGSTOl - l dimer interface (Figiu'es 5.2 on the 
preceding page and 5.6 on page 110). The molecule is observed orientated with its aromatic 
functionality pointing downwards into the diineric cleft, with the giutathionyl portion of 
the molecule extending upwards towards the G-site. Its glycinyl carboxylate is seen to form 
a hydrogen bonding network to the 7-glutamyl amino acid functionality of GSSG via the 
side chain of E85 and two bridging molecules of solvent, while the 7-glutamyl carboxylate 
displaces two water molecules to form a salt bridge with the conserved guanidiniuni of R37 
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Figure 5.3 
A closer inspection of the hGSTOl active site showing the binding of GSSG and GSH in stick 
representation, the latter in translucent. These oxidised and reduced forms of glutathione were 
refined to occupancy values of 0.7 and 0.3 respectively. The weighted 2mFo - DFc electron density 
corresponding to GSSG is shown as gray isomesh contoured to a level of Icr. To reduce distortion, 
bias and noise, the map shown has been 'kicked' using the phenix.maps program |45l (Section 5.2.1 
on page 102). hGSTOl is shown as a cyan cartoon overlaid in a translucent molecular surface. The 
interaction of GSSG with the polypeptide is highlighted in magenta. 
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Figure 5.4 
Oxidised glutathione and associated amino acids within the liGSTOl active site are shown in stick 
representation, coloured according to atom type. GSH was refined to an occupancy of 0.;i and is 
overlaid in translucent stick representation within the G-site. While the corresponding half of GSSG 
shares the polar interactions of GSH previously observed 14], the other half, extending upwards into 
the H-site, exhibits interactions that are principally hydrophobic in character. Relative to the GSH 
bound structure |4|, it's binding has been acconnnodated by a movement of the Y229 hydroxyl by 
4.5 A and the adoption of an alternate conformer of W222. The side chain conformations of nearby 
K57, 1131 and R132 have been disordered (not shown). The crystallographically observed distance 
of all polar contacts are given in A . The edge of nearby 4NPG is visible on the right hand side. 
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Figure 5.5 
The conformational change within the a6-a7 loop associated with GSSG binding in the adjacent 
H-site (gray) is contrasted to that observed in the complex with glutathionyl methylarsenite/HDNB 
(yellow), and in the complex of the native enzyme with glutathione (magenta) |4|. One of the 
terminal glycine groups of GSSG is seen extending into the H-site in a position equivalent to the 
binding of HDNB observed previously (Figure 4.9 on page 78). The associated side chains of W222 
and R132 have likewise adopted alternate conformations, however the latter is no longer stabilised 
by a sulfate mediated salt bridge and its guanadinium group is disordered. Furthermore, the 
alternate rotamer of W222 no longer forms a hydrogen bond with the sulfur lone pair of M187. This 
structural change is suggestive of a 'conformational switch' that is specific to ligand iterations within 
the H-site, since it does not occur in response to either GSH |4| or ascorbate (Section 3.3 on 
page 50) binding within the G-site. The structural plasticity associated with the transition of the q6 
G-terminus from a kinked-helix, to a random coil loop region, is likely to be essential for the 
structural dynamics associated with ligand binding and efficient catalytic turnover. The reader is 
directed to Figure 4.9 on page 78 for cross reference. 
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(Figure 5.7 on page 111). Interestingly, its binding has also stimulated the rearrangement 
of the E91-K114 salt bridges, the only instances of polar interactions between the subunits. 
The side chains of both residues have moved several angstroms towards each other, forming 
a four way salt bridge (Figure 5.8 on page 112). At the apex of this interaction is a 
bridging molecule of solvent located precisely on the crystallographic two-fold, residing 
directly below 4NPG. This molecule of solvent concurrently accepts hydrogen bonds from 
the K114 amine and its symmetry related partner while donating one to the phenacyl 
carbonyl group of 4NPG. While the movement of E91 and K114 from the opposing dimer 
are enforced in this instance by tlie internal symmetry of the crystal, it is hkely that they 
would follow their electrostatic counterparts upon binding of the substrate physiologically. 
Notably, this rearrangement of the only electrostatic interaction between monomers may 
represent a mode of cornnninication and possible cooperation associated with this mode of 
catalysis. This is corroborated by both ligands being observed concurrently despite many 
attempts to visualize hGSTOl complexed to each in isolation. During previous kinetic 
characterizations of this reaction |102| this possibility was not investigated, and future 
work may be warranted to allow an estimation of cooperativity. 
The newly orientated carbon chain of K114 now forms the floor of a hydrophobic 
binding groove accommodating the nitrophenacyl functionality. The remaining walls of 
this cavity are comprised of the lipophilic side chains of A87, L103 and L176. M172 forms 
the end of this greasy pocket (Figure 5.7 on page 111). 
As mentioned above (Section 5.3 on page 102), the binding mode of 4NPG presented 
here, may be representative of a 'ligandin' binding mode also observed in other classes of 
GST |107, 104, 108, 105, 106|. Two crystal structures exemplifying this warrant particular 
mention. The binding of the anti-Schistosomiasis drug Praziquantel to an a class GST 
of the parasitic worm Schistosoma japonica |107|, and the complex formation of the glu-
tathione conjugate, S-(3-iodobenzyl)glutathione with a a class GST of squid |108| are both 
reminiscent of the dimer interface mode of binding that has currently been discovered for 
4NPG. The crystal structures of these enzymatic complexes were sui)erimposed with the 
4 N P G / G S S G ternary complex for comparison (Figure 5.9 on page 113). 
5.3.3 Comparisons with other binding modes of GSSG 
There is only two instances of GSTs complexed to GSSG within the PDB . The first is a 
representative of the human Mu class, hGSTM2-2 (PDB identifier: lYKC) |109|. while the 
110 The ternary complex of liGSTOl with 4NPG and GSSG 
^IZ'f 
Figure 5.6 
4NPG is shown in stick representation, coloured according to atom type. The corresponding region 
of electron density is shown as a weighted 2mFo - DFc map, that has been 'kicked' using 
phenix.maps utility |45| (Section 5.2.1 on page 102), depicted as gray isomesh contoured at a level of 
1(7. A 7-glutamyl amino acid moiety of GSSG is visible in the upper left corner. The crystallographic 
fold of hGSTOl is shown as cyan cartoon overlaid with a translucent molecular surface. As in 
Figure 5.2 on page 104, interactions with the bound compounds are highlighted in yellow. 
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F i g u r e 5.7 
4NPG is siiown in stick representation along with associated amino acid residues, coloured according 
to atom type. O f particular interest is the associated rearrangement of the E91-K114 salt bridges. 
The two residues have moved several A towards each other to concurrently form a hydrogen bonding 
network to 4NPG via a bridging solvent molecule, that is located precisely on the crystallographic 
2-fold. The symmetrically generated instances of these two residues are shown in translucent 
magenta while their position in the glutathione bound native structure |4l are shown in yellow. The 
symmetrically generated copy of 4NPG is not shown for clarity. For a clearer view ol this structural 
change, the reader is directed to Figure 5.8 on the next page. At the other end of the molecule, the 
glycinyl carboxylate is hydrogen bonded to a 7-gutamyl amine of GSSG via the side cham ol ^85 
and solvent molecules (not shown). The 7-glutamyl end of 4NPG on the other hand, is observed to 
form a salt bridge interaction with the guani<linium of IW?. The crystallographic (old of liGS 1 O l is 
shown a-s a cyan cartoon. 
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Figure 5.8 
A view of the E91-K114 salt bridge rearrangements approximately parallel to the crystallographic 
2-fold axis of symmetry. The molecule of hGSTOl in the asymmetric unit is shown as a cyan 
cartoon with its symmetrically generated equivalent in magenta. The new polar interactions 
surrounding 4NPG are shown with dashed lines, with crystallographically observed distances 
reported in A . The position of the symmetrically related ion pairs observed in the native complex 
|4] are shown in stick representation overlaid in translucent yellow. For clarity, other side chains are 
shown only for the molecule within the assymetric unit, coloured according to atom type. 
§5.3 Results find Discussion 113 
F igure 5.9 
The crystallographic fold of hGSTOl is shown as a cyan cartoon with its symmetrically generated 
subunit in magenta. The view is from above the physiological dimer, tilted to the left to allow 
visualisation of ligand binding at the interface. The binding mo<le of 4NPG has been compared to 
the 'ligandin' binding modes of S-(3-iodobenzyl)glutathione (orange) and Praziquantel (blue) m the 
a class of squid and the a class of of S. japonica respectively. The crystal structures of these 
enzymatic complexes were superimposed onto that of hGSTOl using the SSM algorithm in Coot 
1431 The a class S-(3-iodobenzyl)glutathione complex (PDB identifier: 2GSQ) superimposed with a 
rmsd value of 2.44 A over 172 residues while the a class Praziquantel complex (PDB identifier: 
IGTB) superimposed with a rmsd of 2.61 A over 177 residues (not shown for clarity). 
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second is a Sigma class GST derived from the parasitic fluke Fasciola hepatica, FhGSTSl-1 
(PDB identifier: 2WDU, unpublished). These have been overlaid with the hGSTOl C32A 
GSSG/4NPG ternary complex presented here for comparison. Representations of both 
the monomers (Figure 5.10 on the facing page) and physiological dimers (Figure 5.11 on 
page 116) are shown. Inspection of GSSG binding within the former reveals that while the 
enzymes share analogous binding modes of the glutathionyl functionality within the G-site, 
the conformational space sampled by the second half of the disulfide is distinctively differ-
ent. When viewed in context of the physiological dimers, this appears to be attributable to 
the characteristically open dimer interface of hGSTOl-1. Within FhGSTSl-1 for instance, 
the glycinyl motif of GSSG is stabilised by a hydrogen bond to N131 from the equivalent of 
helix a5 in the opposing monomer. Within hGSTOl-1 however, the relative orientation of 
monomers renders such an interaction impossible (Figure 5.11 on page 116). Conversely, 
there is no such interaction within hGSTM2-2. Although like most GST classes, there is 
an interdimeric interaction between the glutathionyl functionality occupying the G-site, 
the absence of these within the Omega class was previously noted not to alter its binding 
mode [4], The difference between the human Mu and Omega classes rather appears to have 
arose from the evolution of a novel G-terminal extension within the latter. Comprised of 
a-helices 9 and 10, this has resulted in a 'deeper' H-site in the Omega class 14]. The corre-
sponding region within the Mu class is occluded by residues of the random coil C-terminus, 
leading to a fundamentally different binding mode. Principally, the glycinyl moiety is seen 
to be stabilised by several polar interactions with the side chains of hGSTM2. Its car-
boxylic tail forms two salt bridge interactions with the guanidinium groups of R107 and 
R165 while its amide carbonyl is hydrogen bonded to the Y115 hydroxyl. The 7-glutamyl 
functionality on the other hand is orientated into the interdimeric cleft. There is a stark 
absence of such polar interactions with the H-site residues of hGSTOl. This, coupled to 
the relatively much deeper H-site pocket has results in a much 'tighter' mode of binding. 
Both ends of the H-site bound glutathionyl functionality are actually orientated away from 
the interdimeric cleft, rather than towards it. The evolution of a relatively open dimer 
interface that has facilitated the novel binding of 4NPG observed here, appears to have 
been coupled with a new recognition mode of GSSG. This is likely to have profoimd im-
plications for this products binding affinity and subsequently, for the catalytic efficiency of 
all hGSTOl-1 mediated chemistry. 
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Figure 5.10 
The structural fold of the liGSTOl C32A monomer is shown ;is a cyan cartoon coniplexed with 
GSSG and 4NPG in stick representation, coloured according to atom type. Overlaid in translucent 
is the GSSG complexes of hGSTM2 (magenta) and FhGSTS (yellow). A magnified view of GSSG 
binding is also given for clarity. While binding of the ligands glutathionyl functionality is seen to be 
generally conserved within the G-site, the second half of the disulfide displays significant 
conformational heterogeneity. 
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Figure 5.11 
The relatively open configuration of the hGSTOl-1 dimer in complex with GSSG and 4NPG is, 
contrasted to the GSSG complexes of the more closed hGSTM2-2 and FhGSTSl-1 dimers. The 
solvent inaccessible area at the hGSTOl-1 dimer interface with ligands removed is 1948 A^ 
compared to 2782 and 2637 A for the hGSTM2-2 and the FhGSTSl-1 dimers, respectively, 
(calculated using the SurfRace algorithm |110|). The physiological dimers above have been aligned 
to the structural unit on the left, accentuating the differences in the relative orientation of 
monomers. Colouring is as stated in Figure 5.10 on the preceding page. A close up of the GSSG 
binding modes has again been shown for clarity. 
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5.3.4 Comparisons with other GSTO orthologs catalysing the reduction 
of aromatic xenobiotics by deglutathionylation 
The white rot fungus Phanerochaete chrysosporium, has recently been characterised to ex-
press 8 different enzymes that appear to belong to the GST Omega class, named PcGSTOl 
to PcGSTOS |111|. These have been categorized into 3 subclasses based on phylogenetic 
analysis and substrate specificity. The subclass If and III enzymes are the most closely 
related to mannnalian orthologs such as l iGSTOl, while the type I enzymes appear to be 
more closely related to bacterial GSTs [112| and the Lambda GSTs of plants |56|. The func-
tional divergence of the Omega class within P. chrysosporium is reflected within the other 
GST families expressed by the organism, that display similar diversity. Combined with an 
equally diverse complement of phase I detoxifying Cytochrome P450 monooxgenases, the 
fungus is able to degrade many recalcitrant compounds including pesticides, halogenated 
aroniatics, polyaromatics and textile dyes |113|. In addition, P. chrysosporium is the only 
known organism capable of completely degrading lignin to carbon dioxide and water. 
Two representatives of the type 1 and type II sub-classes, PcGSTOl and PcGSTOS 
respectively, have recently been biochemically characterised by Meux et.al., accompanied 
by the crystal structure of the former |113|. Both enzymes display characteristic thi-
oltransferase and dehydroascorbate redvictase activity that is dependent on an active site 
cysteine, however PcGSTOl is also capable of catalyzing the reduction of S-glutathionyl-p-
hydroquinone substrates, whereas P c G S T 0 3 is not. Conversely, only P c G S T 0 3 is catalyti-
cally active to 4NPG, and in fac-t displays a catalytic efficiency over an order of magnitude 
higher than observed for l iGSTOl |113|. Of particular interest, both native PcGSTOl 
and P c G S T 0 3 are inactive towards CDNB. however, the glutathione conjugation activity 
of P c G S T 0 3 can be restored in analogous manner to l iGSTOl, by mutating the active 
site cysteine to an alanine. The equivalent active site mutant of PcGSTOl however, re-
mains inactive |113|. This difference in enzymatic activity may be reconciled by compar-
ing sequence conservation within their active sites. While P c G S T 0 3 contains a conserved 
F C P F V Q G-site sequence quite similar to the FCPFAE signature of l iGSTOl. PcGSTOl 
contains a CPVVATR motif that is conserved in orthologs within other species, such as the 
three G S T O homologues identified in S. cerevisiae, designated Gtol to Gto3 |114|, and 
in bacterium such as Sphingobium chlorophenolicmn and E. coli. named PcpF and Y(i_jG 
res[)ectively (Figure 5.18 on page 126). These enzymes have also been identified to func-
tion as S-glutathionyl-p-hydro(iuinone reductases |I12|. This has prompted the suggestion 




A comparison of 4NPG (left) to the structure of a typical S-glutahionyl-p-hydroquinone (right) 
substrate of PcGSTOl |113]. 
for these enzymes to be classified within their own class, designated ^ (Xi) [112, 113]. 
Indeed, this is corroborated by the recent solution of the PcGSTOl-1 crystal structure. 
The enzyme displays a unique N-terminal extension of 77 residues, over 3 times the length 
observed in hGSTOl, and also possesses the novel a9 helix at its C-terminus. Rather than 
subsequently terminating with the short helix alO however, the additional 20 residues of 
the PcGSTOl C-terminal extension forms a coiled motif that also travels antiparallel to 
helix a9, but along its opposite face. This is seen to facilitate an entirely unique mode 
of dimerisation in the enzyme (Figure 5.13 on the facing page), which in contrast to all 
other GSTs, is exclusively mediated by the a-helical C-terminal domain. In addition, this 
C-terminal coil is prevented from adopting the same confirmation as hGSTOl helix alO 
due to this region of space being already filled by a 20 residue insert that forms an unusu-
ally long P2-a2 loop. [113|. In lieu of PcGST03, this structure (PDB identifier: 3PPU) 
has been overlaid with the hGST01/4NPG/GSSG ternary complex for comparison (Fig-
ure 5.13 on the next page). Despite the dramatically different mode of dimerisation, chain 
A of each superimposed with an rmsd value of 2.64 A over 170 residues [43]. 
While the enzyme was observed in complex with GSH within only one of the 2 
monomers within the asymmetric unit, the mode of ligand binding was observed to be 
highly similar to hGSTOl. The successive interactions of L71 and V72 with its glycinyl 
moiety are conserved, as are the polar interactions of its 7-glutamyl zwitterion with E85 
and S86. Similarly, the hydrophobic interaction of this region with F34 has been conser-
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F igure 5.13 
The ternary complex of hGSTOl-l with 4NI^G and GSSG contrasted to tlie novel mode of 
dimerisation observed within the type 1 ortholog of P. chri/sosponum. The crystallographic fold of 
hGSTOl-1 is shown as a cyan cartoon with that of PcGSTOl-l overlaid in magenta. The novel N-
and G-terminal extensions are highlighted in yellow and red respectively, while the 27 residue 02-a2 
loop is shown in black. Despite the disparity in their relative modes of dnnerisation, equivalent 
chains aligned with an rmsd value of 2.64 A over 170 residues |43|. The binding positions of the 
ligands 4NPG, GSSG and GSH are shown in stick representation, coloured according to atom type. 
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vatively replaced with an analogous rotamer of a tryptophan residue. Other interactions 
were nonetheless unprecedented. The guanidiniurn group of R56, belonging to the novel 
N-terniinal extension of PcGSTOl, is seen to form a polar interaction with the cysteinyl-7-
glutamate carbonyl, effectively creating a 'lid' on the binding site. Similarly, the cysteinyl-
glycine carbonyl accepts a hydrogen bond from the indole nitrogen of W119, located within 
the inserted (32-a2 loop structure. In addition, a slightly longer loop at the a2-/33 junction 
facilitates the formation of two polar interactions between the guanidinium group of R155 
and the opposing glycinyl carboxylate of GSH (Figure 5.14 on the facing page). These 
interactions between the novel structural motifs of PcGSTOl create a much more 'closed' 
active site relative to hGSTOl. The solvent accessible surface area of GSH being only 
45 A^, compared to 145 A^ within the equivalent complex of hGSTOl (Figure 5.14 on 
the next page) [4, 113|. Indeed, within the other opposing monomer in which GSH was 
not observed, residues 1-54 were disordered, suggesting that conformational change in the 
N-terminal extension may be required for the substrate to gain access to the G-site. 
The most surprising feature of GSH binding to PcGSTOl however, is perhaps the 
absence of a mixed disulfide bond with the active site residue C86. Its sultliydryl was crys-
tallographically observed to reside 3.9 A away from that of GSH. The latter is rather seen 
to engage in a polar interaction with the side chain hydroxyl of Y223, itself participating 
in a tight hydrogen bonding network with nearby Y281 and Y326. This triad of tyrosine 
residues completely occludes the H-site of overlaid hGSTOl, suggesting a dramatically 
altered mode of GSSG binding. Indeed, while the hydrophobic nitro-benzene group of 
4NPG can easily be modeled within this region of hGSTOl (Figure 5.15 on page 122), the 
putative binding of S-glutathionyl-p-hydroquinone to PcGSTOl would necessitate novel 
interactions whose precise nature are still unclear [113] (Figure 5.16 on page 123). 
The 'ligandin' binding mode observed for 4NPG however, could be conserved. Although 
within the ternary complex of hGSTOl, 4NPG was observed along a crystallographic two 
fold corresponding to the dimer interface, the novel dimerisation of PcGSTOl subvmits has 
exposed the equivalent region to solvent. As could be expected, there has been a concerted 
shift away from the characteristically hydrophobic environment associated with this region 
of hGSTOl-1, to accommodate a complement of charged and polar side chains instead. 
Comparison of 4NPG binding with the overlaid structure of PcGSTOl suggests this has 
not necessarily precluded an equivalent binding mode of S-glutathionyl-p-hydroquinone 
however (Figure 5.17 on page 125). The two residues observed to interact with both 
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F i g u r e 5 . 1 4 
T h e G-site of P c G S T O l is sliown as a magenta cartoon witli GSH and associated amino acid 
residues sliown in sticlc representat ion. T h e binding of GSH. observed with an occupancy of 0.3 in 
the overlaid h G S T O l complex with GSSG and 4NPG, is shown in translucent stick representation 
along with the nearby binding of 4NPG. GSSG is not shown for clarity. Polar interactions are shown 
as dashed lines and the crystallographically observed distances of each quoted in A . 
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Figure 5.15 
The enzymatic binding mode of 4NPG within the hGSTOl H-site was modeled via real space 
refinement |43| into the 2mFo - DFc electron density corresponding to bound GSSG. Ligand 
binding is shown in stick representation, coloured according to atom type. The experimentally 
determined binding of GSSG and 4NPG are overlaid in translucent. The crystallographic fold of 
hGSTOl is shown as a cyan cartoon, covered in a translucent molecular surface. The hypothesised 
binding mode of 4NPG in the active site is highlighted in magenta. Superposition of the PcGSTOl 
crystal structure shows that an analogous binding mode of Ugands would be impossible (Figure 5.16 
on the next page). 
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Figure 5.16 
The superposition of 4NPG binding modeled in Figure 5.15 on tiie preceding page witli the crystal 
structure of PcGSTOl reveals that the H-site of hGSTOl has not been conserved. Its occlusion by 
the side chains of 3 tyrosine residues, engaged in hydrogen bonding network to the thiol of GSH (not 
shown for clarity), suggests that the productive binding of glutathionylated aroniatics and GSSG 
would feature novel interactions that are as yet uncharacterised. The transhicent molecular surface 
of hGSTOl is shown in cyan, with putatively bound 4NPG in stick representation, coloured 
according to atom type. The crystallographic fold and associated residues of PcGSTOl are shown in 
magenta. 
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substrates within the hGSTOl ternary complex of GSSG and 4NPG, R37 and E85, are both 
tightly conserved in the form of PcGSTOl residues R91 and E173, respectively. While the 
sum of these substitutions would create a significantly different electrostatic environment 
for the binding of S-glutathionyl-p-hydroquinone, there is no obvious steric inhibition of 
it doing so. Of particular interest, the substitutions within this region of PcGSTOl are, 
almost without exception, tightly conserved within the sequences of homologues from other 
species also suspected to belong to this subclass of Omega (GST Xi class), but not within 
the type II subclass more closely related to the mammalian enzymes, expected to have the 
same dimerisation mode as hGSTOl-1 (Figure 5.18 on page 126). 
5.3.5 Structural basis for substrate specificity within the Omega class 
A question that must be asked about the phenacyl glutathione reductase activity of 
hGSTOl-1, is why it is not shared by its homologous isozyme, hGST02-2? The recent 
solution of the hGST02 crystal structure by my colleague. Dr. Huina Zhou (unpublished 
data), allows a detailed structural argument to be framed in response. Structural align-
ment of the isozyme with the hGSTOl ternary complex is achieved with a rmsd value of 
0.94 A over 238 residues [43], and the region of the dirner interface associated with binding 
of 4NPG is observed to be remarkably conserved (not shown). The only changes within the 
immediate vicinity of the substrate are the conservative replacements of L103 and Kl lO, 
by F103 and RllO. 
The disparity in enzymatic activity is therefore likely to arise from chemical differences 
associated with the putative binding of 4NPG within the active site. Within this region, 
there are several inconsistencies that may be of relevance. The structure of hGST02 was 
solved in complex with GSH in the G-site, and its mode of binding, as well as the associated 
residues, are highly similar to those of hGSTOl. The non-conservative L71H substitution 
noted previously (Figure 3.10 on page 59) is unlikely to affect binding of 4NPG, since it 
would be expected to interact with its glutathionyl functionality in a similar confirmation. 
The significant structural heterogeneity within the H-site is a much better candidate for the 
observed differences in activity (Figure 5.19 on page 128 and 5.20 on page 129). Based on 
similar complexes of GSTs with derivatives of l-glutathionyl-2,4-dinitrobenzene [33, 115, 
116, 117, 6|, the nitrophenacyl moiety of 4NPG would be expected to bind in the manner 
shown in Figure 5.15 on page 122. Within hGST02 however, several non-conservative 
amino acid substitutions would make such a binding mode difficult. Perhaps the most 
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F i g u r e 5 .17 
A superposi t ion of tiie 4 N P G binding mode to l iGSTOl witii the equivalent region of P c G S T O l 
suggests it may be t ransposable to the binding of S-ghitathionyl-p-liydroquinone. Despite several 
non-conservative amino acid subst i tu t ions within the P. chrysosporitim enzyme, only minor 
conformat ional changes in the associated amino acids would be required to acconmiodatc an 
equivalent binding mode. T h e s t ruc tura l fold of h C S T O f is shown as a cyan cartoon, with the 
observed binding of 4 N P G and associated side chains shown in translucent stick representation, 
coloured according to a tom type. T h e equivalent region of the P c G S T O l is overlaid in magenta, 
which due to its novel mode of dimerisation, is now located at the solvent interface. Pu ta t ive 
residues associated with an equivalent binding mode of S-glutathionyl-p-hydroquinoiie are labelled 
accordingly. T h e equivalent residue to E91 within h G S T O l - 1 , tha t forms an intermolecular salt 
bridge with K114 in the opposing monomer, has been replaced by 11179 within P c G S T O l , and now 
forms an equivalent intramolecular interaction with residue E265 from nearby a(). This interaction 
is indicated with dashed lines, the crystallographically observed distances of each is quoted in A . 
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Figure 5.18 
The multiple sequence alignment of P c G S T O l with members of the GST Xi class from yeast 
(ScGtol-3) , E. coli (EcYqjG) and S. chlorophenolicum (ScPcpF), compared to the the human 
Omega class enzymes and PcGST03 . The highly conserved active site motif is outlined in a red 
box. Based on the complex of hGSTOl with 4NPG, residues hypothesised to feature in a 'ligandin' 
binding mode of S-glutathionyl-p-hydroquinone are marked with coloured asterisks. Those also 
associated with binding of GSH are marked with a blue asterisk, while the positions of the 
R179-E256 salt bridge residues are marked in magenta. The rest are marked in red. Almost without 
exception, these are tightly conserved within the putative Xi class enzymes, but not within 
PcGST03 , expected to possess a mode of dimerisation analogous to the human Omega class. (NB: 
The residue numbering of P c G S T O l in this figure is positive by a value of 31 with respect to the 
rest of the text. This is due to the sequence containing a signaling peptide that was excised prior to 
purification of the recombinant enzyme |113|). 
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striking is the substitution of M187 for Y188, which in a manner reminiscent of residue Y223 
from PcGSTOl (Figure 5.16 on page 123), is observed orientated downwards, partiaUy 
occluding the H-site. Intriguingly, this residue is located at the start of the a6-a7 junction, 
and may also affect enzymatic activity via its steric bulk restricting the conformational 
change associated with substrate binding to hGSTOl (Figure 5.5 on page 108). In addition, 
a radical replacement of G128 with a lysine has occurred at the entrance to the hGST02 
H-site. Although 5.3 A away from the hydroxyl of Y230 from the shifted helix a9, these 
two residues effectively form a 'polar gate' , that together with the side chain of Y188, 
may make the binding of hydrophobic moieties in this region electrostatically and sterically 
impossible. It is possible that a previous gene duplication of an ancestral hGSTOl sequence 
may have allowed divergent evolution away from its structural features adapted for the 
detoxification of hydrophobic xenobiotics, subsequently facilitating the development of 
this enzymes exceptional efficiency towards the reduction of dehydroascorbate. 
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Figure 5.19 
The superposition of hGST02 (Dr. Huina Zhou, unpublished data) H-site residues with the 
modeled binding of 4NPG to hGSTOl shown in Figure 5.15 on page 122 reveals several immoderate 
substitutions that may contribute to their differing enzymatic activity towards S-phenacyl 
glutathione substrates. The side chains of hGST02 (magenta) show that the replacement of a 
methionine by the side chain of Y188 results in a significant occlusion of the H-site pocket. In 
addition, a glycine of helix a4 has been replaced by a lysine at position 128, significantly decreasing 
the size and hydrophobicity of this enzymatic cleft. The structural fold of the hGSTOl ternary 
complex is shown as a cyan cartoon with the putative binding of 4NPG shown in stick 
representation, coloured according to atom type. 
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Figure 5.20 
A translucent molecular surface representation of tlie h G S T 0 2 active site relative to the putative 
binding mode of 4NPG binding within the equivalent region of l iGSTOl shows significant occlusion 
of the H-site. The structural fold, molecular surface and relevant side chains of h G S T 0 2 are shown 
in magenta, with hypothetical contacts of 4NPG highlighted in yellow. Of most interest are the 
residues K128 and Y188. While the hydroxyl group of the latter resides in a position that clashes 
with the para-nitro group of 4NPG, the non-conservative replacement of an a4 glycine with a lysine 
has resulted in dramatic size reduction of this binding cavity. Together with the opposing side chain 
of Y230, this has effectively formed a 'polar gate' to the H-site. While a narrow channel is still 
present below these residues, it is most likely too narrow and electrophilic to accommodate the 
bulky phenacyl moieties of substrates such as 4NPG. I am indebted to Dr. Huina Zhou for allowing 
me to use the coordinates of h G S T 0 2 prior to publication. 
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Chapter 6 
Efforts to discover the mode of 
hGSTOl-1 inhibition 
A limited additive screen and altered purification conditions 
has led to the discovery of two novel crystal forms 
Alzheimer's disease is a neurological disorder that has long been suspected to involve the 
aberrant expression of the pro-inflammatory mediator IL-1 as a causative factor |118|. 
The discovery that liGSTOl-l was the target of a class of diarylsulfonyl urea drugs known 
to inhibit the post translational modification of this cytokine was therefore provocative, 
especially given the previous associations made between this enzyme and the age at onset 
of Alzheimer's disease |119|. 
Yet another type of liGSTOl inhibitor has recently been discovered during the test-
ing of a high-throughput method of selective inhibitor discovery involving a fluorescent 
activity-based probe (32|. Due to upregulation of liGSTOl-l in several cancer cell lines 
tliat show enhanced aggressiveness and therapeutic resistance, it was a prime candidate 
for these researchers to trial their new method. This resulted in the identification of an 
a-chloroacetaniide polyphenol that could {)otently and selectively inhibit the enzyme. An 
aim of this research was to characterise the mechanism by which these compounds in-
hibited liGSTOl crystallographically. While these efforts to date have been unsuccessful, 
they have identified two novel crystal forms of the enzyme. The subsequently solved crystal 
structures have provided valuable insight into the structural dynamics of hGSTOl and are 
discussed in more detail below. 
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6.1 Introduction 
When Interleukiri 1 (IL-1) was discovered in the late 1970's, many researchers found it 
hard to beheve that its varied effects within the body could be attributed to just one 
protein. It was able to trigger fever and activate white blood cells, but also appeared to 
play a tissue destructive role in arthritic joints and influence other proteins within the liver. 
Now known to be a pro-inflammatory cytokine, it has been implicated in a wide variety of 
inflammatory and autoimmune diseases |120]. 
There are two isoforms of the protein, encoded by related but separate genes, and 
their transcribed products are known as IL- la and Il-f/3, respectively [f21|. The latter 
is primarily produced by activated cells of the monocytic lineage, including monocytes, 
macrophages and dendritic cells. While this cytokine has an essential and beneficiary 
role in mediating responses to microbial attack, it can also be damaging. The protein 
has been associated with an increase in tumour malignancy and appears to facilitate tissue 
damage in the pathogenesis of chronic auto-inflammatory conditions such as arthritis [122]. 
The cytokine is therefore not constitutively expressed, but is transcriptionally upregulated 
in response to a variety of stimuli. These typically fall into two categories; (i) Those 
associated with the invasion of pathogens, such as lipopolysaccharide (LPS), and (ii) those 
associated with cell damage, such as extracellular ATP [122, 123|. Unlike most other 
cytokines however, IL-1 requires post-translational processing from its procytokine form in 
order to be efficiently exported from the cell and invoke a response. Tfie post-translational 
processing of IL-1/3 is known to be mediated by the enzyme caspase-1, that cleaves the 
31 kDa translation product into a mature 17 kDa cytokine. This exposes an N-terminal 
signal sequence that allows it to be efficiently exported from the cell [122]. Caspase-1 is now 
known to be regulated by large intracellular protein complexes known as inflammasoines. 
While the precise mechanism by which this occurs is still unclear, the efflux of K+ ions 
from the cell appears to be a key upstream trigger of their activation [122[. In response to 
extracellular ATP for instance, the P2X7 receptor initiates a cascade of chemical events that 
eventually lead to increased IL-1/3 post translational processing and release. Immediately 
following the binding of tfie nucleotide, this receptor undergoes conformational change to 
function as a non-selective cation channel. This is also known to activate several stress 
kinases, transcription factors, phospholipases, cause membrane depolarization and in some 
instances, apoptosis [122, 24[. 
Based on the premise that ionic changes stimulate the post-translational modification 
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of IL-1, Pfizer has identified a series of lead molecules from a screen of known ion channel 
blockers which inhibited the release of ATP-induced IL-1/3 from human monocytes. The 
diarylsulfonyl urea functional group was discovered to be particularly effective, and sev-
eral compounds that showed promising selectively were termed Cytokine Release Inhibitory 
Drugs (CRIDs) [123]. Cell extract derived from LPS-activated/ATP-treated human mono-
cytes in the absence or presence of one such CRID, CP-424174 (Figure 6.1a on the follow-
ing page), showed comparable levels of other signaling molecules such as IL-6 and tumour 
necrosis factor-a, however those treated with the diarylsulfonyl urea showed a 30-fold de-
crease in the levels of 11-1/3 |123. 121|. While the precise mode of action was unknown, 
they were known not to be direct inhibitors of caspase-1 or the interaction of ATP with 
P2X7. Traditional biochemical experiments were therefore performed to discover its target 
within the proteome. When extracts of human monocytes were passed through a CRID 
affinity column, liGSTOl-l bomid selectively and was eluted by a soluble form of the drug. 
In addition. hGSTOl-1 readily incorporated ^"^C-labelled epoxide containing CRIDs in an 
irreversible manner. This was dependent on the presence of an active site cysteine and 
correlated with an inhibition of cytokine production. Interestingly, a CRID-glutathione 
adduct was also capable of inhibiting the ATP-induced post-translational processing of the 
cytokine |24]. 
These findings are provocative given the region of chromosome lOq containing hGSTOl 
and hGST02 has been associated with an earlier age at onset (AAO) of both Parkinson's 
and Alzheimer's disease in genetic mapping studies |119| and that these conditions are 
characterised by augmented levels of IL-1 expression [118, 122|. A SNP within exon 4 
of hGSTOl is associated with a common A140D polymorphism that was subseciuently 
found to associate with the AAO of both conditions, as was another in the promoter 
region of hGST02. The association of these polymorphisms could not be confirmed in 
other populations however |124. 125|. In addition, innmmostaining of the atherosclerosis 
plaques of peoples brains suffering from the closely related condition of vascular dementia 
and carrying the A HOD polymorphism revealed a co-localization of hGSTOl-1 and IL-lot 
|23|. Furthermore, IL-1 is differentially and abnormally over-expressed in the brains of 
Alzheimer's patients. A polymorphism within the promoter region of the IL-la gene, and 
another within a coding region of IL-1/9 gene, have both been associated with the over-
expression of the cytokine and infer an increased risk of developing several auto-innnune 
conditions. Patients homozygous for the IL-la polyniori)hism for instance, are up to 3 
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IC5o=210nm 
(a) An example of the diarylsulfonyl urea 
class of CRIDs found to target GSTOl -1 in 
human monocytes by Laliberte et ai, 
designated CP-424174 [24|. 
IC50 = 120 nm 
(b) The potent and selective a-chloroacetamide 
inhibitor of hGSTOl -1 discovered by Bachovchin et 
ai, [32]. 
Figure 6.1 
Two selective and potent inhibitors of hGSTOl-1 . 
times more likely to develop Alzheimer's disease, and are likely to do so approximately 10 
years earlier than average. If patients are homozygous for both polymorphisms, the risk is 
compounded to over 10 times greater than the rest of the population [118]. 
The inhibition of the Omega class has also been pursued directly. The fact that 
hGSTOl-1 is over expressed in several human cancer cell lines that show enhanced ag-
gressiveness and chemotherapeutic resistance made it an ideal model target for a recently 
developed method of selective inhibitor identification using high-throughput screening with 
fluorescent activity-based probes. Using this technology, these researchers were able to 
identify a polyphenol that was a potent inhibitor of the enzyme. It was determined that 
this a-chloroacetamide possessed an IC50 = 120 nM (Figure 6.1b), using a 4NPG assay 
[32|. 
During this research, samples of both types of inhibitor were obtained from their man-
ufacturers. The aim of subsequent experiments was to crystallographically characterise 
their mode of hCSTOl-l inhibition. To date, these efforts have not been successful, but 
have resulted in the discovery of two novel crystal forms of hGSTOl, whose structures 
have been solved at resolutions of 3.21 and 1.81 A , respectively. The different methodolo-
gies employed, possible reasons for their failings and the insights into hGSTOl structural 
dynamics afforded by two novel crystal lattices are discussed below. 
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6.2 Experimental Methods 
One of the major hurdles facing any crystaUographic investigation of protein interaction 
with lipophihc compounds is the inherent insolubihty of the latter under the saturat-
ing conditions associated with crystal formation. The known crytsallisation conditions of 
hGSTOl-1 for instance 14|, features a precipitating agent of high salt (2.2 M (NH4)2S04), 
creating a fundamental difficulty in providing the relevant inhibitors (Figure 6.1 on the 
facing page) at the concentration required for observation crystallographically. Another 
that was faced during this research was the apparent redox sensitivity of the native en-
zyme. Repeated attempts at observing C32-thiol adducts with substrates and inhibitors 
within crystals of the native enzyme were consistently unsuccessful despite the controlled 
variation of other variables, such as inhibitor concentration, the presence of glutathione 
and pH. It was hypothesised that this may have been due to the oxidation of this residue 
to the sulfenic, sulfinic or sulfonic acid derivatives, or the inability to reduce the mixed 
disulfide bond between the active site cysteine and GSH once it was formed. Such problems 
in the ArsC enzyme of S. aureus (Section 4.3.4 on page 85) have previously been noted in 
the literature [96, 93, 94|. CrystaUographic observation of the active site cysteine-arsenical 
adduct required careful secondary purification with reverse phase HPLC, using buffers pre-
viously deoxygenated with argon gas. in order to purify and crystallise the catalytically 
active enzyme. The present investigation was further complicated by the use of the re-
ducing agent DTT within the published methods of hGSTOl-1 purification |4|. Since the 
selective inhibitors of hGSTOl-1 shown above (Figure 6.1 on the facing page) contain thiol 
reactive functional groups, it was possible that chemically formed adducts with DTT were 
also inhibiting their observation crystallographically. 
To address these issues, several strategies were adopted from a comprehensive review 
of the literature on this topic |126| and combined with strategies applied to the S. aureus 
enzyme |96, 93. 94|. One strategy involved incubating the enzyme with its inhibitors before 
it was concentrated. This approach had two advantages. By introducing the inhibitor prior 
to crytsallisation, it avoided the inherent insolubility associated with the high salt concen-
tration. Although still only marginally soluble in the aqueous protein buffer solution, the 
low concentration of the enzyme allowed a much higher inhibitor to enzyme molar ratio to 
be achieved. 
In addition, the 5 niM DTT included within the final dialysis buffer of previous 
hGSTOl-1 purifications was replaced with a 1 mPvI concentration of its physiological co-
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substrate GSH instead. While the monothiol of GSH is a less effective reducing agent, its 
use in combination with careful deoxygenation of buffers with argon prior to use proved 
sufficient for maintaining protein solubility. It was hoped that this would prevent non-
physiological reactions with ligands, that may have prevented the observation of their bind-
ing modes crystallographically. Unexpectedly however, subsequent hanging drop/vapour 
diffusion experiments using conditions analogous to those identified previously [4], resulted 
in the formation of crystals displaying a completely different morphology, subsequently 
found to belong to the tetragonal space group P4222 (Figure 6.3 on page 141). 
Finally, the review [126] had also noted success in observing complexes with lipophilic 
compounds via the use of limited additive screens, in which additive compounds involved in 
the crytsallisation of such complexes within the PDB were combined with known crytsalli-
sation conditions of the enzyme. One of the screened compounds suggested was guanidine 
hydrochloride, and its addition to the crystallisation conditions has resulted in a transi-
tion from the previously observed trigonal crystal lattice to orthorhombic crystals of space 
group C222i (Figure 6.4 on page 144). 
The experimental parameters associated with this altered methodology of protein pu-
rification, and the subsequent crystallisation of these novel crystal forms are detailed below. 
6.2.1 A redox sensitive purification protocol of hGSTO l native leads to 
two new crystal forms 
A 50 fiL aliquot of electroporation competent E. coli cells of strain BL21 were removed from 
storage at -80°C and transformed with 2 ^L of pHUE.hGSTOl plasmid via electroporation. 
0.5 ml of LB was then added immediately after the application of current to facilitate 
cell recovery. 100 ^L of this solution was then spread onto a LB agar plate (0.2 mg/ml 
Ampicillin) using sterile technique, dried face up and then incubated face down overnight 
at 37°C. The next morning, multiple colonies were observed on the agar plate. One was 
used to inoculate a 50 mL aliquot of LB media (0.2 mg/ml Ampicillin) and subsequently 
incubated at 37°C overnight with gentle shaking. The next morning, bacterial proliferation 
was observed, and 10 mL aliquots of this starter culture were used to inoculate 5 respective 
1 L volumes of media. This LB also contained 0.2 mg/ml of Ampicillin but in contrast 
to previous purifications, was also supplemented with 1 niM of GSH. These cultures were 
subsequently shaken at 37°C for hours until their optical density values at 600 imi were 
in the range of 0.6-0.8, before inducing with 300 ^L of 200 niM IPTG. After culturing 
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for a further 3.5 hours, the media was spun down in a 8K-10 centrifuge (Sigma) at 6500 
rpm for 30 minutes, using a Nr. 12510 rotor at 4°C. The supernatant was then discarded, 
and each of the 5 bacterial pellets resuspended in 50 mL of Buffer A (50 mM sodium 
phosphate, 300 m NaCl, 10% glycerol, IniM GSH, 30 mM imidazole, pH 7.5) that had 
been flushed with argon gas for several minutes immediately prior to use and contained 0.1 
mM of the protease inhibitor AEBSF. This was performed overnight using a mechanical 
stirrer bar at 4°C. The following day, the homogenous cellular resuspensions were lysed 
using a pre-chilled French pressure cell. The lysate was collected into centrifuge tubes and 
after removing floating nuclear material with a transfer pipette, spun down as above. The 
supernatant was then carefully decanted to exclude cellular debris, before vacuum filtering 
through 0.45 /xm filter paper (Millipore) in the cold room. The filtrate was then loaded 
onto a 5 ml 'His-trap' Ni-NTA column (GE Healthcare) using a peristhetic pump. An 
FPLC mediated imidazole gradient was then applied to the column from 0 to 500 mM, 
derived from buflter A that had been deoxygenated with argon gas. Due to the relatively 
high amount of imidazole in the loading buffer (30 mM), non-specific binding to the column 
was observed to be minimal, and absorbance at 280 nm indicated that the vast majority of 
protein had eluted near the start of the gradient. Subsequent analysis of these fractions via 
SDS-PAGE revealed them to almost exclusively contain significant quantities of relatively 
pure hGSTOl-1. The most pure fractions were pooled, and their combined volume found 
to be « 9 5 ml. A cleavage reaction was then performed via the addition of GSH and the 
Usp2 ubiquitinase to a final concentration of 10 mM and 25 Mg/ml respectively, followed 
by incubation at 4°C overnight. 
The protein solution was then dialysed against BuflPer A (0 mM imidazole) that had 
previously been fiushed with argon gas, and subsequently reloaded onto the re-equilibrated 
Ni-NTA column as above. The fiow through was collected in a conical fiask and the column 
was then washed with 3 CV of buffer A containing 0 mM imidazole, followed by a further 
3 CV containing 500 mM of imidazole. Subsequent SDS-PAGE analysis revealed the 
cleavage reaction to have proceeded with near 100% efficiency. A high quantity of pure, 
deubiquitinated hGSTOl was present in the flow through and initial column wash. The 
combined solutions were then dialysed in argon flushed final dialysis buflter overnight (20 
mM Tris, 60 mM NaCl, 1 niM GSH. pH 8). 
Approximately 2/3 of the protein solution was then concentrated using a 10 kDa MWCO 
centrifugal filter device (Amicon). When the volume had been reduced to approximately 
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Figure 6.2 
The diarylsulfonyl urea CP-457324. 
1 ml, the protein concentration was assayed via absorbance at 280 nm using a 'ND-1000' 
spectrophotometer (NanoDrop Technologies), and found to be 17.23 mg/ml . As this was 
deemed a sufficient concentration to facilitate crytsallisation, the protein solution was 
stored at 4°C for later use. 
The remaining i/s of the unconcentrated protein solution was then used for dilute in-
hibitor incubation experiments described in the literature [126]. This technique effectively 
allowed the protein to lipophilic inhibitor ratio to be increased to values that were im-
possible given the high salt environment of the published crytsallisation conditions [4]. 
After a period of incubation in which inhibitor binding and/or covalent modification could 
occur, the protein solution was subsequently concentrated and crytsallisation experiments 
performed. The former step was performed at room temperature in the hope the asso-
ciated increase in reaction rate would be sufficient to ensure inhibition was homogenous 
throughout the solution |126|. In order to determine at what concentration the inhibitors 
should be combined with the protein solutions, their reported IC50 values were considered. 
In the recent fluorescent activity-based probe identification of the a-chloroacetamide in-
hibitor (Figure 6.1b on page 134), a 4NPG assay containing varying concentrations of the 
compound determined its IC50 value to be 120 nM |32], while the in vivo IC50 value of 
the diarylsulfonyl urea CP-424174 (Figure 6.1a on page 134) has been reported as 210 n M 
[127|. A sample of a related diarylsulfonyl urea, CP-457324 (Figure 6.2), whose structure 
and activity are unpublished, had also been obtained from Pfizer pharmaceuticals and 
similarly employed in these experiments. 
Before the inhibitors were combined with purified hGSTOl-1, it was first decided to 
remove the 1 m M of GSH from the storage buffer by dialysis. This step aimed to min-
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iinise its capacity to compete with inhibitor binding in the G-site, and to allow formation 
of secondary reaction products with the thiol sensitive compounds. 5 L of final dialysis 
buffer was therefore prepared containing 20 mM Tris, 300 niM NaCl, pH 8.5, and flushed 
with argon gas for 10 miimtes prior to use. After testing a small volume for precipitation, 
the protein solution was dialysed overnight at 4°C. This eff'ectively diluted the amount of 
GSH present to 6.4 ^M. The next morning the concentration of the protein solution was 
ascertained to be 0.55 mg/ml. Dividing by the calculated molecular weight of the enzyme, 
27565.86 Daltons, the molar concentration was determined to be 20 /iM. The compounds 
were found to be most readily soluble in DMSO (dimethyl sulfoxide), and a 1 mM solution 
was made of each. The 10.7 ml aliquots of protein were then diluted to a final volume of 
28.2 ml with the final dialysis buff'er described above (freshly flushed with argon gas) and 
combined with 300 /iL of a respective 1 mM inhibitor solution. This resulted in the flnal 
concentrations of protein, inhibitor, GSH and DMSO being approximately equal to 7.6 
^M. 10 /.tM, 2 ^M and 1% (v /v) , respectively. The solutions were subsequently incubated 
at room temperature for 2.5 hours before being stored on ice, and then concentrated using 
a respective 10 kDa MWCO centrifugal device (Amicon) at 4°C. When each aliquot was 
reduced to a final volume of between 100-150 /iL, the hGSTOl-1/a-choloracetamide/CP-
424174/CP-4573234 solutions were found to be at concentrations of 25.18, 15.21 and 16.50 
mg/ml respectively. As these concentrations were deemed sufficient to facilitate crytsal-
lisation, they were stored at 4°C and used to set up crytsallisation screens the following 
day. 
6.2.1.1 Experimental conditions associated with h G S T O l crytsallisation and 
structure solvation in a tetragonal crystal lattice 
Strikingly, a precipitant versus pH crytsallisation screen at 4°C based on the previously 
published conditions |4| using the inhibitor protein solutions described above resulted in 
crystals of a completely different morphology (Figure 6.3 on page 141) and were subse-
quently discovered to belong to the tetragonal space group P4222 (Table 6.1 on page 141). 
Although the crystal structure presented here originated from a crystal grown from the 
'dilute inhibitor incubation' protein j)reparation detailed above, this step was not essential 
for crystallisation, since protein concentrated without performing this step also crystallised 
in this space group. Thus, this unexpected change in crystal morphology appears to be 
due to the altered protocol of protein pm'ification (Section 6,2.1 on page 136). Although 
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this crystal form presented the opportunity to crystallographically study the chemistry 
of hGSTOl-1 in the absence of non-physiological thiol reductants, crystals large enough 
for analysis by X-ray diffraction (>100x100x100 jum) were less common than the trigonal 
form studied previously. In light of this, and the limited supply of protein, efforts were 
made to increase the number of experimentally viable crystals via the technique of 'streak 
seeding'. This involved inspecting the drops of the crytsallisation screen after equilibration 
with the well solutions was complete, and identifying drops containing a low precipitant 
concentration, that still remained clear. A drop containing crystals was also identified. Af-
ter careful removal from their reservoirs, a cat's whisker was passed sequentially through 
the drop containing crystals and those that did not. It is thought that the microscopic 
aberrations on the surface of feline whiskers are especially adherent to micro-crystals, some 
of which are then dislodged when submerged in the subsequent pass through the unprecip-
itated crytsallisation drop. This was aimed to create a 'short cut' to the growth phase 
of the phase diagram shown in Figure 2.6 on page 26. By depositing small crystals into 
the pre-equilibrated drops directly, it removes the need for the supersaturatiori usually 
required for nucleation. This technique proved quite successful and increased the numVjer 
of useable crystals by several fold. These were subsequently cryoprotected using lithium 
sulfate and glycerol as described previously and used in X-ray diffraction experiments 
with radiation of energy 13001.25 eV, on the PX2 protein crystallography beamline of the 
Australian Synchrotron, Melbourne, Australia. Further details of crytsallisation and data 
collection are summarised in Table 6.1 on the facing page. The resulting diffraction data 
was indexed, measured and scaled with the HKL2000 package [42|. Phase estimates were 
obtained via molecular replacement as implemented by the Phaser |128| utility in Phenix 
[45] using the previously published native structure (PDB identifier: lEEM) [4| as a search 
model (Table 6.2 on page 142). Subsequent model building and refinement was performed 
alternatively with Coot [43] and the Phenix ]45] programs, respectively. 
6.2.1.2 Experimental conditions associated with the crytsallisation of 
h G S T O l in an orthorhombic lattice. 
The literature review regarding the crytsallisation of protein-ligand complexes by Has-
sell et. al, ]126] also suggested the use of a 'limited-additive screen', in which compounds 
known to increase ligand solubility and crystal quality are combined with previously known 
crytsallisation conditions. A screen of the suggested compounds using the concentrated 
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Figure 6.3 
A redox sensitive purification protocol of h G S T O l iias resulted in the formation of the tetragonal 
crystals shown here, despite the crytsallisation conditions being analogous to those previously 
reported to induce crystal growth in a trigonal lattice [4|. Due to the relatively recalcitrant growth 
of diffraction quality crystals in this form (left) and the limited supply of protein, efforts were made 
to nucleate crystal growth in drops of low precipitant concentration via the method of 'streak 
seeding' (right), using a cat's whisker. 
Crystallisation Experimental parameters of hGSTOl-1 in complex 
with GSH in a tetragonal crystal lattice 
Reservoir solution 1.7 M (NH4)2S04 
100 niM Sodium Acetate pH 4.25 
Crystallisation drop 1 iiL h C S T O l - l (25.18 mg/ml)T 
1 [xL reservoir 
Cryoprotectant solution 2.2 M Li2S04 
100 niM Sodium Acetate pH 4.75 
Sequential transfer from 5% >10 >15% 
Glycerol solution 
Data collection 
Resolution limits, A 50.00-3.21 (3.32-3.2lt) 
Space group P4222 
Unit Cell, A a - b - 129.66 c^l49.13 
Total reflections 307 192 
Unique reflections 21 224 
Completeness, % 99.0 (93.5t) 
l a 35.3 (6.0t) 
Redundancy 14.5 (13.7^) 
Refinement 
Rcryst/R-free, % 20.4/24.9 
rnisd bonds, A 0.011 
rmsd angles, ° 1.471 
Number of waters 10 
Ligands GSH, glycerol, acetate, SOJ^ C r 
t the highest resolution shell. "F, previously incubated with a molar excess of the 
CP-424174 inhibitor. 
Table 6.1 
Crystallisation details and structure determination statistics of the hGSTOl native complex with 
GSH in space group P42'22. 
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Search Model LLC Rotation Translation Packing 
(log-likelihood function function index 
gain) Z-score Z-score 
Protein monomer 1 293 6.1 22.9 0 
Protein monomer 2 1059 7.5 40.1 0 
Protein monomer 3 2118 5.4 40.9 0 
Protein monomer 4 3179 4.9 37.5 0 
Table 6.2 
Molecular replacement statistics from Phaser [128] of the hGSTOl native complex with GSH in 
space group P4222. 
batch of protein that had not been used in the dilute inhibitor incubation experiments 
(Section 6.2.1 on page 136) had resulted in a novel orthorhombic crystal form of h G S T O l -
1 when the previously published (NH4)2S04/Na Acetate condition |4| was combined with 1 
M guanidine hydrochloride. Like the tetragonal lattice discussed previously, this suggests 
it is the altered method of protein purification, and not the presence of inhibitors that 
facilitated crytsallisation in the new morphology. Application of analogous crytsallisation 
conditions to the 'dilute inhibitor incubation' protein preparations detailed above how-
ever (Section 6.2.1 on page 136), resulted in numerous crystals derived from all 3 of the 
inhibitor/protein solutions (Figure 6.4 on page 144). These were subsequently cryopro-
tected using a solution of lithium sulfate, sodium acetate and guanidine hydrochloride, 
with or without the addition of glycerol. X-ray diffraction experiments upon these crystals 
were also performed at the Australian synchrotron, using the same settings as above. The 
resulting datasets were also phased using molecular replacement (Table 6.4 on the next 
page) as implemented by Phaser [128] with PDB entry lEEM as the search model. A 
structure derived from one of the best quality datasets, diffracting to a resolution of 1.8 A, 
is presented below. Despite the excellent diffractive qualities of these crystals, subsequent 
analysis of the datasets with the phenix.xtriage utility of Phenix |45] revealed that all crys-
tals of this space group were almost perfectly pseudo merohedrally twinned (Table 6.5 on 
page 144). Thus, Refmac [129] was used with amplitude based twinning refinement turned 
on in subsequent refinements, alternated with rounds of manual model building in Coot 
[43[. Further details about crytsallisation and data collection are summarised in Table 6.3 
on the next page. 
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Crystallisation Crystallisation and structure determination statistics 
of liGSTOl native in a C-centered orthorhonibic 
crystal lattice 
Reservoir solution 2.1 M (NH4)2S04 
100 mM Sodium Acetate pH 4.6 
1 M Guanidine hydrochloride 
Crystallisation drop 1 [iL hCSTOl (15.21 mg/rril)T 
1 [iL reservoir 
Cryoprotectant solution 2.2 M Li2S04 
100 mM Sodiiun Acetate pH 4.75 
1 M Guanidine hydrochloride 
Data collection 
Resolution limits, A 50.00-1.81 (1.87-1.81T) 
Space group C222i 
Unit Cell A a=59.06 b-102.29 c=^259.25 
Total reflections 504 266 
Unique reflections 95 970 
Completeness, % 99.9 (99.2t) 
I a 23.2 (1.3 '^) 
Redundancy 5.3 (3.4t) 
Refinement 
Rcryst, Rfree- % 23.9/27.9 
rnisd bonds, A 0.012 
rmsd angles, ° 1.891 
Number of waters 395 
Ligands GSH. glycerol, acetate. DMSO, Tris, SOJ^ 
ICH6N3I + , c i -
CP-424174 (Figure 6.1b on page 134). 
Table 6.3 
Crystallisation details and structure determination statistics of the l iGSTOl native complex with 
GSH in space group C222i . 
Search Model LLC Rotation Translation Packing 
function function index 
Z-score Z-score 
Protein monomer 1 232 13.5 12.9 0 
Protein monomer 2 780 11.2 21.2 11 
Table 6.4 
Molecular replacement statistics from Phaser |128| of the l iGSTOl native enzyme in space group 
C222i . 
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Figure 6.4 
A limited additive screen |126| of the published conditions of hGSTOl crytsalUsation [4| combined 
with an altered method of purification has resulted in the new crystal morphology shown above. 
Despite excellent diffractive qualities, the nearly perfect pseudo merohedral twinning (Table 6.5) of 
this C-centered orthorhombic crystal lattice first needed to be overcome before the associated 
structure of hGSTOl could be characterised (Table 6.3 on the previous page). 




























Twinning analysis statistics from phenix.xtriage |45|. 
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6.3 Results and Discussion 
The tetragonal and orthorhonibic crystal lattices were discovered to contain 4 and 2 
molecules within their asymmetric units respectively (Figure 6.5 on page 147). Although 
the tetragonal structure was solved at the modest resolution of 3.21 A, the high level of 
NCS present was effectively employed to increase the observation to parameter ratio of the 
dataset, allowing the resolution of clearly defined electron density and good crystallographic 
R-factors (Table 6.1 on page 141). The four monomers were seen to be forming two pairs of 
physiological dimers (consisting of chains AC and BD) via 2 non-crystallographic two fold 
axes of symmetry. Conformational change was clearly observable to have destroyed the 
secondary structure of the C-terminal helix a9. The resulting random coil configuration 
within this region was unique to each, and the short helix alO was completely disordered. 
Electron density within the 4 molecules terminated between residues 223-227 (Figure 6.6 
on page 148). Since several residues in this region have previously been shown to play 
important roles in ligand binding within the H-site (Sections 5.3 on page 102 and 4.3 on 
page 71), this may reflect conformational plasticity that could have a specific purpose dur-
ing catalysis. This hypothesis is corroborated by similar conformational changes we have 
observed in the liGSTOl A155 isoform, that displays increased enzymatic activity in vitro, 
but appears to cause a deficiency in vivo due to an associated instability of the enzyme 
(Appendix A on page 181). 
Within the active site of this tetragonal crystal form, GSH was observed forming a 
mixed disulfide with C32 as observed previously |4| within all four chains. While the 
mode of complex formation within the G-site was generally conserved, a slightly altered 
conformation of GSH was refined within the G-site of chain D, although this may be due 
to its conformation being insufficiently restrained by the poorly defined electron density 
(not shown) in tliis region relative to the other 3 chains (Figure 6.6 on page 148). 
Crystallographic disorder of the C-terminal domain was also observed in the orthorhoni-
bic lattice, although in this instance, it ai)pears to have been a prerequisite for crystal 
formation. Helices ad and alO of the liGSTOl crystal structure previously published 
|4| overlap with one another when superimposed into this space groui) (Figure 6.7 on 
page 150), a physical restraint that is reflected in the high packing index reported by 
Phaser (Table 6.4 on page 143) that used this structure as the search model. The complete 
disorder of this region ajjpears to he essential for crystal contacts of the asynunetric unit to 
occur. This crystal form was dependent on the i)resence of 1 M guanidine hydrochloride, a 
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potent denaturing agent of proteins. It is probable that this compound was able to induce 
crytsallisation in this space group due to its denaturing properties further disordering the 
already labile C-terrninal helices, thereby allowing the necessary crystal contacts to occur. 
Although the inherent pseudo merohedral twinning of this crystal form has resulted in 
high crystallographic R-factors given the resolution (Table 6.3 on page 143), the quality 
of the electron density is unquestionable, allowing many structural features to be observed 
with certainty. Any inferences based on this crystal structure must be made with caution 
however, since the high concentration of a known protein denaturant may have artificially 
influenced its structural fold in ways that are not physiologically relevant. Nevertheless, 
its structural congruency with the structure previously published (rmsd of 0.41 over 207 
residues) implies this is minimal within the regions resolved within electron density. While 
the active sites of both monomers were devoid of ligands, a guanidinium ion was observed 
tightly bound to the carboxylate of E85 in chain A (Figure 6.8 on page 151), while the C32 
thiol of chain B appears to have been derivatized to the sulfenic acid derivative (Figure 6.9 
on page 152), possibly by the X-ray beam. 
6.3.1 S t ruc tu ra l features of h G S T O l - 1 w i t h i n t he t e t r agona l la t t ice , 
P4222 
Despite attempts to remove the tripeptide by dialysis prior to crytsallisation, all molecules 
within the asymmetric unit of the P4222 crystal form were observed to be covalently bound 
to GSH, in an analogous confirmation to that observed within the previously published 
trigonal lattice [4|. Significant changes were observed within the adjacent H-site however, 
due to conformational heterogeneity within the C-termirms. This was observed in all 4 
molecules of the asymmetric unit, but the structural changes observed were unique in each 
(Figure 6.6 on page 148). Despite completely different crystal contacts, the remainder of 
the structure is remarkably similar to the equivalent complex with GSH crystallised in 
the trigonal space group, P3i21 |4|. The observation of similar crystallographic disorder 
in this region within other space groups (Appendix A on page 181 and the orthorhombic 
lattice presented here) suggests this conformational flexibility may serve an important 
physiological role within the body. 
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Figure 6.5 
A comparison of the pviblisiied s t ruc ture of l i G S T O l (gray) |4| with the asymmetr ic uni ts comprising 
the te t ragonal (magenta) and C-centered orthorliomt)ic (cyan) crystal s t ruc tures presented here. 
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Figure 6.6 
A comparison of tiie publisiied P3i21 complex of hGSTOl witli GSH (translucent magenta) |4| with 
the equivalent regions of the 4 molecules within the P4222 asymmetric unit (cyan). Shown clockwise 
from the top is the superposition of chains A (rsmd = 0.76 A over 220 residues), B (rmsd = 0.83 A 
over 217 residues), C (rmsd = 0.76 A over 216 residues) and D (rmsd 0.91 A over 217 residues) 
with the coordinates of PDB entry lEEM. The mixed disulfide observed with GSH, associated side 
chains, and two H-site residues identified to be involved in GSSG binding (Figure 4.11 on page 81), 
R182 and W222, are shown in stick representation, coloured according to atom type. The later is 
shown in translucent within chain D due it's side chain being disordered. NB: helix a4 has been 
omitted for clarity in viewing H-site conformational change. 
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6.3 .2 Structural features of h G S T O l - 1 within the C-centered or-
thorhombic lattice, C222i 
The high resohition crystal structure of hGSTOl with a C-ceutered orthorhombic lattice 
displays an interesting crystal packing within its asymmetric unit that precludes the for-
mation of helices aD-lO in its structure. The residues associated with these elements of 
secondary structure were not observed due to disorder. While the structural rearrangement 
was likely to have been initiated by the 1 M concentration of guanidinium hydrochloride 
present in the crytsallisation conditions, that fact that structural flexibility within this 
region has also been observed within other crystal forms of the enzyme (Appendix A on 
page 181 and the tetragonal crystal form discussed above) suggests it may have phys-
iological relevance. In support of this hypothesis, the structural fold of the remaining 
polypeptide chains is remarkably similar to that observed in other crystal forms. The two 
chains within the C222i asymmetric unit, A and B. superimpose on the single molecule 
comprising the trigonal space group asymmetric unit |4| with rmsd values of 0.41 A over 
207 residues, and 0.47 A over 204 residues, respectively. The novel crystal contacts of the 
C222i asymmetric unit, contrasted to the published structure of hGSTOl is shown in more 
detail in Figure 6.7 on the following page. 
It is possible that the apparent conformational change in the C-terminal extension 
may have affected the binding affinity of GSH and/or the inhibitor. Both G-sites within 
the asymmetric unit were found to be unexpectedly empty, despite these crystals corning 
from the same protein purification/dilute inhibitor incubation as that used to grow the 
tetragonal complex with GSH presented above. A guanidinium ion is observed tightly 
binding to the carboxylate of E85 within chain A (Figure 6.8 on page 151), while in chain 
B, the active site cysteine appears to have been derivatized to the sulfenic acid (Figure 6.9 
on page 152). Given the care taken to ensure reducing conditions during pmification, it is 
probable that this occurred subsequent to exposure within the X-ray beam. 
6.3.3 Hypothesised mechanism of h G S T O l inhibition 
It was disappointing that despite every care being taken to remove potentially competitive 
ligands from the experimental conditions, and the subsequent development of a novel, re-
dox sensitive purification protocol leading to the crytsallisation of hGSTOl in two novel 
morphologies, the mode of hGSTOl inhibition could not be confirmed crystallographically 
in the {)resent study. Within lower resolution crystal structiu'es of the C222i crystal form. 
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Figure 6.7 
A representation of the novel mode of crystal packing within the recently discovered orthorhombic 
crystal form of hGSTOl. The asymmetric unit of space group C222i is shown in cyan with the 
previously published structure (PDB identifier: lEEM), superimposed on chain B in magenta. 
When viewed from above, one can see that the two helices at the interface, a9 and qIO, are 
incompatible with the current mode of crystal packing. In yellow is a crystallographically related 
symmetry partner that forms the physiological dimer with chain A of the asymmetric unit. 
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Figure 6.8 
The observed active site residues of chain A within the C222i crystals of hGSTOl. The 
crystallograpliic fold of hGSTOl within the orthorhombic lattice is shown as a cyan cartoon, 
overlaid in translucent magenta with the published trigonal lattice str\icture |4|. Both active sites 
were unexpectedly empty, suggesting associated conformational change in the C-terniinus (helices 
q9 and alO) may have decreased this sites affinity for GSH (since co-purified protein crystallised in 
a GSH complex within the tetragonal lattice above). Active site residues are shown in stick 
representation coloured according to atom type, with associate 2mFo — DFc electron density 
depicted as gray isomesh, contoured at a level of 1.5 a. A guanidinium ion was observed tightly 
bound to the carboxylate of E85. 
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Figure 6.9 
The observed active site residues of chain B within C222i crystals of hGSTOl , shown in a manner 
analogous to Figure 6.8 on the preceding page. The active site cysteine was observed to have been 
derivatized to the sulfenic acid, possibly via radiation damage in the X-ray beam. 
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residual 'blobs' of density were often observed in the G-site, indicating that inhibitors may 
have been boimd at a low occupancy (not shown), however attempts to model these with 
logical fragments of the respective compounds were misuccessful. In the 'dilute inhibitor 
incubation' experiments described previously (Section 6.2.1 on page 136), the final con-
centration of inhibitors (10 //M) was in a slight molar excess relative to the enzyme (7.6 
/iM). While this was deemed to be sufficient given the reportedly high affinity of these 
compomids for the liGSTOf active site |32, 24|, this technique may have proved more suc-
cessful by significantly increasing this molar ratio. Based on the previous characterisation 
of enzymatic inhibition by similar compounds however, a logical hypothesis can be framed 
as to the mechanism by which hGSTOl inhibition would proceed. 
Perhaps the most insightful information about the activity of the diarylsulfonyl urea 
inhibitors developed by Pfizer (Figures 6.1a on page 134 and 6.2 on page 138) can be 
found in previous work that aimed to discover the mechanism of the anti-timiom- agent 
Suloferuir |130|, a clear progenitor of these next generation CRIDs |127|. These researchers 
showed that this compound was metabolised to the glutathione conjugate in vivo, and sub-
sequently degraded to the mecaptmic acid. Interestingly, they noted that the former was 
a potent inhibitor of glutathione reductase |130|. This glutathione conjugate (Figure 6.10 
on page 155) was characterised by mass spectrometry |130|, and could be expected to 
have an analogous structure to the corresponding active site cysteinyl, or free glutathionyl 
conjugates of the CRIDs CP-424174 and CP-457324 studied here. As noted previously, 
the glutathione conjugates of these compounds were also capable of inhibiting the post-
translatioiial processing of IL-1/? |24|. Wether liGSTOl-l is most effectively inhibited by 
the compounds themselves or their metabolical derivatives is unknown (Figure 6.11 on 
I)age 156). 
The a-chloroacetamide inhibitor (Figure 6.1b on page 134) however, would be expected 
to exclusively inhibit hGSTOl via a direct interaction with the enzyme (Figure 6.12 on 
page 157). It has been previously noted to function via covalent modification of the ac-
tive site cysteine j32|. and this would be expected to feature nucleophilic attack upon its 
chloroacetyle group. This is the most probable leaving group within its structure, and its 
small size would be incompatible with the precise selectivity with which it reportedly binds 
hGSTOl if mediated thorough a glutathionyl conjugate intermediate. Tlie polyaromatic 
functionalities would instead be exj)ecte(l to form tight hydrophobic interactions with sev-
eral residues within the active site, such as F34, that would optimally orient its carbonyl 
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group for nucleophilic attack by C32. The resulting secondary amine would be protonated, 
leaving the catalytically essential thiol inactivated by covalent modification. 




O N H . 
Glutathione conjugate of Sulofenor 
Figure 6 .10 
The anti-cancer compound Siilofenur and its glutathione conjugated metabolite |130|. 
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CP-424174 
NHa 
Figure 6 .11 
Hypothesised meclianisms of h G S T O l inliibition by diarylsulfonyl ureas sucii as CP-424174. 
Covalent modification of the active site cysteine could occur via a direct interaction or a 
rnetabohcally derived glutathione conjugate |24]. 
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The inhibi t ion of h G S T O I by the Q-chloroacetamide recently identified by Bachovchin et. al, |32| is 




In conclusion, the crystallographic investigation of mechanism in the human enzyme, 
hGSTOl-1, has yielded considerable insight into the relationships between its structural 
adaptability and the chemical reactions it performs. States associated with the catalysis 
of almost all of its small molecule substrates have been obtained in high resolution crystal 
structures. These include the binding of the product ascorbate within the active site and 
the concurrent binding of glutathionyl methylarsenite with a derivative of the model sub-
strate CDNB. The ternary complex of the enzyme with GSSG and 4NPG has also been 
obtained, in which the latter was observed at the dimer interface in a position that may 
reflect a 'ligandin' binding mode or a preliminary docking position of the substrate. In 
addition, efforts to crystallographically characterise the mode of liGSTOl-l inhibition has 
resulted in its structure being solved within two novel crystal forms. Each of these results 
is reflected upon in more detail below. 
The binding mode of ascorbate within the active site was unexpected (Chapter 3 on 
page 43). Rather than revealing the position of the product at the conclusion of the de-
hydroascorbate reduction reaction cycle as intended, this binding mode is suggestive of 
product inhibition, in which intracellular ascorbate concentrations may self regulate in 
vivo. This conclusion is evidenced by the mutually exclusive mode of ascorbate binding 
with the formation of a cysteine-GSII mixed disulfide, and the lack of planarity and double 
bond conjugation in the superposed substrate |48|, both of which would make the observed 
TT-stacking interaction with F34 unfavourable. It's isozyme hGST02-2, has a nuK;h higher 
activity towards this substrate and is in fact, the most efficient nuunnuilian dehydroascor-
bate reductase characterised to date |25]. This implies that the findings within this research 
may have important physiological applications if such a binding mode was foimd to be 
conserved between the two. Indeed, a comparison of the region associated with ascorbate 
binding (Figure 3.10 on page 59) suggests this to be the case. This superposition identifies 
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H71 as the only non-conservative amino acid substitution within the equivalent region of 
hGST02. Its replacement of a leucine in the active site of l iGSTOl may convey an associ-
ated decrease in affinity of this inhibitory binding mode, contributing to the higher level of 
enzymatic activity observed. Conversely, its capacity to act as a general base within the re-
action mechanism may also contribute to the increase in catalytic efficiency observed. This 
reaction has typically been thought to proceed via a ping-pong mechanism involving the 
formation of a covalent cysteinyl-thioketal intermediate, that collapses to yield the reduced 
product and a mixed disulfide upon nucleophilic attack by GSH (Figure 3.1 on page 44). 
This is the mechanism proposed by researchers studying this reaction as catalysed by the 
D H A R of spinach chloroplasts, who also found evidence of product inhibition by ascorbate 
during their kinetic analysis of the enzyme |54|. Substantial evidence has been presented 
for a different mechanism however, based on the characterization of a D H A R enzyme of A. 
thaliana [56] that shows significant sequence similarity to hGSTO l (Figure 3.8 on page 56). 
These authors could not observe the hypothesised cysteinyl-thioketal intermediate by ESI-
TOF MS, and pointing out that in chemical systems analogous to dehydroascorbate, the 
attack of a cysteine thiol would lead to a dead-end thioketal-enzyme complex, suggest a 
SET mechanism instead (Figure 3.7 on page 55). Such a mechanism would be consistent 
with the well established ability of thiol compounds to act as hydride donors during radical 
reactions [56|. Further research characterising this reaction within the Omega class should 
involve a thorough kinetic analysis that investigates both the mode of product inhibition 
inferred by the structural findings presented here, and evaluates the actuality of either 
a ping-pong or SET mechanism of dehydroascorbate reduction. The latter may also be 
investigated by carefully controlled electron paramagnetic resonance (EPR) experiments 
with dehydroascorbate in the presence and absence of the enzyme. Site directed muta-
genesis experiments of H71 within hGST02-2 are also warranted in order to quantitate 
its contribution to the higher activity of this enzyme relative to l iGSTOl-l . The altered 
catalytic turnover of this substrate associated with genetic polymorphisms may be the 
causative factor implicating the omega class in the AAO of Alzheimer's and Parkinson's 
disease in genetic mapping studies |22, 49]. Both of these conditions have been associated 
with oxidative stress, to which ascorbate plays a key protective role within the body and 
in particular, the brain, where its concentration is most tightly regulated [50|. 
Perhaps the most interesting finding of this investigation into the mechanism of 
hGSTO l was the identification of a glutathionylated methyl arsenical bound within its 
active site (Figure 4.6 on page 75). This supports previous findings tliat glutatliionylated, 
trivalent methyl arsenicals are the required substrate for the hAS3MT enzyme (711, and 
helps resolve conjecture in the literature regarding the identity of intermediates within 
this metabolic pathway |25, 68, 69. 70|. This information is crucial to obtaining a more 
detailed understanding of the pathoniechanisms of chronic arsenic toxicity currently affect-
ing approximately 100 million people in the geographical region surrounding Bangladesh 
|75|, and to obtaining a more fundamental understanding of the pharmacology of ATO 
in its treatment of APL in combination with ATRA |78|. While initial investigations in-
dicated that the cytotoxic affect of this compound may be mediated via the generation 
of ROS |81, 82|, it has since been conclusively shown to affect apoptosis via a direct in-
teraction with the 'zinc finger' region within the PML domain. Together with ATRA 
binding to the R ARa half of the fusion protein, it is thought that there is an associated 
conformational change that favours SUMOylation, degradation, and subsequent abolition 
of its inhibitory effect on cellular differentiation (Figure 4.2 on page 64) |80|. Since it is 
possible that ATO may affect these changes indirectly, via metabolites such as the glu-
tathionyl methylarsenite species observed here, their identification may prove crucial to 
obtaining a better understanding of this interaction. Such information may also aid in 
the application of this treatment to other forms of cancer. PML has been implicated to 
play a vital role in maintaining quiescent populations of LICs implicated as the source 
of many relapses |85|. It has also been shown to be a key regulator of the p53 tumour 
suppressor, mutations in which are the most connaon genetic event in the formation of 
metastatic human cancers. PML has been found to actively upregulate the transcription 
of mutant p53 and is an important factor in the oncogenic 'gain of function properties 
exhibited by this protein |86|. In addition, a glutathione derivative of trivalent arsenic, 
p-4-(N -(S-glutathionylacetyl)aminolphenylarsenoxide, is currently undergoing clinical tri-
als as a potent anti-cancer agent |87|. Its efficacy may now be reconciled in terms of it 
being a structural analogue of the metabolic intermediate that has currently been observed 
crystallographically. A thorough understanding of the catalytic mechanism associated with 
methyl arsenate reduction could benefit from tlie unequivocal determination of the bind-
ing order of substrates. This could be achieved by careful kinetic analysis of the reaction, 
however given the close proximity of two tryptophan residues in the active site (VV180 and 
\'V222), fluorescence experiments may also aid the elucidation of this reactions binding 
sequence. Indeed, a similar tec:hnique has recently been applied to gain a more funda-
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mental understanding of the mechanism of an arsenate reductase from E. coli [1011. In 
addition, the hydroxyl group of Y229 was observed to be participating in a solvent medi-
ated hydrogen bonding interaction with the lone pair of arsenic (Figure 4.6 on page 75). 
This residue is located within the labile C-terminal helix a9, and may be the best candi-
date for the as yet unidentified hydrogen bond donor of the Omega class, observed within 
other GST classes to stabilise the GSH associated thiolate during catalysis. This tightly 
conserved residue is therefore also a prime candidate for future site directed mutagenesis 
studies. While an associated Y229F mutagenic PGR reaction was performed during this 
research, the time constraints of this project precluded the resulting DNA product from 
being sequenced, and the associated isozyme being characterised. 
Serendipitously, the structure revealing bound glutathionyl methylarsenite also revealed 
the binding of HDNB, a derivative of the historical GST substrate GDNB. While subse-
quently confirmed by the binding of GSSG, this was the first confirmation of the predicted 
hGSTOl-1 H-site, and its binding was observed to be associated with several aspects of 
structural change. Alternate conformers of R132 and W222 were observed, the former of 
which was seen to be stabilised by a novel salt bridge with a sulfate ion (Figure 4.8 on 
page 77). It also appears to have triggered a 'conformational switch' in the adjacent a6-7 
loop (Figure 4.9 on page 78), that was also corroborated by the glycinyl moiety of GSSG 
binding in the same position (Figure 5.5 on page 108). This has provided valuable insight 
into the structural dynamics of the hGSTOl H-site, and may represent a structural adap-
tation that could be essential for efficient catalytic turnover and enzymatic promiscuity. 
This latter binding mode of GSSG was observed in a ternary complex of hGSTOl 
and 4NPG. In lieu of the phenacyl glutathione substrate, this disulfide was observed in 
the active site instead, and is the first time its binding mode has been confirmed crystal-
lographically, despite it being a hypothesised product of all hGSTOl-1 mediated chem-
istry. Gomparison with other complexes of GSTs with GSSG in the PDB (Figures 5.10 on 
page 115 and 5.11 on page 116) revealed a tightly conserved binding mode of the G-site 
bound half of the molecule, that corresponded well with the previously observed binding 
mode of GSH [4]. The conformational space sampled by the other half of the molecule 
however, was seen to be of a much greater variety. The evolution of a relatively wide dimer 
interface within the Omega class appears to have precluded inter-dirneric interactions with 
the product molecule while the appendage of its two C-terminal helices (a9-10) has resulted 
in a much deeper H-site. This is observed to have created a nnich 'tighter' binding mode 
within l iGSTOl relative to the other two examples. In the binding mode observed here, the 
H-site bound half of the molecule is actually orientated away from, rather than towards, 
the interdimeric cleft. This is expected to have profound implications for this products 
binding affinity, and subsequently, for all aspects of hGSTOl-1 mediated chemistry. 
Conversely, 4NPG was found to bind along the crystallographic two fold corresponding 
to the hCSTOl-l dimer interface. While repeated attempts failed to observe its binding 
mode within the active site, the binding of HDNB suggested its nitrophenacyl moiety could 
be accommodated in a similar position, as did the molecular modeling of the compound 
into the electron density associated with bound GSSG (Figure 5.15 on page 122). This 
crystallographically observed position may be representative of a 'ligandin' binding mode. 
Indeed, similar examples of ligand binding at the dimer interface have been observed crys-
tallographically in other GSTs (Figure 5.9 on page 113). The mutually inclusive nature of 
4NPG's binding with GSSG, coupled with their close proximity within the crystal structure 
however, suggests this may be a preliminary docking position of the substrate. Repeated 
attempts to observe both of these compounds independently have been unsuccessful, sug-
gesting that this crystal structure may feature as part of the physiological reaction cycle, 
with 4NPG moving concertedly into the active site with GSSG departure. 
Finally, efforts to discover the mode of inhibition by diarylsulfonyl urea GRIDs |24l and 
an a-chloroacetamide [32| have ultimately proved unsuccessful but have allowed the struc-
ture of hGSTOl-1 to be solved in two new crystal forms. Strikingly, the first of these, that 
is comprised of the tetragonal space group P4222, crystallised from conditions that were di-
rectly analogous to those previously published to yield crystals of a trigonal lattice |4|. The 
only variable being the conditions associated with purification of the protein (Section 6.2.1 
on page 136), it would appear that the altered redox conditions associated with this new 
method were sufficient to induce a change in crystal morphology. The resulting strvicture 
was subseciuently found to contain 4 monomers, comprising 2 physiological dimers, within 
its asymmetric unit. While the best diffraction obtained was to a modest resolution of 3.2 
A , the high level of NGS was effectively utilised to obtain clear electron density in which to 
model the polypeptide chains. A structural change was observed in the G-terminal helix a9 
that was unique to each monomer, however the residues associated with the short alO helix 
previously observed to follow |4| was completely disordered in all of them (Figure 6.6 on 
page 148). This crystal structure appears to rei)resent a structurally dynamic state of the 
enzyme that lies at a position upon the potential energy landscape that is distinct from the 
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state previously crystallised in space group P3i21 |4]. This state apparently has a much 
higher affinity for GSH, since every molecule of the asymmetric unit was observed forming 
a mixed disulfide with the tripeptide despite at tempts to remove it from the experimental 
conditions by dialysis prior to crystallisation (Section 6.2.1 on page 136). Furthermore, it 
would appear that the energy level represented by this crystal structure does not have a 
predisposition to a C-terminal extension with ordered secondary structure. 
The second novel crystal form, discovered to belong to a C-centered orthorhombic 
lattice of space group C222i, possessed much better diffractive qualities, but was unfor-
tunately found to be pseudo merohedrally twinned. After overcoming this problem via 
amplitude based twinning refinement within Refmac |44|, the resulting structure was also 
found to feature a dramatic conformational change within its C-terniinus. This time it 
actually appeared to be a pre-requisite for crystal formation however, with the observed 
crystal contacts completely precluding the formation of helices a9 and alO. While the 
presence of 1 M guanidine hydrochloride was necessary for crystallisation in this morphol-
ogy and undoubtedly contributed to the C-terminal crystallographic disorder observed, it 
is likely this structural change has a physiological basis. Taken together with highly similar 
structural plasticity observed in the tetragonal space group presented here and the struc-
ture of the hGST01A155 isoform we have recently published (Appendix A on page 181), 
there is compelling evidence that C-terminal conformational change is an essential physio-
logical characteristic of hGSTOl-1 mediated catalysis. Since several residues in this region 
have been identified in the current study to be essential for ligand binding within the H-
site, it is probable that this conformational change is associated with efficient entry and/or 
release of these compounds from the active site. 
It is possible that the variety of conformational space sampled by the C-terminus of 
hGSTOl within its various crystal forms is representative of different enzymatic conforma-
tions that are separated by small differences in free energy. The variations in the solvent 
environments associated with each crystal form is selective for each. These neighbouring 
states within the free energy landscape may feature as part of an 'induced fit' mechanism, 
by which the binding of certain substrates favour particular conformations. Indeed, this 
phenomena has been observed previously in the human GST a class, in which a sinn-
lar, novel C-terminal helix is dependent on ligand binding in order to assume an ordered 
secondary structure |131|. 
While the size of the l iGSTOl-l physiological dinier (55 kDa) has historically been 
considered too large for analysis by NMR spectroscopy, recent advances in both the resolv-
ing power of spectrometers and experimental techniques may allow this conformational 
change to be quanti tated in concert with reaction of substrates in solution. The tech-
nique of Lanthanide tag labeling of proteins using the cell free synthesis incorporation of 
\umatural amino acids currently being developed by my colleagues |132, 133| is one such 
technique that may allow the structural plasticity of this region to be characterized within 
the context of enzymatic catalysis. 
It is disappointing that despite the development of a new purification protocol that has 
lead to the discovery of two new crystal forms, the mode of hGSTOl-1 inhibition has been 
unable to be characterised crystallographically. With more time devoted to this research 
project, it is likely that this could have been achieved. Further research aimed at imcovering 
the mechanism by which these compounds inhibit hGSTOl-1 would do well to repeat the 
'dilute inhibitor incubation' experiments outlined in Section 6.2.1 on page 136, but with 
an increased concentration of inhibitors and varied levels of GSH. The purification of the 
C32A and C32S active site nmtations using this new purification protocol and subsequent 
analysis within these novel crystal forms may also prove invaluable in gaining further 
insight into the chemical mechanisms employed by this enzyme. 
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Appendix A 
Novel Folding and Stability Defects 
Cause a Deficiency of Human 
Glutathione Transferase Omega 1 
Myself and colleagues have recently published the crystal structure of the E155/E208 
variant of this polymorphic enzyme. The coordinates have been submitted to the Protein 
Data Bank (PDB), deposition code 3LFL. Published in conjunction with the results of 
stability and unfolding experiments, our findings suggest that the enzyme possesses an 
increased propensity to unfold and once partially denatured, has an impaired ability to 
refold again. This agreed with the crystallographic data showing that the deletion of 
glutamate 155 results in the premature termination of helix o(5, concm-rently increasing 
flexibility of the N-terniinal domain and the amount of hydrophobic residues at the solvent 
interface |134|. 
Although the preliminary coordinates of this structm-e were submitted as part of my 
honours thesis, subsequent refinement and interpretation that made this paper possible 
was performed during my PhD candidature. 
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The polymorphic deletion of Glu-155 from human glutathi-
one transferase omegal (GSTOl-1) occurs in most popula-
tions. Although the recombinant AGlu-155 enzyme expressed 
in Escherichia coli is active, the deletion causes a deficiency of 
the active enzyme in vivo. The crystal structure and the fold-
ing/unfolding kinetics of the AGlu-155 variant were deter-
mined in order to investigate the cause of the rapid loss of the 
enzyme in human cells. The crystal structure revealed altered 
packing around the Glu-155 deletion, an increase in the pre-
dicted solvent-accessible area and a corresponding reduction 
in the buried surface area. This increase in solvent accessibility 
was consistent with an elevated Stern-Volmer constant. The 
unfolding of both the wild type and AGlu-155 enzyme in urea 
is best described by a three-state model, and there is evidence 
for the more pronounced population of an intermediate state 
by the AGlu-155 enzymes. Studies using intrinsic fluorescence 
revealed a free energy change around 14.4 kcal/mol for 
the wild type compared with around 8.6 kcal/mol for the 
AGlu-155 variant, which indicates a decrease in stability asso-
ciated with the Glu-155 deletion. Urea induced unfolding of 
the wild type GSTOl-1 was reversible through an initial fast 
phase followed by a second slow phase. In contrast, the AGlu-
155 variant lacks the slow phase, indicating a refolding defect. 
It is possible that in some conditions in vivo, the increased 
solvent-accessible area and the low stability of the AGlu-155 
variant may promote its unfolding, whereas the refolding de-
fect limits its refolding, resulting in GSTOl-1 deficiency. 
The omega class glutathione transferases (GSTO)^ are 
among the more recently identified members of the cytosolic 
glutathione transferase super family (1, 2). Members of the 
omega class have a number of novel features and have been 
implicated in important metabolic pathways and in the etiol-
ogy of some common neurological diseases (3-7). In contrast 
to the other human GSTs, which have active site tyrosine or 
serine residues, the omega class GSTs have an active site cys-
* This vKork was supported by National Health and Medical Research Coun-
cil Project Grant 366731. 
The atomic coordmates and structure factors (code 3LFL) have been deposited 
in the Protein Data Bank, Research Coliaboratory for Structural Bioinformat-
ics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/). 
' To whom correspondence should be addressed: Curtin School of Medical 
Research, Australian National University, P. O. Box 334, Canberra, ACT 
2601, Australia. Tel.: 61-2-61254714; Fax: 61 -2-61254712; E-mail: Philip. 
Board@anu.edu.au. 
^ The abbreviations used are: GSTO, o m e g a class glutathione transferase; 
ANS, 1 -anilino-8-naphthalenesulfonate. 
teine residue that is essential for its primary catalytic activities 
(1). The omega class GSTs were originally shown to catalyze 
thioltransferase and ascorbate reductase reactions, and other 
studies have shown that they also catalyze the reduction of 
monomethyl arsenate in the methylation pathway for the dis-
position of arsenic (3, 4). In addition, recent studies have 
shown that GSTOl-1 has S-phenacyl glutathione reductase 
activity and plays a significant role in the biotransformation of 
a-haloketones (8, 9). As well as these catalytic activities, 
GSTOl -1 has been implicated in the post-translational proc-
essing and activation of the proinflammatory mediator inter-
leukin-1/3 (10) and has also been found to act as an inhibitor 
of cardiac muscle ryanodine receptor Ca "^* channels (11). In-
terestingly, some genetic mapping studies have strongly im-
plicated an omega class GST as a factor influencing the age at 
onset of Alzheimer and Parkinson diseases (5, 6, 12). Other 
studies have implicated genetic variation in GSTOl in vascu-
lar dementia, stroke, and cerebrovascular atherosclerosis (7, 
13). The mechanism by which genetic variation mediates 
these effects has not been determined, but it could be via the 
effects on the activity or expression of the omega class GSTs. 
Previous studies have identified a range of polymorphisms 
in the GSTO genes (2, 3, 14). Although a number of single 
nucleotide polymorphisms have been identified in non-coding 
regions, their effects on transcription, splicing, and mRNA 
stability have yet to be evaluated (15). In contrast, several 
polymorphisms in coding regions have been studied in more 
detail (2, 3, 14, 16). A polymorphic deletion of three base pairs 
at the junction of exon 4 and intron 4 is of particular interest. 
This deletion could result in the deletion of Glu-155 or a 
splicing abnormality. This polymorphism has been identified 
in a range of different ethnic groups reaching a frequency of 
>10% in one Chinese sample (2, 14, 17-19). The deletion oc-
curs in two haplotypes characterized by a Glu or Lys at posi-
tion 208 (19). Recombinant expression of the Glu-155 dele-
tion variant in Escherichia coli affords an active enzyme that 
has decreased heat stability (2, 19). We recently reported that 
the T-47D breast cancer cell line is hemizygous for the Glu-
155 deletion allele and is deficient in GSTOl -1 enzymatic 
activity (20). In addition, lymphoblastoid cell lines from indi-
viduals who were heterozygous for the Glu-155 deletion were 
reported to have only 50% of normal catalytic activity with 
4-nitrophenacylglutathione, a specific G S T O l - 1 substrate 
(20). These studies suggest that the Glu-155 deletion variant 
is very compromised in vivo. 
Given the role played by GSTOl -1 in the disposition of 
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flammatory drugs (10) as well as the proposed role of genetic 
variation in GSTOl in the progress of several neurological 
disorders (6, 7), it is apparent that natural polymorphisms in 
GSTOl that affect function are of significant pharmacoge-
netic and clinical interest. Consequently we have investigated 
the effect of the polymorphic Glu-155 deletion on the enzyme 
structure and stability by solving its crystal structure and 
studying its unfolding equilibrium. 
EXPERIMENTAL PROCEDURES 
Expression of Recombinant GSTOl-1 Variants—In this 
study several recombinant GSTOl -1 isoenzymes have been 
studied. There is a common polymorphism where Asp-140 
substitutes Ala-140. This substitution does not appear to in-
fluence function, but because Ala-140 is the most common 
allele, we refer to it as the wild type and the substituted vari-
ant as A140D. In each case the Glu-155 deletion variants have 
alanine at residue 140. cDNAs encoding GSTOl wild type, 
GST01-A140D, GSTOl AGIu-155/Glu-208, and GSTOl 
AGlu-155/Lys-208 were cloned into the pHUE expression 
vector and transfected into E. coli BL21(DE3). The expression 
and purification of recombinant proteins using the pHUE 
vector and ubiquitin cleavage techniques have been previously 
described in detail (21). Briefly, the recombinant HiSj,-ubiq-
uit in-GSTO fusion protein was purified by chromatography 
on nickel-agarose. The His-ubiquitin fusion moiety was re-
moved by digestion with the catalytic core of Usp2 and re-
chromatography on nickel-agarose. The purified proteins 
were dialyzed against 20 mM Tris, pH 8, 60 mM NaCI, 5 mM 
dithiothreitol for storage and crystallization experiments. 
Crystallization and Structural Determination ofGSTOl-1 
AGlu-155/Glu-208—Unsuccessful at tempts were made to 
grow crystals of GSTOl AGlu-155 under identical conditions 
to those reported for the native enzyme (1). The protein was, 
therefore, subjected to the index screen (Hampton Research) 
to find new conditions. The vapor diffusion technique was 
employed using a 96-well sitting drop crystallization tray 
(Nunc, Roskilde, Denmark). For screening, 1 jA of protein (12 
mg/ml) was mixed with 1 of 10 mM glutathione and 1 ijlI of 
reservoir solution. Reservoirs contained 100 jjl] of each screen 
condition. The tray was then sealed with Crystal Clear tape 
(Hampton Research) and allowed to equilibrate at 18 °C. After 
6 days, crystals were observed in condition 62 (0.1 M Tris, pH 
8.5, 0.2 M trimethyl amine A^-oxide dihydrate, 20% (w/v) poly-
ethylene glycol monomethyl ether 2000). Scaling up was 
achieved via a doubling of the overall crystallization volume 
using the same method. Crystals were flash-frozen at 100 K 
using an Oxford cryostream. Cryoprotection was by sequen-
tial transfer to artificial mother liquor containing 20% glycerol 
by 5% increments. The crystals were then transferred to liquid 
nitrogen and stored until subsequent data collection using a 
Rigaku RU-200 rotating anode x-ray generator with mirror 
optics and Mar345 desktop beamline. Processing of data col-
lected from a single crystal was performed using the programs 
DENZO and SCALEPACK (22). Phase information was ob-
tained by molecular replacement using the structure of the 
native enzyme (1) as a search model with the program 
MOLREP (23). Model rebuilding to match experimental den-
sity, including the deletion of Glu-155, was achieved with the 
programs O (24) and Coot (25) and alternated with restrained 
refinement by the program REFMAC (26). The program 
PHENIX (27) was then employed for the final stages of refine-
ment using the simulated annealing option with default set-
tings. Finally, the program MolProbity (28) was used to add 
hydrogens to the structure and diagnose Asn/Gln/His flips 
before validation deposition (PDB code 3LFL). 
Spectroscopy and Activity Measurements—kW fluorescence 
data were measured on PerkinElmer Life Sciences LS SOB lu-
minescence spectrophotometer . Tryptophan fluorescence was 
used to monitor structural change. Excitation was at 295 nm, 
and fluorescence was recorded in the range of 3 0 5 - 4 3 0 nm. 
l-Anilino-8-naphthalenesulfonate (ANS) was added to pro-
tein samples in a molar ratio of 50:1 (29) and equilibrated for 
50 min for complete interaction. ANS binding spectra were 
recorded in the range of 405-540 n m with excitation at 390 
nm. Enzymatic activity was determined with the G S T O l - 1 
specific substrate S-(4-nitrophenacyl)-glutathione as de-
scribed previously (9). 
Tryptophan Fluorescence Quenching by Acrylamide—kcry\-
amide (8 M) was added to 1 fiM G S T O l proteins (calculated 
by a molar extinction coefficient of 82,800 M" ' c m ' ' at 280 
nm) to achieve different concentrations and mixed thor-
oughly. Fluorescence intensities were monitored at 336 nm. 
Each protein sample was repeated at least three times and 
then averaged. Quenching data were analyzed by the Stern-
Volmer equation (30), 
-p - 1 = KJQ] (Eq.1) 
where and F are the fluorescence intensities before and 
after the addition of acrylamide, [Q] is the acrylamide concen-
tration, and /Csv is the Stern-Volmer constant, which can re-
flect the burial of t ryptophan residues and, thus, indicate the 
protein accessibility. 
Circular Dichroism Measurement—CitcuXzv dichroism 
(CD) was monitored on Chirascan"'^'^ Circular Dichroism 
Spectrometer (Applied Photophysics) using a cuvette with a 
0.1-cm light path. Ellipticity at 222 nm was collected and plot-
ted against variation of urea concentration. 
Equilibrium Unfolding Experiments—Viea-induced unfold-
ing experiments were performed in 20 mM sodium dihydro-
gen phosphate with 40 mM ammonium phosphate, pH 7.0, at 
1 iJLM protein concentration. To reach equilibrium, protein 
samples with different urea concentrations (0 - 9 M) were in-
cubated at 30 °C for 5 h and then cooled down to room tem-
perature for intrinsic fluorescence, ANS binding, and circular 
dichroism measurements. For the analysis of the intrinsic 
fluorescence the ratio of emission intensity at 333 nm (folded 
protein) and 355 nm (unfolded protein) was determined, and 
the relative intensity at 475 nm was determined for ANS 
binding. Data f rom three-four separate replicates f rom two 
purification batches of each protein were averaged. 
Urea unfolding curves were fitted to a two-state ( N j ^ 2U) 
unfolding model or a three-state model (N2 ^ 2U) (31, 
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TABLE 1 
X-ray data collection and refinement statistics 
r.m.s.d., root mean square deviation. 
Space group P2,2,2 
Unit cell parameters (A) fl = 73.0, fc = 201.9, c = 53.4 
Reflections measured/unique 389,373/44,498 
Resolution range (A) 36.51-2.10(2.18-2.10)" 
R-merge (%) 12.8 (37.0)" 
Completeness 94.4 (80.7)" 
Mean Hal 21.4 (3.5)" 
(%) 19.91/26.05 
r.m.s.d. bonds (A) 0.008 
r.m.s.d. angles 1.120" 
PDB accession code 3LFL 
" The highest resolution bin. 
FIGURE 1. Structural changes induced by the deletion of Glu-155. /A, a 
view perpendicular to the crystallographic 2-fold axis of the native structure 
(translucent ye//ow), the AGIu-155 A monomer [cyan), and the non-crystallo-
graphic 2-fold axis of the AGIu-155 B and C monomers {magenta), which 
produce the GST01 -1 physiological dimer. The position of Glu-155 and GSH 
is shown In stick representation. B, a closer Inspection of the deletion site 
within the AGIu-155 A-monomer {cyan) compared with the wild type en-
zyme (yellow) Is shown. Changes to the associated residue side chain con-
formations are In stick representation. The new interaction formed at the 
dimer Interface is also visible. The adjacent monomer Is shown In magenta. 
The figures were generated using PyMol. 
of native, intermediate, and denatured state were calculated 
by a previously described method (32). 
Protein Refolding—Refolding of unfolded proteins was de-
tected u s i n g S-(4-nitrophenacyl)-glutathione reduction assay 
and tryptophan fluorescence recovery. For activity reversibil-
ity, proteins were brought to a concentration of 1 /xm in 6 m 
FIGURE 2. The flexibility of helix a9 observed in the AGIu-155 structure. 
a closer view of the A monomer active site reveals several key differences 
compared with the native enzyme. Of most interest Is the different rotamer 
adopted byTrp-222, dramatically Increasing the hydrophobiclty within the 
conserved H-slte. The AGIu-155 A-monomer Is shown In cyan compared 
with the wild type enzyme In yellow. B, comparison of the native structure 
to that of the B monomer reveals much more pronounced structural 
change. Helix a9 has shifted toward the site of glutathione binding by sev-
eral angstroms, dramatically reducing the size of the H-slte. The AGIu-155 
B-monomer Is shown In magenta with the overlaid native structure In yel-
low. The figures were generated using PyMol. 
urea and allowed to unfold for 5 h at 30 °C. The proteins were 
then diluted 6 times and allowed to refold at room tempera-
ture. Enzyme activity was determined after 1 h. When refold-
ing was monitored by intrinsic fluorescence, 30 /xm proteins 
were fully unfolded in 7.4 m urea. The enzymes were then di-
luted 10 times, and the emission intensities were recorded 
every minute. Curve fitting was undertaken in SigmaPlot Ver-
sion 10.0. 
RESULTS 
Crystal Structure of GSTOl \Glu-155/Lys-208—To deter-
mine whether the deletion of Glu-155 caused any significant 
structural alterations, we crystallized and solved the structure 
of the GSTOl AGlu- 155/Glu-208 variant. The crystals were 
found to be of a different space group (P2,2,2) compared with 
the native enzyme (P3i21) and diffracted to 2.1 A . Table 1 
summarizes the crystallographic data and model statistics. 
o 
(3 
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Molecular replacement in MOLREP (23) revealed three 
monomers in the asymmetric unit. Monomer A sits adjacent 
to a crystallographic 2-fold axis so as to form a physiological 
dimer with its crystallographic partner (A-A). Monomers B 
and C form a second dimer (B-C). The overall topology is 
similar to that of the wild type enzyme, except for the follow-
ing; the deletion of residue Glu-155 results in the premature 
termination of helix a5 and a conformational change in the 
helix aS to a6 loop (Fig. lA). Its subsequent removal from the 
search model required significant rebuilding of the associated 
residues, a process coupled with restrained refinement until 
local aberrations in the mF^ - DF^ electron density map were 
removed. As shown in Fig. IB, several perturbations in the 
surrounding structure contribute to this enzyme altered phe-
notype. The hydrophobic interactions (not shown in this fig-
ure) of adjacent residues Val-156 and Leu-157 have been dis-
rupted by Ca translations of 5.3 and 8.0 A , respectively. This 
has caused Val-156 to be exposed to solvent. The transloca-
tion of Leu-157, on the other hand, has produced a new inter-
action with Leu-119 and, of particular interest, an interaction 
with the side chain of Pro-68 from the other subunit in the 
physiological dimer, effectively creating a new interaction at 
dimer interface. In addition, the Thr-158 Ca has shifted by 
6.4 A, allowing its side chain to occupy the position previously 
inhabited by that of Val-156. Such changes have contributed 
to an increase in the water accessibility of Leu-157 to >100 
A^ and an increase in the buried area at the interface of twice 
this magnitude. In total there are only 7 contacts <3.5 A be-
tween residues 150-164 of aS and residues 192-202 of 
loop-a7 in the AGlu-155/Glu-208 enzyme, 18 fewer than in 
02 0.3 
Acfytamide (M) 
FIGURE 3. Tryptophan fluorescence quenching by acrylamide. The ex-
perimental values and trend lines are shown as wild type (•), A140D (O), 
AGIu-l 55/GIU-208 (T), and AGIu-155/Lys-208 (A). 
the wild type enzyme. The altered packing has likely played a 
role in the observed refolding anomaly of Glu-155 deletion 
variants discussed below. The alterations in the dimer inter-
face do not appear to preclude the formation of heterodimers 
between wild type and deletion-containing monomers. 
The potential flexibility of the C-terminal region can be 
observed in the AGIu-155/Glu-208 structure. Comparison of 
the active site of monomer A with the wild type enzyme re-
veals a rotation of the putative "H-site" residue, Trp-222, re-
sulting in the removal of its indole nitrogen from the binding 
pocket, increasing its hydrophobic character. As shown in Fig. 
2A, the entrance to the binding pocket has also been partially 
occluded by the movement of Arg-183 and Tyr-229. Helix q:9, 
of monomer A, which forms part of the active site, has shifted 
away from the GSH binding pocket (G-site), possibly to ac-
commodate movements in residues Tyr-229 and Trp-222 
(Fig. 2/4). Although the B and C monomers display similar 
structural changes relating to the deletion site, it is the con-
formational shift of their C termini that is most remarkable. 
As shown in Fig. 2B helix a9 of monomer B has moved to-
ward the G-site and rotated so that Leu-228 and Tyr-229 
block the H-site entrance. There is a significant rearrange-
ment of Trp-222, which has been excluded from the H-site 
and is stacked against helix a6, exposed to bulk solvent. The 
net effect is to make the "H-site" smaller. Furthermore, the 
last 10-14 residues forming helix alO and its connecting loop 
fail to show substantial mF^ — DF^ density in monomers B 
and C. These significant changes do not appear to be a conse-
quence of crystal packing, as the crystal contacts in each mon-
omer are different. The different conformations seen in the 
two dimers (A-A and B-C) may, therefore, reflect the confor-
mational space sampled in solution. Such helix a9 movements 
may be crucial to the binding of ligands of variable size and 
shape, for example monomethyl arsonate and 
dehydroascorbate. 
Equilibrium Unfolding/Folding of GSTOl ^Glu-lS5/ 
G/M-20S—Initially, to determine whether the deletion of Glu-
155 caused subtle changes to the enzyme conformation in 
solution, the Stern-Volmer constant (K^^) was calculated by 
quenching the natural tryptophan fluorescence using acryl-
amide. Linear Stern-Volmer plots revealed a clear difference 
between the variant enzymes with the Glu-155 deletion and 
the enzymes with A or D at residue 140 (Fig. 3). This differ-
ence is reflected numerically in K^^ for each enzyme (5.258 
(R^ = 0.9989) for wild type (Ala-140), 5.840 
(R^ = 0.9982) for A140D, 6.975 (R^ = 0.999) for AGIu-155/ 
Glu-208, and 7.299 = 0.9979) for AGlu-155/Lys-208). The 













Interface and surface area (SA) of AGIu-155/Glu-208 and wild type crystal structure 
All calculations come from online PISA (35) of EBI services. 
Solved res idues SA of d i m e r 
To ta l bu r i ed a rea 
of d i m e r 
Tota l SA of 
T r p res idues 
in d i m e r 
Bur ied a rea of 
d i m e r in t e r face 
A' A' A' A' 
G S T O l wild type Ser-5-Leu-241 20,961.5 3,859.9 32.48 1,885.6 
(PDB code 1 HEM) 
AGlu-155 m o n o m e r A .Ser-5-Leu-240 21,639.1 3,317.3 33.74 2,116.6 
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FIGURE 4. The equilibriuin unfolding of GST01-1 in urea. Unfolding was monitored by tryptophan fluorescence expressed as the ratio of fluorescence at 
333 nm to the fluorescence at 355 nm (a), ellipticity at 222 nm of circular dichroism (b), and relative intensity of ANS binding (c). The three state curve fits for 
Nj-M- Ij 2U are shown in o and c, and the pane/5/mmed/ore/ybe/owo and c show the residuals obtained after fitting the data to either two or three state 
models. The calculated population of the native, intermediate, and unfolded states of GSTOl-1 as a function of urea concentration are plotted for wild type 
and A140D in pone/d (so/Zd/me for wild type and dos/ied//ne for A140D), AGIu-155/Glu-208 in pone/e, and AGIu-155/Lys-208 in pone/f. The experimental 
values for each enzyme are shown as wild type (•), A140D (O), AGIu-155/Glu-208 (•), and AGIu-155/Lys-208 (A). 
sibility of t ryp tophan residues. This is suppor ted by calcu-
lations f rom the crystal s t ruc ture of increased accessible 
surface area of total protein and of t ryp tophan residues in 
the AGlu-155 (Table 2). 
Characterization of Urea-induced Unfolding—The unfold-
ing of the G S T O l - 1 enzymes in the presence of urea was ex-
amined using tryptophan fluorescence, CD, and ANS binding 
(Fig. 4). The fluorescence data (Fig. 4a) for the wild type and 
A140D enzymes indicate that they do not begin unfolding 
before the urea concentration exceeds 3.7 M and by visual in-
spection appear to exhibit a single transition phase. In con-
trast, the equilibrium denaturation of the AGIu-155 enzymes 
start to show an unfolding signal below 1 M urea and clearly 
have a biphasic transition profile. The difference in the un-
folding profiles between the Glu-155-containing and AGIu-
155 enzymes is also evident in the CD data (Fig. 'ib) where the 
AGIu-155 enzymes start losing their helical secondary struc-
ture content at the lowest concentrations of urea. It is also of 
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interest to note that at the starting point of the unfolding 
curve in Fig. 4b the AGlu-155 variants have a lower helical 
content than the wild type enzymes, which is consistent with 
the AGlu-155/Glu-208 structure. The data from the ANS 
binding measurements (Fig. 4c) provide the clearest evidence 
that the unfolding profiles of the AGlu-155 enzymes are dif-
ferent from the Glu-155-containing enzymes. Using trypto-
phan fluorescence, protein concentration dependence was 
observed for the transition phase of the wild type enzyme and 
notably only during the second transition phase of the AGlu-
155/Glu-208 enzyme (Fig. 5). Taken together, these data sug-
gested that the equilibrium unfolding of the wild type and 
A140D enzymes might be described by a two-state model 
( N j 2U), whereas the unfolding of the AGlu-155 enzymes 
might best be described by a three-state unfolding model 
FIGURE 5. The protein concentration dependence of equilibrium un-
folding of GST01-1 variants in urea. The unfilled symbols represent deter-
minations at 1 ixM protein, and the filled symbols represent determinations 
at 8 ixM protein. The circles in panel A represent the wild type enzyme, and 
the triangles in panel B represent the AGIu-155/Glu-208 variant. 
(N2 ^ I2 ^ 2U), where I j represents a partially unfolded di-
meric intermediate (33, 34). 
Tryptophan fluorescence and ANS binding data from the 
AGlu-155 enzymes were fitted to a three-state model with an 
R^ > 0.999, whereas the fitting of fluorescence data f rom the 
wild type and A1400 enzymes to a two-state model gave a 
lower R'^  (0.9986 and 0.9974, respectively) and lower free en-
ergy values (6.41 and 5.15 kcal/mol, respectively) that were 
inconsistent with the previously observed lower thermal sta-
bility for AGlu-155 enzymes (2). When the three-state model 
was used to re-fit the data f rom the wild type and A140D en-
zymes, a better fit (Fig. 4a) with a higher R^ (0.9996 and 
0.9993, respectively) was obtained. The distribution of residu-
als for a two-state and three-state fit for the wild type and 
A140D enzymes is shown in Fig. 4a, and the residual sums of 
squares for wild type and A140D enzymes were also improved 
from 0.0037 and 0.0062 to 0.0010 and 0.0017. Based on the 
fitting result, equilibrium denaturation of the wild type and 
A140D proteins appears to be better described by a three-
state unfolding model. Given the absence of protein concen-
tration dependence through the first transition phase of the 
AGlu-155 enzyme (Fig. 5), it appears that the transition inter-
mediate formed by the AGlu-155 enzymes is likely to be a 
dimer (33, 34). However it is not clear whether this is the case 
for wild type and A140D enzymes. 
The population of the transition intermediate appears to 
differ significantly between the Glu-155 containing and AGlu-
155 enzymes. Based on the three-state model, the fractions of 
the transitional intermediate and the native and unfolded 
states at different urea concentrations were calculated and 
plotted (Fig. 4, d - f ) . The population of intermediate formed 
by the wild type and A140D enzymes is largely overlapped by 
the unfolded fraction, suggesting that this intermediate is very 
transitory and may indicate why there is no obvious interme-
diate state reflected in the equilibrium unfolding curves. In 
contrast, the intermediate of the AGlu-155 enzymes is clearly 
distinguishable at lower urea concentrations and has an in-
creased area of exposed hydrophobic surface as illustrated by 
the ANS binding data (Fig. 4c). 
Thermodynamic Analysis of Urea-induced Unfolding—The 
thermodynamic parameters for the Glu-155 containing and 
Glu-155 deletion enzymes are shown in Table 3. The three-
state fit of tryptophan fluorescence data f rom the wild type 
and A140D enzymes provided a similar total free energy 
change of 14.4 and 14.3 kcal/mol, respectively, which is larger 
TABLE 3 
Thermodynamic parameters characterizing the urea-induced unfolding transition monitored by tryptophan fluorescence and ANS binding 
T h e data were fi t ted to a three-s ta te transi t ion model via a d imeric in termediate . 
" I N ^ I [Urea] , , , . , ' " l - U [Urea l , , , . , 
kcal/mot kcal/mol/M M kcal/mol kcal/mol/M M kcal/mol 
Tryptophan f luorescence 
W T 8.51 ± 0.46 1.81 ± 0.11 4.69 ± 0.06 5.91 ± 2.42 1.00 ± 0.36 5.91 ± 0.33 14.42 
A 1 4 0 D 9.16 ± 0.82 2.02 ± 0.20 4.55 ± 0.09 5.14 ± 1.67 0.87 ± 0.26 5.94 ± 0.22 14.3 
AGIu-155/Glu-208 2.84 ± 0.79 1.48 ± 0.37 1.92 ± 0.12 5.78 + 0.35 1.37 ± 0.08 4.22 ± 0.03 8.62 
AGIu-155/Lys-208 3.34 ± 0.97 1.80 + 0.49 1.86 ± 0.11 5..39 ± 0.31 1.29 ± 0.07 4.19 ± 0.03 8.73 
A N S binding 
W T 7.65 + 2.43 2.45 ± 0.80 3.11 ± 0.11 7.07 ± 0.42 1.44 ± 0.08 4.91 ± 0.03 14.72 
A140D 5.43 ± 2.41 2.10 ± 0.91 2.58 ± 0 . 1 4 5.58 ± 0.57 1.13 + 0.12 4.93 ± 0.06 11.01 
AGlu-155/Glu-208 3.51 ± 1.55 1.95 ± 0.77 1.77 ± 0.17 6.54 ± 0.58 1.55 ± 0 . 1 3 4.20 ± 0.04 10.05 
AGlu-155/Lys-208 3.89 ± 1.64 1.88 ± 0.79 2.06 ± 0.15 4.98 ± 0.62 1.27 ± 0.14 3.92 ± 0.07 8.87 
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than that obtained for the AGIu-155 enzymes (8.6 and 8.7 
kcal/mol for AGlu-155/Glu-208 and AGlu-155/Lys-208, re-
spectively). Similar results were obtained from the A N S bind-
ing data. T h e main difference between the wild type and the 
AGIu-155 variant occurs in the initial unfolding to the transi-
tion intermediate . Studies using intrinsic f luorescence re-
vealed a free energy change for this first transit ion of around 
8.5 kcal/mol for the wild type compared with around 2.8 kcal/ 
mol for the AGIu-155 variant. T h e s e data suggest that the 
enzymes with the G l u - 1 5 5 deletion are less stable than Glu-
155-containing enzymes, and the lower stability of AGIu-155 
enzymes c o m e s primarily from a propensity to enter the first 
transition phase. 
Reversibility of Unfolding—The ability of the enzymes to 
re-fold after urea- induced unfolding was evaluated by fluores-
cence recovery and the restoration of catalytic activity (Fig. 6). 
T h e two methods used here to monitor the refolding gave 
similar results. Refolding of the wild type Glu-155-conta in ing 
enzymes was essentially complete after 1 h with the recovery 
of around 95%. In contrast , the enzymes with the G l u - 1 5 5 
deletion regained only around 7 0 % of their original activity or 
f luorescence intensity over this period. 
T o identify whether the lower recovery of G l u - 1 5 5 deletion 
enzyme c a m e from a lower refolding rate, an exponential re-
gression analysis was applied to the fluorescence recovery 
data. For the wild type and A 1 4 0 D enzymes, a two-phase ex-
ponential regression was better than a single-phase exponen-
tial regression as improvements in the fit were observed in R~ 
(0 .9984 and 0 . 9 9 9 2 compared with 0 . 9 9 2 4 and 0 .9900, respec-
I 2 } 4 J t 7 >0 
Mimilc 
FIGURE 6. Refolding of GST01 variants. Symbols and solid curves represent 
the recovery of fluorescence. The right-hand columris show the recovery of 
activity with 4-nitrophenacylglutathione as a substrate (mean ± S.D.). 
lively) in the S.E. of est imates (0 .0050 and 0 . 0 0 6 9 compared 
with 0 . 0 1 3 5 and 0 .0158, respectively) and in the residual sums 
of squares (0 .0005 and 0 .0002 compared with 0 . 0 0 2 2 and 
0 .0030 , respectively). Interestingly the refolding data for the 
AGlu- 155/Lys-208 variant could be fitted to a single phase or 
two-phase exponential regression with the same R^ (0 .9978) 
and residual sums of squares (0 .0003) and a similar S.E. 
(0 .0053 and 0 .0058 , respectively). However the two-phase ex-
ponential regression generated an unusually high k^  o f over 
2 2 0 0 min ' and other unusual parameters, suggesting that a 
single phase exponential analysis is more appropriate for the 
AGlu-155/Lys-208 variant. 
Therefore , the refolding curve of wild type and A 1 4 0 D en-
zymes monitored by fluorescence was better fitted by a two-
phase exponential equation, which respectively gave 3 .18 ± 
0 .57 and 3 .34 ± 0 .52 min ' for and 0.22 ± 0 .06 min ' and 
0 .27 ± 0 .05 min ' for k.^ , whereas the refolding of AGIu-155/ 
Lys-208 variant followed single-phase exponential kinetics 
with a rate of 4 .04 ± 0 .80 min This suggests that the AGIu-
155 variants still have a similar fast-refolding phase like the 
wild type and A 1 4 0 D enzymes but have lost the second slow 
refolding phase as shown in Fig. 6. 
DISCUSSION 
Previous studies have indicated that the polymorphic dele-
tion of G l u - 1 5 5 causes a deficiency of G S T O l - 1 in cell lines, 
but the mechanism causing this deficiency is not clear. As the 
deletion can potentially alter splicing at the end of exon 4, we 
previously undertook Northern blotting analysis to el iminate 
a splicing defect as a cause of the G S T O l - 1 deficiency (20). 
That study showed that T 4 7 D breast cancer cells that are 
hemizygous for the G l u - 1 5 5 deletion allele produce m R N A of 
the appropriate size, suggesting that abnormal splicing is un-
likely to be the cause of the deficiency. Previous pulse-chase 
studies in T 4 7 D cells indicate that the G l u - 1 5 5 deletion pro-
tein has a shorter than normal ii^ (20). Although this variant 
can be expressed as an active enzyme in E. coli, the recombi-
nant enzyme is relatively heat-sensitive (20). Given the clini-
cal interest in G S T O l - 1 , we were interested in determining 
the mechanism by which the G l u - 1 5 5 deletion mediates this 
deficiency. 
T h e crystal structure indicated that the deletion of G l u - 1 5 5 
caused only small perturbations of the overall protein fold. 
Although there is a slight decrease in the volume and appar-
ent accessibility of the H site, the distinct structural forms of 
AGIu-155 dimers observed in the crystal structures point to-
ward increased flexibility of the protein. Th is may explain the 
previously observed increase in catalytic activity of AGIu-155 




T A B L E 4 
The activity of recombinant wild type and AGIu-155 G S T O l -1 variants with a range of substrates 
All activities are shown as /j,mol/min/mg, mean ± S.D. C D N B . l -chloro-2.4,dinitrobenzene; 2 ,4 -DCPG; S-(2,4-dichlorophenacylglutathione). All data were cotnpiled 
E n z y m e C D N B Thiol transferase Dehydroascorbate Monomethyl arsonate Dimethyl arsonate 2 , 4 - D C P G 
Human G S T O l - 1 
AGIu-155, Glu-208 
AGIu-155 ,1 .ys-208 
0 .047 ± 0.01 
0 . 0 3 9 ± 0.01 
0 . 0 6 3 ± 0.01 
2 ± 0.21 
2.6 ± 0 .26 
6 ± 0 .09 
4 .8 ± 0.07 
3.6 ± 0 .36 
0 .13 ± 0 .005 
0 .25 ± 0 .045 
0.21 ± 0 .03 
0 .33 ± 0 .037 
0 .65 ± 0 .007 
0 .67 ± 0 . 0 6 6 
0 .12 ± 0 .006 
0 .3 ± 0 . 0 1 4 
0.37 ± 0 .015 
1.3 ± 0 . 1 
1.3 ± 0 .05 
1.1 ± 0 .03 
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catalysis of diverse substrates are more accessible to the flexi-
ble mutant protein. T h e catalytic activity of the recombinant 
A G l u - 1 5 5 enzymes and the absence of immunological ly de-
tectable G S T O l - 1 in T 4 7 D cells suggest that the deletion may 
cause a defect in stability or folding rather than a loss of func-
tion. W e found several structural factors that could have a 
deleterious impact on stability including the increase in the 
water accessible surface area, a reduction in buried hydropho-
bic surface area, and the large decrease in molecular contacts 
between helices a5 and a7. Even the increased buried area of 
dimer interface was not a positive factor because of the con-
comitant increase in the surface area of solvent-exposed hy-
drophobic residues. 
T h e lower free energy change supports the lower 
stability of the A G l u - 1 5 5 enzymes. W e also found evidence 
that at low urea concentrat ions the AGlu-155 enzymes form a 
transitional intermediate that is not significantly populated 
by the Glu-155-conta in ing enzymes. Because their first transi-
tion is not dependent on the protein concentrat ion, the un-
folding intermediate formed by the AGlu-155 enzymes ap-
pears to be a dimer with more hydrophobic area exposure 
revealed by the A N S binding data. T h e nature of the interme-
diate formed by the Glu-155-conta in ing enzymes is difficult 
to identify with the present data. 
T h e capacity of the Glu-155 deletion variants to refold after 
complete unfolding in urea was limited compared with the Glu-
155 containing Ala-140 and Asp-140 enzymes (Fig. 6). This limi-
tation only occurred during the second slow phase of refolding. 
Because refolding is usually thought to be the reverse of unfold-
ing, the refolding of the Glu-155 deletion enzymes is probably 
limited by the population of the transitional intermediate. As 
mentioned above, the intermediate has a larger exposed hydro-
phobic surface, which probably promotes precipitation or pre-
vents further refolding of the protein resulting in the lack of the 
second slow phase for the AGlu-155 enzymes. Intracellular pro-
teins are dynamic and may be subjected to conformational 
changes under different intracellular conditions. It is possible 
that the increased accessibility to solvent and decreased contacts 
in the Glu-155 deletion enzyme may promote unfolding and 
restrict refolding by presenting a barrier of increased hydropho-
bic surface exposure, leading to a dynamic equilibrium that fa-
vors an unfolded state in vivo. 
W e , therefore, conclude that the deletion of Glu-155 causes 
G S T O l - 1 deficiency by its low stability, resulting from its in-
creased propensity to unfold, and a novel mechanism that inhib-
its refolding. T h e structural characteristics of the deletion mu-
tant, including a high accessible surface area and less buried 
hydrophobic area as well as altered packing around AGlu-155 
agree with these observations. T h e results help us to understand 
the impact of the Glu-155 deletion allele on the level of 
G S T O l - 1 activity in vivo, which may contribute to the observed 
association of G S T O l - 1 with the age at onset of Alzheimer dis-
ease and the activation of the pro-inflammatory cytokine IL-l j3. 
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